Background  ||| S:24 E:43 ||| NNP
Glycosaminoglycans  ||| S:43 E:62 ||| NNP
( ||| S:62 E:63 ||| -LRB-
GAGs ||| S:63 E:67 ||| NNP
)  ||| S:67 E:69 ||| -RRB-
are  ||| S:69 E:73 ||| VBP
negatively  ||| S:73 E:84 ||| RB
charged  ||| S:84 E:100 ||| VBN
polysaccharides  ||| S:100 E:116 ||| RB
derived  ||| S:116 E:124 ||| VBN
from  ||| S:124 E:129 ||| IN
an  ||| S:129 E:132 ||| DT
amino  ||| S:132 E:138 ||| JJ
hexose ||| S:138 E:144 ||| NN
.  ||| S:144 E:146 ||| .
They  ||| S:146 E:151 ||| PRP
are  ||| S:151 E:163 ||| VBP
structural  ||| S:163 E:174 ||| JJ
and  ||| S:174 E:178 ||| CC
functional  ||| S:178 E:189 ||| JJ
modulators  ||| S:189 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
extracellular  ||| S:203 E:225 ||| JJ
matrices  ||| S:225 E:234 ||| NN
that  ||| S:234 E:239 ||| WDT
play  ||| S:239 E:244 ||| VBP
important  ||| S:244 E:254 ||| JJ
roles  ||| S:254 E:260 ||| NNS
in  ||| S:260 E:263 ||| IN
CNS  ||| S:263 E:267 ||| NNP
development  ||| S:267 E:279 ||| NN
and  ||| S:279 E:291 ||| CC
repair ||| S:291 E:297 ||| NN
.  ||| S:297 E:299 ||| .
They  ||| S:299 E:304 ||| PRP
exhibit  ||| S:304 E:312 ||| VBD
both  ||| S:312 E:317 ||| DT
stimulatory  ||| S:317 E:329 ||| NN
and  ||| S:329 E:333 ||| CC
inhibitory  ||| S:333 E:352 ||| JJ
influences  ||| S:352 E:363 ||| NNS
on  ||| S:363 E:366 ||| IN
neurite  ||| S:366 E:374 ||| JJ
outgrowth  ||| S:374 E:384 ||| NN
and  ||| S:384 E:388 ||| CC
survival ||| S:388 E:396 ||| NN
.  ||| S:396 E:398 ||| .
Evidence  ||| S:398 E:415 ||| NN
demonstrates  ||| S:415 E:428 ||| VBZ
the  ||| S:428 E:432 ||| DT
ability  ||| S:432 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
heparin  ||| S:443 E:451 ||| JJ
sulfates  ||| S:451 E:460 ||| NNS
( ||| S:460 E:461 ||| -LRB-
HSs ||| S:461 E:464 ||| NNP
)  ||| S:464 E:466 ||| -RRB-
to  ||| S:466 E:469 ||| TO
bind  ||| S:469 E:482 ||| VB
to  ||| S:482 E:485 ||| TO
growth ||| S:485 E:491 ||| NN
/ ||| S:491 E:492 ||| CD
trophic  ||| S:492 E:500 ||| CD
factors  ||| S:500 E:508 ||| NNS
and  ||| S:508 E:512 ||| CC
selectively  ||| S:512 E:524 ||| RB
regulate  ||| S:524 E:533 ||| VB
such  ||| S:533 E:546 ||| JJ
factors ||| S:546 E:553 ||| NNS
'  ||| S:553 E:555 ||| POS
receptors.  ||| S:555 E:566 ||| NNP
[  ||| S:566 E:568 ||| -LRB-
1  ||| S:568 E:570 ||| CD
2  ||| S:570 E:572 ||| CD
]  ||| S:572 E:574 ||| -RRB-
.  ||| S:574 E:576 ||| .
They  ||| S:576 E:581 ||| PRP
can  ||| S:581 E:585 ||| MD
act  ||| S:585 E:589 ||| VB
as  ||| S:589 E:592 ||| IN
co-receptors  ||| S:592 E:613 ||| JJ
of  ||| S:613 E:616 ||| IN
growth ||| S:616 E:622 ||| NN
/ ||| S:622 E:623 ||| CD
trophic  ||| S:623 E:631 ||| NNS
and  ||| S:631 E:635 ||| CC
survival  ||| S:635 E:644 ||| NN
factors  ||| S:644 E:652 ||| NNS
to  ||| S:652 E:655 ||| TO
regulate  ||| S:655 E:664 ||| VB
cell  ||| S:664 E:677 ||| NN
behavior  ||| S:677 E:686 ||| NN
and ||| S:686 E:689 ||| CC
/ ||| S:689 E:690 ||| NNP
or  ||| S:690 E:693 ||| CC
restrict  ||| S:693 E:702 ||| VB
diffusion  ||| S:702 E:712 ||| NNS
and  ||| S:712 E:716 ||| CC
create  ||| S:716 E:723 ||| VB
a  ||| S:723 E:725 ||| DT
relatively  ||| S:725 E:744 ||| RB
high  ||| S:744 E:749 ||| JJ
local  ||| S:749 E:755 ||| JJ
concentration  ||| S:755 E:769 ||| NN
of  ||| S:769 E:772 ||| IN
ligand ||| S:772 E:778 ||| NN
.  ||| S:778 E:788 ||| .
Pigment  ||| S:788 E:796 ||| JJ
epithelium-derived  ||| S:796 E:815 ||| JJ
factor  ||| S:815 E:822 ||| NN
( ||| S:822 E:823 ||| -LRB-
PEDF ||| S:823 E:827 ||| NNP
)  ||| S:827 E:829 ||| -RRB-
is  ||| S:829 E:832 ||| VBZ
an  ||| S:832 E:843 ||| DT
extracellular  ||| S:843 E:857 ||| JJ
neuronal  ||| S:857 E:866 ||| JJ
differentiation  ||| S:866 E:882 ||| NN
and  ||| S:882 E:886 ||| CC
survival  ||| S:886 E:895 ||| NN
factor  ||| S:895 E:910 ||| NN
for  ||| S:910 E:914 ||| IN
cells  ||| S:914 E:920 ||| NNS
derived  ||| S:920 E:928 ||| VBN
from  ||| S:928 E:933 ||| IN
the  ||| S:933 E:937 ||| DT
retina  ||| S:937 E:944 ||| NN
and  ||| S:944 E:948 ||| CC
CNS ||| S:948 E:951 ||| NNP
.  ||| S:951 E:953 ||| .
It  ||| S:953 E:956 ||| PRP
induces  ||| S:956 E:972 ||| VBZ
neuronal  ||| S:972 E:981 ||| JJ
differentiation  ||| S:981 E:997 ||| NN
in  ||| S:997 E:1000 ||| IN
retinoblastoma  ||| S:1000 E:1015 ||| NN
cells ||| S:1015 E:1020 ||| NNS
,  ||| S:1020 E:1022 ||| ,
protects  ||| S:1022 E:1039 ||| VBZ
retina  ||| S:1039 E:1046 ||| JJ
neurons  ||| S:1046 E:1054 ||| NNS
( ||| S:1054 E:1055 ||| -LRB-
including  ||| S:1055 E:1065 ||| VBG
photoreceptors ||| S:1065 E:1079 ||| NN
)  ||| S:1079 E:1081 ||| -RRB-
from  ||| S:1081 E:1086 ||| IN
death  ||| S:1086 E:1092 ||| NN
by  ||| S:1092 E:1103 ||| IN
apoptosis  ||| S:1103 E:1113 ||| NN
and  ||| S:1113 E:1117 ||| CC
other  ||| S:1117 E:1123 ||| JJ
insults ||| S:1123 E:1130 ||| NN
,  ||| S:1130 E:1132 ||| ,
and  ||| S:1132 E:1136 ||| CC
has  ||| S:1136 E:1140 ||| VBZ
a  ||| S:1140 E:1142 ||| DT
morphogenetic  ||| S:1142 E:1156 ||| JJ
effect  ||| S:1156 E:1171 ||| NN
on  ||| S:1171 E:1174 ||| IN
photoreceptor  ||| S:1174 E:1188 ||| JJ
cells  ||| S:1188 E:1194 ||| NNS
[  ||| S:1194 E:1196 ||| -LRB-
3  ||| S:1196 E:1198 ||| CD
4  ||| S:1198 E:1200 ||| CD
5  ||| S:1200 E:1202 ||| CD
6  ||| S:1202 E:1204 ||| CD
]  ||| S:1204 E:1206 ||| -RRB-
.  ||| S:1206 E:1208 ||| .
It  ||| S:1208 E:1211 ||| PRP
also  ||| S:1211 E:1216 ||| RB
has  ||| S:1216 E:1228 ||| VBZ
neurotrophic  ||| S:1228 E:1241 ||| JJ
effects  ||| S:1241 E:1249 ||| NNS
on  ||| S:1249 E:1252 ||| IN
neurons  ||| S:1252 E:1260 ||| NN
from  ||| S:1260 E:1265 ||| IN
the  ||| S:1265 E:1269 ||| DT
cerebellum ||| S:1269 E:1279 ||| NN
,  ||| S:1279 E:1289 ||| ,
hippocampus  ||| S:1289 E:1301 ||| NN
and  ||| S:1301 E:1305 ||| CC
spinal  ||| S:1305 E:1312 ||| JJ
cord  ||| S:1312 E:1317 ||| NN
[  ||| S:1317 E:1319 ||| -LRB-
7  ||| S:1319 E:1321 ||| CD
8  ||| S:1321 E:1323 ||| CD
9  ||| S:1323 E:1325 ||| CD
10  ||| S:1325 E:1328 ||| CD
11  ||| S:1328 E:1331 ||| CD
12  ||| S:1331 E:1334 ||| CD
]  ||| S:1334 E:1336 ||| -RRB-
.  ||| S:1336 E:1338 ||| .
In  ||| S:1338 E:1341 ||| IN
the  ||| S:1341 E:1353 ||| DT
intact  ||| S:1353 E:1360 ||| JJ
retina ||| S:1360 E:1366 ||| NN
,  ||| S:1366 E:1368 ||| ,
this  ||| S:1368 E:1373 ||| DT
factor  ||| S:1373 E:1380 ||| NN
is  ||| S:1380 E:1383 ||| VBZ
identified  ||| S:1383 E:1394 ||| VBN
as  ||| S:1394 E:1397 ||| IN
a  ||| S:1397 E:1399 ||| DT
secreted  ||| S:1399 E:1416 ||| JJ
protein  ||| S:1416 E:1424 ||| NN
associated  ||| S:1424 E:1435 ||| VBN
by  ||| S:1435 E:1438 ||| IN
ionic  ||| S:1438 E:1444 ||| JJ
interactions  ||| S:1444 E:1457 ||| NNS
with  ||| S:1457 E:1462 ||| IN
the  ||| S:1462 E:1474 ||| DT
interphotoreceptor  ||| S:1474 E:1493 ||| JJ
matrix  ||| S:1493 E:1500 ||| NNS
[  ||| S:1500 E:1502 ||| -LRB-
13  ||| S:1502 E:1505 ||| CD
14  ||| S:1505 E:1508 ||| CD
]  ||| S:1508 E:1510 ||| -RRB-
,  ||| S:1510 E:1512 ||| ,
where  ||| S:1512 E:1518 ||| WRB
GAGs  ||| S:1518 E:1523 ||| NNS
are  ||| S:1523 E:1527 ||| VBP
the  ||| S:1527 E:1539 ||| DT
major  ||| S:1539 E:1545 ||| JJ
polyanionic  ||| S:1545 E:1557 ||| JJ
components ||| S:1557 E:1567 ||| NNS
.  ||| S:1567 E:1577 ||| .
Biochemically ||| S:1577 E:1590 ||| NNP
,  ||| S:1590 E:1592 ||| ,
PEDF  ||| S:1592 E:1597 ||| NNP
is  ||| S:1597 E:1600 ||| VBZ
a  ||| S:1600 E:1602 ||| DT
50-kDa  ||| S:1602 E:1609 ||| JJ
glycoprotein  ||| S:1609 E:1622 ||| NN
with  ||| S:1622 E:1635 ||| IN
structural  ||| S:1635 E:1646 ||| JJ
homology  ||| S:1646 E:1655 ||| NN
to  ||| S:1655 E:1658 ||| TO
members  ||| S:1658 E:1666 ||| NNS
of  ||| S:1666 E:1669 ||| IN
the  ||| S:1669 E:1673 ||| DT
serine-protease  ||| S:1673 E:1697 ||| JJ
inhibitor  ||| S:1697 E:1707 ||| NNS
( ||| S:1707 E:1708 ||| -LRB-
serpin ||| S:1708 E:1714 ||| LS
)  ||| S:1714 E:1716 ||| -RRB-
superfamily  ||| S:1716 E:1728 ||| NNS
[  ||| S:1728 E:1730 ||| -LRB-
3  ||| S:1730 E:1732 ||| CD
15  ||| S:1732 E:1735 ||| CD
]  ||| S:1735 E:1737 ||| -RRB-
.  ||| S:1737 E:1739 ||| .
However ||| S:1739 E:1746 ||| RB
,  ||| S:1746 E:1748 ||| ,
it  ||| S:1748 E:1751 ||| PRP
has  ||| S:1751 E:1763 ||| VBZ
no  ||| S:1763 E:1766 ||| DT
inhibitory  ||| S:1766 E:1777 ||| JJ
effects  ||| S:1777 E:1785 ||| NNS
on  ||| S:1785 E:1788 ||| IN
proteases ||| S:1788 E:1797 ||| NN
.  ||| S:1797 E:1799 ||| .
Its  ||| S:1799 E:1803 ||| PRP$
neurotrophic  ||| S:1803 E:1824 ||| JJ
activities  ||| S:1824 E:1835 ||| NNS
are  ||| S:1835 E:1839 ||| VBP
independent  ||| S:1839 E:1851 ||| JJ
of  ||| S:1851 E:1854 ||| IN
its  ||| S:1854 E:1858 ||| PRP$
protease  ||| S:1858 E:1867 ||| JJ
inhibition  ||| S:1867 E:1886 ||| JJ
potential  ||| S:1886 E:1896 ||| NN
but  ||| S:1896 E:1900 ||| CC
dependent  ||| S:1900 E:1910 ||| JJ
on  ||| S:1910 E:1913 ||| IN
its  ||| S:1913 E:1917 ||| PRP$
interaction  ||| S:1917 E:1929 ||| NN
with  ||| S:1929 E:1942 ||| IN
cell-surface  ||| S:1942 E:1955 ||| JJ
receptors  ||| S:1955 E:1965 ||| NNS
[  ||| S:1965 E:1967 ||| -LRB-
9  ||| S:1967 E:1969 ||| CD
12  ||| S:1969 E:1972 ||| CD
16  ||| S:1972 E:1975 ||| CD
17  ||| S:1975 E:1978 ||| CD
18  ||| S:1978 E:1981 ||| CD
]  ||| S:1981 E:1983 ||| -RRB-
.  ||| S:1983 E:1985 ||| .
PEDF  ||| S:1985 E:1990 ||| NNP
has  ||| S:1990 E:1994 ||| VBZ
high  ||| S:1994 E:2007 ||| JJ
binding  ||| S:2007 E:2015 ||| JJ
affinity  ||| S:2015 E:2024 ||| NN
for  ||| S:2024 E:2028 ||| IN
cell-surface  ||| S:2028 E:2041 ||| JJ
receptors  ||| S:2041 E:2051 ||| NNS
in  ||| S:2051 E:2054 ||| IN
human  ||| S:2054 E:2068 ||| JJ
retinoblastoma  ||| S:2068 E:2083 ||| NN
Y-79  ||| S:2083 E:2088 ||| CD
cells  ||| S:2088 E:2094 ||| NNS
( ||| S:2094 E:2095 ||| -LRB-
K  ||| S:2095 E:2117 ||| NNP
d  ||| S:2117 E:2129 ||| SYM
=  ||| S:2129 E:2131 ||| SYM
2.7  ||| S:2131 E:2135 ||| CD
nM ||| S:2135 E:2137 ||| NN
) ||| S:2137 E:2138 ||| -RRB-
,  ||| S:2138 E:2140 ||| ,
which  ||| S:2140 E:2146 ||| WDT
is  ||| S:2146 E:2149 ||| VBZ
mediated  ||| S:2149 E:2158 ||| VBN
by  ||| S:2158 E:2161 ||| IN
interactions  ||| S:2161 E:2174 ||| NNS
between  ||| S:2174 E:2182 ||| IN
a  ||| S:2182 E:2192 ||| DT
region  ||| S:2192 E:2199 ||| NN
spanning  ||| S:2199 E:2208 ||| VBG
amino  ||| S:2208 E:2214 ||| JJ
acid  ||| S:2214 E:2219 ||| NN
positions  ||| S:2219 E:2229 ||| NNS
78-121  ||| S:2229 E:2236 ||| VBP
of  ||| S:2236 E:2239 ||| IN
the  ||| S:2239 E:2243 ||| DT
PEDF  ||| S:2243 E:2256 ||| NNP
polypeptide  ||| S:2256 E:2268 ||| NN
and  ||| S:2268 E:2272 ||| CC
the  ||| S:2272 E:2276 ||| DT
extracellular  ||| S:2276 E:2290 ||| JJ
domains  ||| S:2290 E:2298 ||| NN
of  ||| S:2298 E:2301 ||| IN
the  ||| S:2301 E:2305 ||| DT
receptor  ||| S:2305 E:2322 ||| NN
protein  ||| S:2322 E:2330 ||| NN
[  ||| S:2330 E:2332 ||| -LRB-
18  ||| S:2332 E:2335 ||| CD
]  ||| S:2335 E:2337 ||| -RRB-
.  ||| S:2337 E:2339 ||| .
Blockage  ||| S:2339 E:2348 ||| NNP
of  ||| S:2348 E:2351 ||| IN
these  ||| S:2351 E:2357 ||| DT
interactions  ||| S:2357 E:2370 ||| NN
inhibits  ||| S:2370 E:2387 ||| VBD
the  ||| S:2387 E:2391 ||| DT
PEDF  ||| S:2391 E:2396 ||| NNP
neurotrophic  ||| S:2396 E:2409 ||| NN
effects ||| S:2409 E:2416 ||| NNS
.  ||| S:2416 E:2418 ||| .
PEDF  ||| S:2418 E:2423 ||| NNP
also  ||| S:2423 E:2428 ||| RB
has  ||| S:2428 E:2432 ||| VBZ
binding  ||| S:2432 E:2448 ||| JJ
affinity  ||| S:2448 E:2457 ||| NN
for  ||| S:2457 E:2461 ||| IN
GAGs ||| S:2461 E:2465 ||| NNP
,  ||| S:2465 E:2467 ||| ,
such  ||| S:2467 E:2472 ||| JJ
as ||| S:2472 E:2474 ||| RB
,  ||| S:2474 E:2476 ||| ,
heparin ||| S:2476 E:2483 ||| NN
,  ||| S:2483 E:2485 ||| ,
heparin-  ||| S:2485 E:2494 ||| JJ
and  ||| S:2494 E:2506 ||| CC
chondroitin-sulfates ||| S:2506 E:2526 ||| JJ
,  ||| S:2526 E:2528 ||| ,
but  ||| S:2528 E:2532 ||| CC
this  ||| S:2532 E:2537 ||| DT
affinity  ||| S:2537 E:2546 ||| NN
is  ||| S:2546 E:2549 ||| VBZ
~1000-fold  ||| S:2549 E:2560 ||| RB
lower  ||| S:2560 E:2574 ||| JJR
than  ||| S:2574 E:2579 ||| IN
for  ||| S:2579 E:2583 ||| IN
the  ||| S:2583 E:2587 ||| DT
receptor  ||| S:2587 E:2596 ||| NN
( ||| S:2596 E:2597 ||| -LRB-
e.g. ||| S:2597 E:2601 ||| NNP
,  ||| S:2601 E:2603 ||| ,
K  ||| S:2603 E:2625 ||| NNP
d  ||| S:2625 E:2637 ||| SYM
4  ||| S:2637 E:2639 ||| CD
μM  ||| S:2639 E:2642 ||| NN
for  ||| S:2642 E:2646 ||| IN
the  ||| S:2646 E:2650 ||| DT
heparin-PEDF  ||| S:2650 E:2663 ||| JJ
interactions ||| S:2663 E:2675 ||| NNS
)  ||| S:2675 E:2677 ||| -RRB-
[  ||| S:2677 E:2679 ||| -LRB-
14  ||| S:2679 E:2682 ||| CD
19  ||| S:2682 E:2685 ||| CD
]  ||| S:2685 E:2687 ||| -RRB-
.  ||| S:2687 E:2697 ||| .
The  ||| S:2697 E:2701 ||| DT
binding  ||| S:2701 E:2709 ||| JJ
to  ||| S:2709 E:2712 ||| TO
GAGs  ||| S:2712 E:2717 ||| NNP
is  ||| S:2717 E:2720 ||| VBZ
mediated  ||| S:2720 E:2729 ||| VBN
by  ||| S:2729 E:2732 ||| IN
ionic  ||| S:2732 E:2738 ||| JJ
interactions  ||| S:2738 E:2759 ||| NNS
between  ||| S:2759 E:2767 ||| IN
an  ||| S:2767 E:2770 ||| DT
area  ||| S:2770 E:2775 ||| NN
clustered  ||| S:2775 E:2785 ||| VBN
with  ||| S:2785 E:2790 ||| IN
positively  ||| S:2790 E:2801 ||| RB
charged  ||| S:2801 E:2809 ||| VBN
lysines  ||| S:2809 E:2825 ||| VBN
of  ||| S:2825 E:2828 ||| IN
PEDF  ||| S:2828 E:2833 ||| NNP
and  ||| S:2833 E:2837 ||| CC
the  ||| S:2837 E:2841 ||| DT
negatively  ||| S:2841 E:2852 ||| RB
charged  ||| S:2852 E:2860 ||| VBN
GAGs ||| S:2860 E:2864 ||| JJ
.  ||| S:2864 E:2866 ||| .
In  ||| S:2866 E:2869 ||| IN
the  ||| S:2869 E:2873 ||| DT
PEDF  ||| S:2873 E:2886 ||| NNP
spatial  ||| S:2886 E:2894 ||| JJ
structure ||| S:2894 E:2903 ||| NN
,  ||| S:2903 E:2905 ||| ,
the  ||| S:2905 E:2909 ||| DT
putative  ||| S:2909 E:2918 ||| JJ
GAG  ||| S:2918 E:2922 ||| NNP
binding  ||| S:2922 E:2930 ||| JJ
domain  ||| S:2930 E:2937 ||| NN
is  ||| S:2937 E:2948 ||| VBZ
distinct  ||| S:2948 E:2957 ||| VBN
from  ||| S:2957 E:2962 ||| IN
and  ||| S:2962 E:2966 ||| CC
non-overlapping  ||| S:2966 E:2982 ||| JJ
with  ||| S:2982 E:2987 ||| IN
the  ||| S:2987 E:2991 ||| DT
neurotrophic  ||| S:2991 E:3012 ||| JJ
active  ||| S:3012 E:3019 ||| JJ
region  ||| S:3019 E:3026 ||| NN
[  ||| S:3026 E:3028 ||| -LRB-
14  ||| S:3028 E:3031 ||| CD
20  ||| S:3031 E:3034 ||| CD
]  ||| S:3034 E:3036 ||| -RRB-
.  ||| S:3036 E:3046 ||| .
Because  ||| S:3046 E:3054 ||| IN
PEDF  ||| S:3054 E:3059 ||| NNP
coexists  ||| S:3059 E:3068 ||| NN
with  ||| S:3068 E:3073 ||| IN
GAGs  ||| S:3073 E:3078 ||| JJ
in  ||| S:3078 E:3081 ||| IN
extracellular  ||| S:3081 E:3103 ||| JJ
matrices  ||| S:3103 E:3112 ||| NN
and  ||| S:3112 E:3116 ||| CC
has  ||| S:3116 E:3120 ||| VBZ
binding  ||| S:3120 E:3128 ||| JJ
affinity  ||| S:3128 E:3137 ||| NN
for  ||| S:3137 E:3141 ||| IN
them ||| S:3141 E:3145 ||| PRP
,  ||| S:3145 E:3147 ||| ,
it  ||| S:3147 E:3150 ||| PRP
is  ||| S:3150 E:3153 ||| VBZ
of  ||| S:3153 E:3164 ||| IN
interest  ||| S:3164 E:3173 ||| NN
to  ||| S:3173 E:3176 ||| TO
investigate  ||| S:3176 E:3188 ||| VB
the  ||| S:3188 E:3192 ||| DT
role  ||| S:3192 E:3197 ||| NN
of  ||| S:3197 E:3200 ||| IN
GAGs  ||| S:3200 E:3205 ||| JJ
on  ||| S:3205 E:3208 ||| IN
PEDF  ||| S:3208 E:3213 ||| NNP
activity ||| S:3213 E:3221 ||| NN
.  ||| S:3221 E:3231 ||| .
Given  ||| S:3231 E:3237 ||| VBN
that  ||| S:3237 E:3242 ||| IN
binding  ||| S:3242 E:3250 ||| VBG
to  ||| S:3250 E:3253 ||| TO
cell-surface  ||| S:3253 E:3266 ||| JJ
receptors  ||| S:3266 E:3276 ||| NN
is  ||| S:3276 E:3279 ||| VBZ
the  ||| S:3279 E:3283 ||| DT
first  ||| S:3283 E:3297 ||| JJ
step  ||| S:3297 E:3302 ||| NN
in  ||| S:3302 E:3305 ||| IN
the  ||| S:3305 E:3309 ||| DT
biological  ||| S:3309 E:3320 ||| JJ
activity  ||| S:3320 E:3329 ||| NN
of  ||| S:3329 E:3332 ||| IN
PEDF ||| S:3332 E:3336 ||| NNP
,  ||| S:3336 E:3338 ||| ,
we  ||| S:3338 E:3341 ||| PRP
used  ||| S:3341 E:3346 ||| VBD
human  ||| S:3346 E:3360 ||| JJ
retinoblastoma  ||| S:3360 E:3375 ||| NN
Y-79  ||| S:3375 E:3380 ||| CD
cells  ||| S:3380 E:3386 ||| NNS
and  ||| S:3386 E:3390 ||| CC
their  ||| S:3390 E:3396 ||| PRP$
conditioned  ||| S:3396 E:3408 ||| JJ
media  ||| S:3408 E:3414 ||| NNS
( ||| S:3414 E:3415 ||| -LRB-
CM ||| S:3415 E:3417 ||| NNP
)  ||| S:3417 E:3427 ||| -RRB-
as  ||| S:3427 E:3430 ||| IN
sources  ||| S:3430 E:3438 ||| NNS
of  ||| S:3438 E:3441 ||| IN
functional  ||| S:3441 E:3452 ||| JJ
PEDF  ||| S:3452 E:3457 ||| NN
receptors  ||| S:3457 E:3467 ||| NNS
and  ||| S:3467 E:3471 ||| CC
extracellular  ||| S:3471 E:3493 ||| JJ
matrix  ||| S:3493 E:3500 ||| JJ
components ||| S:3500 E:3510 ||| NNS
,  ||| S:3510 E:3512 ||| ,
respectively ||| S:3512 E:3524 ||| RB
,  ||| S:3524 E:3526 ||| ,
to  ||| S:3526 E:3529 ||| TO
examine  ||| S:3529 E:3537 ||| VB
the  ||| S:3537 E:3541 ||| DT
GAG  ||| S:3541 E:3545 ||| NNP
content  ||| S:3545 E:3561 ||| NN
in  ||| S:3561 E:3564 ||| IN
CM  ||| S:3564 E:3567 ||| NNP
and  ||| S:3567 E:3571 ||| CC
their  ||| S:3571 E:3577 ||| PRP$
effects  ||| S:3577 E:3585 ||| NNS
on  ||| S:3585 E:3588 ||| IN
PEDF  ||| S:3588 E:3593 ||| NNP
ligand-receptor  ||| S:3593 E:3617 ||| JJ
interactions ||| S:3617 E:3629 ||| NNS
.  ||| S:3629 E:3631 ||| .
The  ||| S:3631 E:3635 ||| DT
data  ||| S:3635 E:3640 ||| NNS
suggest  ||| S:3640 E:3648 ||| VBP
that  ||| S:3648 E:3653 ||| IN
heparan  ||| S:3653 E:3661 ||| JJ
sulfate  ||| S:3661 E:3677 ||| NN
participates  ||| S:3677 E:3690 ||| VBZ
in  ||| S:3690 E:3693 ||| IN
the  ||| S:3693 E:3697 ||| DT
formation  ||| S:3697 E:3707 ||| NN
of  ||| S:3707 E:3710 ||| IN
a  ||| S:3710 E:3712 ||| DT
PEDF  ||| S:3712 E:3717 ||| NNP
binding  ||| S:3717 E:3725 ||| JJ
complex  ||| S:3725 E:3741 ||| NN
with  ||| S:3741 E:3746 ||| IN
its  ||| S:3746 E:3750 ||| PRP$
cell-surface  ||| S:3750 E:3763 ||| JJ
receptor ||| S:3763 E:3771 ||| NN
,  ||| S:3771 E:3773 ||| ,
and  ||| S:3773 E:3777 ||| CC
constitutes  ||| S:3777 E:3789 ||| VBZ
a  ||| S:3789 E:3791 ||| DT
positive  ||| S:3791 E:3808 ||| JJ
modulator  ||| S:3808 E:3818 ||| NN
for  ||| S:3818 E:3822 ||| IN
the  ||| S:3822 E:3826 ||| DT
PEDF-receptor  ||| S:3826 E:3840 ||| JJ
interactions ||| S:3840 E:3852 ||| NNS
.  ||| S:3852 E:3876 ||| .
Results  ||| S:3876 E:3903 ||| NNS
Complex  ||| S:3903 E:3911 ||| JJ
formation  ||| S:3911 E:3921 ||| NN
between  ||| S:3921 E:3929 ||| IN
PEDF  ||| S:3929 E:3934 ||| NNP
and  ||| S:3934 E:3938 ||| CC
component ||| S:3938 E:3947 ||| NN
( ||| S:3947 E:3948 ||| -LRB-
s ||| S:3948 E:3949 ||| LS
)  ||| S:3949 E:3951 ||| -RRB-
in  ||| S:3951 E:3964 ||| IN
media  ||| S:3964 E:3970 ||| NNS
conditioned  ||| S:3970 E:3982 ||| VBN
by  ||| S:3982 E:3985 ||| IN
retinoblastoma  ||| S:3985 E:4000 ||| NN
cells  ||| S:4000 E:4016 ||| NNS
To  ||| S:4016 E:4019 ||| TO
determine  ||| S:4019 E:4029 ||| VB
whether  ||| S:4029 E:4037 ||| IN
PEDF  ||| S:4037 E:4042 ||| NNP
interacts  ||| S:4042 E:4052 ||| NN
with  ||| S:4052 E:4057 ||| IN
component ||| S:4057 E:4066 ||| NN
( ||| S:4066 E:4067 ||| -LRB-
s ||| S:4067 E:4068 ||| LS
)  ||| S:4068 E:4080 ||| -RRB-
in  ||| S:4080 E:4083 ||| IN
media  ||| S:4083 E:4089 ||| NNS
conditioned  ||| S:4089 E:4101 ||| VBN
by  ||| S:4101 E:4104 ||| IN
retinoblastoma  ||| S:4104 E:4119 ||| NN
cells  ||| S:4119 E:4125 ||| NNS
( ||| S:4125 E:4126 ||| -LRB-
CM ||| S:4126 E:4128 ||| NNP
) ||| S:4128 E:4129 ||| -RRB-
,  ||| S:4129 E:4131 ||| ,
we  ||| S:4131 E:4144 ||| PRP
used  ||| S:4144 E:4149 ||| VBD
an  ||| S:4149 E:4152 ||| DT
ultrafiltration  ||| S:4152 E:4168 ||| JJ
assay ||| S:4168 E:4173 ||| NN
.  ||| S:4173 E:4175 ||| .
In  ||| S:4175 E:4178 ||| IN
this  ||| S:4178 E:4183 ||| DT
assay ||| S:4183 E:4188 ||| NN
,  ||| S:4188 E:4190 ||| ,
soluble  ||| S:4190 E:4208 ||| JJ
PEDF  ||| S:4208 E:4213 ||| NN
of  ||| S:4213 E:4216 ||| IN
50-kDa  ||| S:4216 E:4223 ||| NNP
is  ||| S:4223 E:4226 ||| VBZ
filtered  ||| S:4226 E:4235 ||| VBN
through  ||| S:4235 E:4243 ||| IN
a  ||| S:4243 E:4245 ||| DT
membrane  ||| S:4245 E:4254 ||| NN
with  ||| S:4254 E:4259 ||| IN
an  ||| S:4259 E:4272 ||| DT
exclusion  ||| S:4272 E:4282 ||| NN
limit  ||| S:4282 E:4288 ||| NN
of  ||| S:4288 E:4291 ||| IN
MW  ||| S:4291 E:4294 ||| NNP
100,000 ||| S:4294 E:4301 ||| CD
,  ||| S:4301 E:4303 ||| ,
however  ||| S:4303 E:4311 ||| RB
it  ||| S:4311 E:4314 ||| PRP
is  ||| S:4314 E:4317 ||| VBZ
retained  ||| S:4317 E:4336 ||| VBN
upon  ||| S:4336 E:4341 ||| IN
formation  ||| S:4341 E:4351 ||| NN
of  ||| S:4351 E:4354 ||| IN
a  ||| S:4354 E:4356 ||| DT
complex  ||| S:4356 E:4364 ||| JJ
larger  ||| S:4364 E:4371 ||| JJR
than  ||| S:4371 E:4376 ||| IN
this  ||| S:4376 E:4381 ||| DT
limit  ||| S:4381 E:4387 ||| NN
[  ||| S:4387 E:4389 ||| -LRB-
14  ||| S:4389 E:4392 ||| CD
]  ||| S:4392 E:4404 ||| -RRB-
.  ||| S:4404 E:4406 ||| .
The  ||| S:4406 E:4410 ||| DT
binding  ||| S:4410 E:4418 ||| JJ
reactions  ||| S:4418 E:4428 ||| NNS
were  ||| S:4428 E:4433 ||| VBD
with  ||| S:4433 E:4438 ||| IN
a  ||| S:4438 E:4440 ||| DT
given  ||| S:4440 E:4446 ||| VBN
125I-PEDF  ||| S:4446 E:4466 ||| CD
concentration  ||| S:4466 E:4480 ||| NN
and  ||| S:4480 E:4484 ||| CC
CM ||| S:4484 E:4486 ||| NNP
.  ||| S:4486 E:4488 ||| .
Incubations  ||| S:4488 E:4500 ||| NNP
were  ||| S:4500 E:4505 ||| VBD
at  ||| S:4505 E:4508 ||| IN
4°C  ||| S:4508 E:4512 ||| CD
to  ||| S:4512 E:4515 ||| TO
minimize  ||| S:4515 E:4534 ||| VB
enzymatic  ||| S:4534 E:4544 ||| JJ
degradation  ||| S:4544 E:4556 ||| NN
of  ||| S:4556 E:4559 ||| IN
proteins  ||| S:4559 E:4568 ||| NNS
and  ||| S:4568 E:4572 ||| CC
glycosaminglycans  ||| S:4572 E:4600 ||| NN
during  ||| S:4600 E:4607 ||| IN
the  ||| S:4607 E:4611 ||| DT
reaction ||| S:4611 E:4619 ||| NN
.  ||| S:4619 E:4621 ||| .
We  ||| S:4621 E:4624 ||| PRP
found  ||| S:4624 E:4630 ||| VBD
that  ||| S:4630 E:4635 ||| IN
22 ||| S:4635 E:4637 ||| CD
%  ||| S:4637 E:4639 ||| NN
of  ||| S:4639 E:4642 ||| IN
125I-PEDF  ||| S:4642 E:4652 ||| NNP
was  ||| S:4652 E:4666 ||| VBD
retained  ||| S:4666 E:4675 ||| VBN
by  ||| S:4675 E:4678 ||| IN
the  ||| S:4678 E:4682 ||| DT
membrane  ||| S:4682 E:4691 ||| NN
in  ||| S:4691 E:4694 ||| IN
the  ||| S:4694 E:4698 ||| DT
presence  ||| S:4698 E:4707 ||| NN
of  ||| S:4707 E:4710 ||| IN
concentrated  ||| S:4710 E:4733 ||| JJ
CM ||| S:4733 E:4735 ||| NNP
,  ||| S:4735 E:4737 ||| ,
compared  ||| S:4737 E:4746 ||| VBN
to  ||| S:4746 E:4749 ||| TO
only  ||| S:4749 E:4754 ||| RB
4 ||| S:4754 E:4755 ||| CD
%  ||| S:4755 E:4757 ||| NN
retention  ||| S:4757 E:4767 ||| NN
in  ||| S:4767 E:4770 ||| IN
the  ||| S:4770 E:4774 ||| DT
presence  ||| S:4774 E:4783 ||| NN
of  ||| S:4783 E:4796 ||| IN
defined  ||| S:4796 E:4804 ||| JJ
medium  ||| S:4804 E:4811 ||| NN
( ||| S:4811 E:4812 ||| -LRB-
non-conditioned  ||| S:4812 E:4828 ||| JJ
medium ||| S:4828 E:4834 ||| NN
)  ||| S:4834 E:4836 ||| -RRB-
concentrated  ||| S:4836 E:4849 ||| VBN
in  ||| S:4849 E:4862 ||| IN
an  ||| S:4862 E:4865 ||| DT
identical  ||| S:4865 E:4875 ||| JJ
fashion ||| S:4875 E:4882 ||| NN
.  ||| S:4882 E:4884 ||| .
Specific  ||| S:4884 E:4893 ||| JJ
retention ||| S:4893 E:4902 ||| NN
,  ||| S:4902 E:4904 ||| ,
termed  ||| S:4904 E:4911 ||| VBD
PEDF  ||| S:4911 E:4926 ||| NNP
bound ||| S:4926 E:4931 ||| NN
,  ||| S:4931 E:4933 ||| ,
was  ||| S:4933 E:4937 ||| VBD
calculated  ||| S:4937 E:4948 ||| VBN
by  ||| S:4948 E:4951 ||| IN
subtracting  ||| S:4951 E:4963 ||| VBG
the  ||| S:4963 E:4967 ||| DT
retention  ||| S:4967 E:4977 ||| NN
in  ||| S:4977 E:4990 ||| IN
defined  ||| S:4990 E:4998 ||| JJ
media  ||| S:4998 E:5004 ||| NNS
from  ||| S:5004 E:5009 ||| IN
that  ||| S:5009 E:5014 ||| DT
in  ||| S:5014 E:5017 ||| IN
CM ||| S:5017 E:5019 ||| NNP
.  ||| S:5019 E:5021 ||| .
Figure  ||| S:5021 E:5028 ||| NN
1shows  ||| S:5028 E:5035 ||| NN
that  ||| S:5035 E:5040 ||| IN
PEDF  ||| S:5040 E:5055 ||| NNP
was  ||| S:5055 E:5059 ||| VBD
specifically  ||| S:5059 E:5072 ||| RB
retained  ||| S:5072 E:5081 ||| VBN
when  ||| S:5081 E:5086 ||| WRB
mixed  ||| S:5086 E:5092 ||| VBN
with  ||| S:5092 E:5097 ||| IN
soluble  ||| S:5097 E:5115 ||| JJ
conditioned  ||| S:5115 E:5127 ||| JJ
media  ||| S:5127 E:5133 ||| NNS
and  ||| S:5133 E:5137 ||| CC
the  ||| S:5137 E:5141 ||| DT
value  ||| S:5141 E:5147 ||| NN
for  ||| S:5147 E:5151 ||| IN
PEDF  ||| S:5151 E:5156 ||| NNP
bound  ||| S:5156 E:5162 ||| NN
increased  ||| S:5162 E:5182 ||| VBD
proportionally  ||| S:5182 E:5197 ||| VBN
to  ||| S:5197 E:5200 ||| TO
the  ||| S:5200 E:5204 ||| DT
concentration  ||| S:5204 E:5218 ||| NN
factor  ||| S:5218 E:5225 ||| NN
of  ||| S:5225 E:5228 ||| IN
the  ||| S:5228 E:5232 ||| DT
media  ||| S:5232 E:5248 ||| NNS
( ||| S:5248 E:5249 ||| -LRB-
Fig.  ||| S:5249 E:5254 ||| NNP
1A ||| S:5254 E:5256 ||| NNP
) ||| S:5256 E:5257 ||| -RRB-
.  ||| S:5257 E:5259 ||| .
Interestingly ||| S:5259 E:5272 ||| RB
,  ||| S:5272 E:5274 ||| ,
protease  ||| S:5274 E:5283 ||| JJ
treatment  ||| S:5283 E:5293 ||| NN
of  ||| S:5293 E:5296 ||| IN
the  ||| S:5296 E:5300 ||| DT
CM  ||| S:5300 E:5313 ||| NNP
did  ||| S:5313 E:5317 ||| VBD
not  ||| S:5317 E:5321 ||| RB
abolish  ||| S:5321 E:5329 ||| VB
the  ||| S:5329 E:5333 ||| DT
binding  ||| S:5333 E:5341 ||| NN
( ||| S:5341 E:5342 ||| -LRB-
Fig.  ||| S:5342 E:5347 ||| NNP
1B ||| S:5347 E:5349 ||| NNP
) ||| S:5349 E:5350 ||| -RRB-
.  ||| S:5350 E:5352 ||| .
These  ||| S:5352 E:5358 ||| DT
observations  ||| S:5358 E:5381 ||| NNS
revealed  ||| S:5381 E:5390 ||| VBD
that  ||| S:5390 E:5395 ||| IN
the  ||| S:5395 E:5399 ||| DT
retained  ||| S:5399 E:5408 ||| JJ
forms  ||| S:5408 E:5414 ||| NNS
in  ||| S:5414 E:5417 ||| IN
the  ||| S:5417 E:5421 ||| DT
CM  ||| S:5421 E:5424 ||| NNP
were  ||| S:5424 E:5429 ||| VBD
PEDF  ||| S:5429 E:5444 ||| NNP
complexes  ||| S:5444 E:5454 ||| VBD
≥  ||| S:5454 E:5456 ||| CD
100-kDa ||| S:5456 E:5463 ||| CD
,  ||| S:5463 E:5465 ||| ,
and  ||| S:5465 E:5469 ||| CC
that  ||| S:5469 E:5474 ||| IN
the  ||| S:5474 E:5478 ||| DT
majority  ||| S:5478 E:5487 ||| NN
of  ||| S:5487 E:5490 ||| IN
these  ||| S:5490 E:5506 ||| DT
complexes  ||| S:5506 E:5516 ||| NNS
were  ||| S:5516 E:5521 ||| VBD
formed  ||| S:5521 E:5528 ||| VBN
with  ||| S:5528 E:5533 ||| IN
soluble  ||| S:5533 E:5541 ||| JJ
CM  ||| S:5541 E:5544 ||| NN
components  ||| S:5544 E:5555 ||| NNS
other  ||| S:5555 E:5571 ||| JJ
than  ||| S:5571 E:5576 ||| IN
proteins ||| S:5576 E:5584 ||| NNS
.  ||| S:5584 E:5614 ||| .
Heparin  ||| S:5614 E:5622 ||| NNP
and  ||| S:5622 E:5626 ||| CC
HS  ||| S:5626 E:5629 ||| NNP
in  ||| S:5629 E:5632 ||| IN
the  ||| S:5632 E:5636 ||| DT
conditioned  ||| S:5636 E:5648 ||| JJ
media  ||| S:5648 E:5654 ||| NNS
with  ||| S:5654 E:5669 ||| IN
affinity  ||| S:5669 E:5678 ||| NN
for  ||| S:5678 E:5682 ||| IN
PEDF  ||| S:5682 E:5697 ||| NNP
GAGs  ||| S:5697 E:5702 ||| NNP
and  ||| S:5702 E:5706 ||| CC
polyanions  ||| S:5706 E:5717 ||| NN
in  ||| S:5717 E:5720 ||| IN
the  ||| S:5720 E:5724 ||| DT
CM  ||| S:5724 E:5727 ||| NNP
were  ||| S:5727 E:5732 ||| VBD
fractionated  ||| S:5732 E:5745 ||| VBN
by  ||| S:5745 E:5758 ||| IN
anion-exchange  ||| S:5758 E:5773 ||| JJ
column  ||| S:5773 E:5780 ||| NN
chromatography  ||| S:5780 E:5795 ||| VBZ
followed  ||| S:5795 E:5804 ||| VBN
by  ||| S:5804 E:5817 ||| IN
PEDF-affinity  ||| S:5817 E:5831 ||| JJ
column  ||| S:5831 E:5838 ||| NN
chromatography  ||| S:5838 E:5853 ||| NNS
( ||| S:5853 E:5854 ||| -LRB-
Fig.  ||| S:5854 E:5859 ||| CD
2 ||| S:5859 E:5860 ||| CD
) ||| S:5860 E:5861 ||| -RRB-
.  ||| S:5861 E:5863 ||| .
The  ||| S:5863 E:5867 ||| DT
GAG  ||| S:5867 E:5881 ||| NNP
content  ||| S:5881 E:5889 ||| NN
was  ||| S:5889 E:5893 ||| VBD
followed  ||| S:5893 E:5902 ||| VBN
by  ||| S:5902 E:5905 ||| IN
staining  ||| S:5905 E:5914 ||| NN
with  ||| S:5914 E:5919 ||| IN
Toluidine  ||| S:5919 E:5929 ||| NNP
Blue-O  ||| S:5929 E:5946 ||| NNP
( ||| S:5946 E:5947 ||| -LRB-
Fig.  ||| S:5947 E:5952 ||| NNP
2C ||| S:5952 E:5954 ||| NNP
, ||| S:5954 E:5955 ||| ,
2D ||| S:5955 E:5957 ||| NNP
, ||| S:5957 E:5958 ||| ,
2E ||| S:5958 E:5960 ||| CD
) ||| S:5960 E:5961 ||| -RRB-
.  ||| S:5961 E:5963 ||| .
The  ||| S:5963 E:5967 ||| DT
final  ||| S:5967 E:5973 ||| JJ
fraction  ||| S:5973 E:5982 ||| NN
( ||| S:5982 E:5983 ||| -LRB-
CM  ||| S:5983 E:5986 ||| NNP
PEDF ||| S:5986 E:5990 ||| NNP
)  ||| S:5990 E:5992 ||| -RRB-
contained  ||| S:5992 E:6012 ||| VBD
components  ||| S:6012 E:6023 ||| NNS
with  ||| S:6023 E:6028 ||| IN
binding  ||| S:6028 E:6036 ||| JJ
affinity  ||| S:6036 E:6045 ||| NN
for  ||| S:6045 E:6049 ||| IN
PEDF  ||| S:6049 E:6054 ||| NNP
that  ||| S:6054 E:6059 ||| IN
stained  ||| S:6059 E:6077 ||| NN
with  ||| S:6077 E:6082 ||| IN
Toluidine  ||| S:6082 E:6092 ||| NNP
Blue-O  ||| S:6092 E:6099 ||| NNP
and  ||| S:6099 E:6103 ||| CC
migrated  ||| S:6103 E:6112 ||| NN
as  ||| S:6112 E:6115 ||| IN
high  ||| S:6115 E:6120 ||| JJ
molecular  ||| S:6120 E:6140 ||| JJ
weight  ||| S:6140 E:6147 ||| NN
GAGs ||| S:6147 E:6151 ||| NN
.  ||| S:6151 E:6163 ||| .
To  ||| S:6163 E:6166 ||| TO
determine  ||| S:6166 E:6176 ||| VB
the  ||| S:6176 E:6180 ||| DT
type  ||| S:6180 E:6185 ||| NN
of  ||| S:6185 E:6188 ||| IN
sulfated  ||| S:6188 E:6197 ||| JJ
GAG  ||| S:6197 E:6201 ||| NN
in  ||| S:6201 E:6204 ||| IN
the  ||| S:6204 E:6208 ||| DT
media ||| S:6208 E:6213 ||| NNS
,  ||| S:6213 E:6215 ||| ,
we  ||| S:6215 E:6228 ||| PRP
designed  ||| S:6228 E:6237 ||| VBD
a  ||| S:6237 E:6239 ||| DT
spectrophotometric  ||| S:6239 E:6258 ||| JJ
assay  ||| S:6258 E:6264 ||| NNS
using  ||| S:6264 E:6270 ||| VBG
heparinase  ||| S:6270 E:6281 ||| NNS
and  ||| S:6281 E:6295 ||| CC
heparitinase ||| S:6295 E:6307 ||| NN
,  ||| S:6307 E:6309 ||| ,
specific  ||| S:6309 E:6318 ||| JJ
degrading  ||| S:6318 E:6328 ||| JJ
enzymes  ||| S:6328 E:6336 ||| NN
for  ||| S:6336 E:6340 ||| IN
heparin  ||| S:6340 E:6348 ||| NN
and  ||| S:6348 E:6362 ||| CC
HS ||| S:6362 E:6364 ||| NNP
,  ||| S:6364 E:6366 ||| ,
respectively  ||| S:6366 E:6379 ||| RB
( ||| S:6379 E:6380 ||| -LRB-
Fig.  ||| S:6380 E:6385 ||| CD
3 ||| S:6385 E:6386 ||| CD
) ||| S:6386 E:6387 ||| -RRB-
.  ||| S:6387 E:6389 ||| .
The  ||| S:6389 E:6393 ||| DT
activities  ||| S:6393 E:6404 ||| NNS
of  ||| S:6404 E:6407 ||| IN
both  ||| S:6407 E:6412 ||| DT
GAG  ||| S:6412 E:6426 ||| NNP
lyases  ||| S:6426 E:6433 ||| VBD
reached  ||| S:6433 E:6441 ||| VBN
a  ||| S:6441 E:6443 ||| DT
plateau  ||| S:6443 E:6451 ||| NN
by  ||| S:6451 E:6454 ||| IN
one  ||| S:6454 E:6458 ||| CD
hour  ||| S:6458 E:6463 ||| NN
of  ||| S:6463 E:6466 ||| IN
incubation  ||| S:6466 E:6477 ||| NNS
( ||| S:6477 E:6478 ||| -LRB-
Figs.  ||| S:6478 E:6494 ||| NNP
3A ||| S:6494 E:6496 ||| NNP
, ||| S:6496 E:6497 ||| ,
3C ||| S:6497 E:6499 ||| CD
)  ||| S:6499 E:6501 ||| -RRB-
and  ||| S:6501 E:6505 ||| CC
the  ||| S:6505 E:6509 ||| DT
degradation  ||| S:6509 E:6521 ||| NN
of  ||| S:6521 E:6524 ||| IN
GAG  ||| S:6524 E:6528 ||| NNP
substrates  ||| S:6528 E:6539 ||| NN
between  ||| S:6539 E:6547 ||| IN
0-30  ||| S:6547 E:6562 ||| CD
μg  ||| S:6562 E:6565 ||| NNS
was  ||| S:6565 E:6569 ||| VBD
linear ||| S:6569 E:6575 ||| VBN
.  ||| S:6575 E:6577 ||| .
Both  ||| S:6577 E:6582 ||| DT
CM  ||| S:6582 E:6585 ||| NNP
and  ||| S:6585 E:6589 ||| CC
CM  ||| S:6589 E:6592 ||| NNP
PEDFcontained  ||| S:6592 E:6606 ||| JJ
substrates  ||| S:6606 E:6627 ||| NN
for  ||| S:6627 E:6631 ||| IN
heparinase  ||| S:6631 E:6642 ||| NN
and  ||| S:6642 E:6646 ||| CC
heparitinase  ||| S:6646 E:6659 ||| NNS
( ||| S:6659 E:6660 ||| -LRB-
Figs.  ||| S:6660 E:6666 ||| NNP
3B ||| S:6666 E:6668 ||| NNP
, ||| S:6668 E:6669 ||| ,
3D ||| S:6669 E:6671 ||| CD
) ||| S:6671 E:6672 ||| -RRB-
.  ||| S:6672 E:6674 ||| .
The  ||| S:6674 E:6678 ||| DT
amount  ||| S:6678 E:6695 ||| NN
of  ||| S:6695 E:6698 ||| IN
GAGs  ||| S:6698 E:6703 ||| NNP
was  ||| S:6703 E:6707 ||| VBD
determined  ||| S:6707 E:6718 ||| VBN
by  ||| S:6718 E:6721 ||| IN
comparison  ||| S:6721 E:6732 ||| NN
of  ||| S:6732 E:6735 ||| IN
the  ||| S:6735 E:6739 ||| DT
amount  ||| S:6739 E:6746 ||| NN
of  ||| S:6746 E:6749 ||| IN
Δ  ||| S:6749 E:6761 ||| NNP
4-hexuronate  ||| S:6761 E:6774 ||| NNP
produced  ||| S:6774 E:6783 ||| VBD
with  ||| S:6783 E:6788 ||| IN
CM  ||| S:6788 E:6791 ||| NNP
samples  ||| S:6791 E:6799 ||| NNS
to  ||| S:6799 E:6802 ||| TO
the  ||| S:6802 E:6806 ||| DT
standard  ||| S:6806 E:6825 ||| JJ
curves  ||| S:6825 E:6832 ||| NN
with  ||| S:6832 E:6837 ||| IN
commercial  ||| S:6837 E:6848 ||| JJ
GAGs ||| S:6848 E:6852 ||| NN
.  ||| S:6852 E:6854 ||| .
The  ||| S:6854 E:6858 ||| DT
estimated  ||| S:6858 E:6868 ||| JJ
content  ||| S:6868 E:6876 ||| NN
of  ||| S:6876 E:6889 ||| IN
GAGs  ||| S:6889 E:6894 ||| JJ
in  ||| S:6894 E:6897 ||| IN
CM  ||| S:6897 E:6900 ||| NNP
varied  ||| S:6900 E:6907 ||| VBD
between  ||| S:6907 E:6915 ||| IN
12.4-22.7  ||| S:6915 E:6925 ||| CD
μg ||| S:6925 E:6927 ||| CD
/ ||| S:6927 E:6928 ||| CD
ml  ||| S:6928 E:6931 ||| NN
for  ||| S:6931 E:6935 ||| IN
heparin  ||| S:6935 E:6943 ||| NN
and  ||| S:6943 E:6957 ||| CC
between  ||| S:6957 E:6965 ||| IN
9-10  ||| S:6965 E:6970 ||| CD
μg ||| S:6970 E:6972 ||| CD
/ ||| S:6972 E:6973 ||| CD
ml  ||| S:6973 E:6976 ||| NN
for  ||| S:6976 E:6980 ||| IN
HS-like  ||| S:6980 E:6988 ||| JJ
molecules ||| S:6988 E:6997 ||| NNS
,  ||| S:6997 E:6999 ||| ,
among  ||| S:6999 E:7005 ||| IN
media  ||| S:7005 E:7021 ||| NNS
conditioned  ||| S:7021 E:7033 ||| VBN
by  ||| S:7033 E:7036 ||| IN
three  ||| S:7036 E:7042 ||| CD
different  ||| S:7042 E:7052 ||| JJ
batches  ||| S:7052 E:7060 ||| NNS
of  ||| S:7060 E:7063 ||| IN
Y-79  ||| S:7063 E:7068 ||| CD
cells ||| S:7068 E:7073 ||| NNS
.  ||| S:7073 E:7075 ||| .
The  ||| S:7075 E:7089 ||| DT
estimated  ||| S:7089 E:7099 ||| JJ
GAG  ||| S:7099 E:7103 ||| NNP
content  ||| S:7103 E:7111 ||| NN
in  ||| S:7111 E:7114 ||| IN
CM  ||| S:7114 E:7117 ||| NNP
PEDFranged  ||| S:7117 E:7128 ||| FW
0.2-1.8  ||| S:7128 E:7136 ||| FW
μg ||| S:7136 E:7138 ||| FW
/ ||| S:7138 E:7139 ||| FW
μl  ||| S:7139 E:7142 ||| FW
and  ||| S:7142 E:7156 ||| CC
0.1-0.4  ||| S:7156 E:7164 ||| CD
μg ||| S:7164 E:7166 ||| CD
/ ||| S:7166 E:7167 ||| CD
μl  ||| S:7167 E:7170 ||| NN
for  ||| S:7170 E:7174 ||| IN
heparin  ||| S:7174 E:7182 ||| NN
and  ||| S:7182 E:7186 ||| CC
HS ||| S:7186 E:7188 ||| NNP
,  ||| S:7188 E:7190 ||| ,
respectively ||| S:7190 E:7202 ||| RB
.  ||| S:7202 E:7204 ||| .
Similar  ||| S:7204 E:7222 ||| JJ
assays  ||| S:7222 E:7229 ||| NN
were  ||| S:7229 E:7234 ||| VBD
followed  ||| S:7234 E:7243 ||| VBN
with  ||| S:7243 E:7248 ||| IN
chondroitinase  ||| S:7248 E:7263 ||| JJ
ABC ||| S:7263 E:7266 ||| NNP
,  ||| S:7266 E:7268 ||| ,
but  ||| S:7268 E:7272 ||| CC
its  ||| S:7272 E:7286 ||| PRP$
substrates ||| S:7286 E:7296 ||| NN
,  ||| S:7296 E:7298 ||| ,
ΔDi4S ||| S:7298 E:7303 ||| NNP
,  ||| S:7303 E:7305 ||| ,
dermatan  ||| S:7305 E:7314 ||| NN
and  ||| S:7314 E:7318 ||| CC
ΔDi6S ||| S:7318 E:7323 ||| NNP
,  ||| S:7323 E:7325 ||| ,
in  ||| S:7325 E:7328 ||| IN
CM  ||| S:7328 E:7331 ||| NNP
were  ||| S:7331 E:7336 ||| VBD
below  ||| S:7336 E:7352 ||| IN
detection  ||| S:7352 E:7362 ||| JJ
limits ||| S:7362 E:7368 ||| NNS
.  ||| S:7368 E:7370 ||| .
These  ||| S:7370 E:7376 ||| DT
results  ||| S:7376 E:7384 ||| NNS
demonstrated  ||| S:7384 E:7397 ||| VBN
that  ||| S:7397 E:7402 ||| IN
CM  ||| S:7402 E:7405 ||| NNP
and  ||| S:7405 E:7419 ||| CC
CM  ||| S:7419 E:7422 ||| NNP
PEDFcontained  ||| S:7422 E:7436 ||| NNP
heparin-  ||| S:7436 E:7445 ||| NNP
and  ||| S:7445 E:7449 ||| CC
HS-like  ||| S:7449 E:7457 ||| JJ
molecules ||| S:7457 E:7466 ||| NNS
,  ||| S:7466 E:7478 ||| ,
demonstrating  ||| S:7478 E:7492 ||| VBG
that  ||| S:7492 E:7497 ||| IN
Y-79  ||| S:7497 E:7502 ||| CD
cells  ||| S:7502 E:7508 ||| NNS
produced  ||| S:7508 E:7517 ||| VBD
GAGs  ||| S:7517 E:7522 ||| JJ
with  ||| S:7522 E:7527 ||| IN
binding  ||| S:7527 E:7545 ||| JJ
affinity  ||| S:7545 E:7554 ||| NN
for  ||| S:7554 E:7558 ||| IN
PEDF ||| S:7558 E:7562 ||| NNP
.  ||| S:7562 E:7592 ||| .
Media  ||| S:7592 E:7598 ||| NNS
conditioned  ||| S:7598 E:7610 ||| VBN
by  ||| S:7610 E:7613 ||| IN
retinoblastoma  ||| S:7613 E:7628 ||| NN
cells  ||| S:7628 E:7634 ||| NNS
enhances  ||| S:7634 E:7653 ||| VBZ
the  ||| S:7653 E:7657 ||| DT
125I-PEDF  ||| S:7657 E:7667 ||| JJ
binding  ||| S:7667 E:7675 ||| NN
to  ||| S:7675 E:7678 ||| TO
cell-surface  ||| S:7678 E:7691 ||| JJ
receptors  ||| S:7691 E:7711 ||| NNS
We  ||| S:7711 E:7714 ||| PRP
have  ||| S:7714 E:7719 ||| VBP
demonstrated  ||| S:7719 E:7732 ||| VBN
previously  ||| S:7732 E:7743 ||| RB
that  ||| S:7743 E:7748 ||| IN
biologically  ||| S:7748 E:7771 ||| JJ
active  ||| S:7771 E:7778 ||| JJ
125I-PEDF  ||| S:7778 E:7788 ||| NN
binds  ||| S:7788 E:7794 ||| VBZ
specifically ||| S:7794 E:7806 ||| RB
,  ||| S:7806 E:7808 ||| ,
competitively  ||| S:7808 E:7822 ||| RB
and  ||| S:7822 E:7836 ||| CC
with  ||| S:7836 E:7841 ||| IN
high  ||| S:7841 E:7846 ||| JJ
affinity  ||| S:7846 E:7855 ||| NN
to  ||| S:7855 E:7858 ||| TO
cell-surface  ||| S:7858 E:7871 ||| JJ
receptors  ||| S:7871 E:7881 ||| NNS
of  ||| S:7881 E:7884 ||| IN
Y-79  ||| S:7884 E:7899 ||| CD
cells  ||| S:7899 E:7905 ||| NNS
[  ||| S:7905 E:7907 ||| -LRB-
18  ||| S:7907 E:7910 ||| CD
]  ||| S:7910 E:7912 ||| -RRB-
.  ||| S:7912 E:7914 ||| .
Because  ||| S:7914 E:7922 ||| IN
the  ||| S:7922 E:7926 ||| DT
reaction  ||| S:7926 E:7935 ||| NN
conditions  ||| S:7935 E:7946 ||| NNS
were  ||| S:7946 E:7961 ||| VBD
identical  ||| S:7961 E:7971 ||| JJ
to  ||| S:7971 E:7974 ||| TO
those  ||| S:7974 E:7980 ||| DT
used  ||| S:7980 E:7985 ||| VBN
for  ||| S:7985 E:7989 ||| IN
biological  ||| S:7989 E:8000 ||| JJ
assays ||| S:8000 E:8006 ||| NN
,  ||| S:8006 E:8008 ||| ,
the  ||| S:8008 E:8022 ||| DT
binding  ||| S:8022 E:8030 ||| JJ
reactions  ||| S:8030 E:8040 ||| NNS
were  ||| S:8040 E:8045 ||| VBD
performed  ||| S:8045 E:8055 ||| VBN
in  ||| S:8055 E:8058 ||| IN
the  ||| S:8058 E:8062 ||| DT
presence  ||| S:8062 E:8071 ||| NN
of  ||| S:8071 E:8074 ||| IN
media  ||| S:8074 E:8090 ||| NNS
conditioned  ||| S:8090 E:8102 ||| VBN
by  ||| S:8102 E:8105 ||| IN
the  ||| S:8105 E:8109 ||| DT
cells  ||| S:8109 E:8115 ||| NNS
for  ||| S:8115 E:8119 ||| IN
16  ||| S:8119 E:8122 ||| CD
hours  ||| S:8122 E:8128 ||| NNS
( ||| S:8128 E:8129 ||| -LRB-
CM ||| S:8129 E:8131 ||| NNP
) ||| S:8131 E:8132 ||| -RRB-
.  ||| S:8132 E:8134 ||| .
We  ||| S:8134 E:8147 ||| PRP
investigated  ||| S:8147 E:8160 ||| VBD
the  ||| S:8160 E:8164 ||| DT
effect  ||| S:8164 E:8171 ||| NN
of  ||| S:8171 E:8174 ||| IN
components  ||| S:8174 E:8185 ||| NNS
of  ||| S:8185 E:8188 ||| IN
the  ||| S:8188 E:8192 ||| DT
CM ||| S:8192 E:8194 ||| NNP
,  ||| S:8194 E:8196 ||| ,
a  ||| S:8196 E:8198 ||| DT
source  ||| S:8198 E:8215 ||| NN
of  ||| S:8215 E:8218 ||| IN
extracellular  ||| S:8218 E:8232 ||| JJ
matrix ||| S:8232 E:8238 ||| NN
,  ||| S:8238 E:8240 ||| ,
on  ||| S:8240 E:8243 ||| IN
the  ||| S:8243 E:8247 ||| DT
PEDF-receptor  ||| S:8247 E:8271 ||| JJ
interactions  ||| S:8271 E:8284 ||| NNS
using  ||| S:8284 E:8290 ||| VBG
CM  ||| S:8290 E:8293 ||| NNP
and  ||| S:8293 E:8297 ||| CC
non-conditioned  ||| S:8297 E:8313 ||| JJ
defined  ||| S:8313 E:8321 ||| JJ
media  ||| S:8321 E:8337 ||| NNS
in  ||| S:8337 E:8340 ||| IN
radioligand  ||| S:8340 E:8352 ||| JJ
binding  ||| S:8352 E:8360 ||| JJ
assays ||| S:8360 E:8366 ||| NN
.  ||| S:8366 E:8368 ||| .
Comparison  ||| S:8368 E:8379 ||| NN
of  ||| S:8379 E:8382 ||| IN
reactions  ||| S:8382 E:8392 ||| NNS
in  ||| S:8392 E:8405 ||| IN
the  ||| S:8405 E:8409 ||| DT
absence  ||| S:8409 E:8417 ||| NN
and  ||| S:8417 E:8421 ||| CC
presence  ||| S:8421 E:8430 ||| NN
of  ||| S:8430 E:8433 ||| IN
CM  ||| S:8433 E:8436 ||| NNP
showed  ||| S:8436 E:8443 ||| VBD
that  ||| S:8443 E:8448 ||| IN
the  ||| S:8448 E:8452 ||| DT
specific  ||| S:8452 E:8471 ||| JJ
PEDF-binding  ||| S:8471 E:8484 ||| JJ
to  ||| S:8484 E:8487 ||| TO
Y-79  ||| S:8487 E:8492 ||| CD
cell-surface  ||| S:8492 E:8505 ||| JJ
receptors  ||| S:8505 E:8515 ||| NNS
was  ||| S:8515 E:8519 ||| VBD
6.8-fold  ||| S:8519 E:8538 ||| CD
higher  ||| S:8538 E:8545 ||| JJR
with  ||| S:8545 E:8550 ||| IN
conditioned  ||| S:8550 E:8562 ||| JJ
medium  ||| S:8562 E:8569 ||| NN
than  ||| S:8569 E:8574 ||| IN
with  ||| S:8574 E:8579 ||| IN
defined  ||| S:8579 E:8587 ||| JJ
medium  ||| S:8587 E:8604 ||| NN
( ||| S:8604 E:8605 ||| -LRB-
Fig.  ||| S:8605 E:8610 ||| CD
4 ||| S:8610 E:8611 ||| CD
) ||| S:8611 E:8612 ||| -RRB-
.  ||| S:8612 E:8614 ||| .
Note  ||| S:8614 E:8619 ||| NN
that  ||| S:8619 E:8624 ||| IN
with  ||| S:8624 E:8629 ||| IN
the  ||| S:8629 E:8633 ||| DT
binding  ||| S:8633 E:8641 ||| JJ
method  ||| S:8641 E:8648 ||| NN
used ||| S:8648 E:8652 ||| VBN
,  ||| S:8652 E:8654 ||| ,
the  ||| S:8654 E:8668 ||| DT
amount  ||| S:8668 E:8675 ||| NN
of  ||| S:8675 E:8678 ||| IN
125I-PEDF  ||| S:8678 E:8688 ||| NNP
retained  ||| S:8688 E:8697 ||| VBD
in  ||| S:8697 E:8700 ||| IN
CM  ||| S:8700 E:8703 ||| NNP
without  ||| S:8703 E:8711 ||| IN
cells  ||| S:8711 E:8717 ||| NNS
is  ||| S:8717 E:8720 ||| VBZ
the  ||| S:8720 E:8734 ||| DT
same  ||| S:8734 E:8739 ||| JJ
to  ||| S:8739 E:8742 ||| TO
the  ||| S:8742 E:8746 ||| DT
amount  ||| S:8746 E:8753 ||| NN
of  ||| S:8753 E:8756 ||| IN
non-specific  ||| S:8756 E:8769 ||| JJ
125I-PEDF  ||| S:8769 E:8779 ||| CD
binding  ||| S:8779 E:8797 ||| NNS
( ||| S:8797 E:8798 ||| -LRB-
reactions  ||| S:8798 E:8808 ||| NNS
with  ||| S:8808 E:8813 ||| IN
cells  ||| S:8813 E:8819 ||| NNS
and  ||| S:8819 E:8823 ||| CC
in  ||| S:8823 E:8826 ||| IN
the  ||| S:8826 E:8830 ||| DT
presence  ||| S:8830 E:8839 ||| NN
of  ||| S:8839 E:8842 ||| IN
50-fold  ||| S:8842 E:8860 ||| CD
molar  ||| S:8860 E:8866 ||| JJ
excess  ||| S:8866 E:8873 ||| NN
of  ||| S:8873 E:8876 ||| IN
unlabeled  ||| S:8876 E:8886 ||| JJ
PEDF ||| S:8886 E:8890 ||| NNP
)  ||| S:8890 E:8892 ||| -RRB-
[  ||| S:8892 E:8894 ||| -LRB-
18  ||| S:8894 E:8897 ||| CD
]  ||| S:8897 E:8899 ||| -RRB-
,  ||| S:8899 E:8901 ||| ,
indicating  ||| S:8901 E:8922 ||| VBG
retention  ||| S:8922 E:8932 ||| NN
by  ||| S:8932 E:8935 ||| IN
PEI-treated  ||| S:8935 E:8947 ||| JJ
glass-fiber  ||| S:8947 E:8959 ||| JJ
filters  ||| S:8959 E:8967 ||| NNS
of  ||| S:8967 E:8980 ||| IN
PEDF-receptor  ||| S:8980 E:8994 ||| JJ
or  ||| S:8994 E:8997 ||| CC
GAG-PEDF-receptor  ||| S:8997 E:9015 ||| JJ
complexes  ||| S:9015 E:9025 ||| NNS
rather  ||| S:9025 E:9032 ||| RB
than  ||| S:9032 E:9047 ||| IN
PEDF-GAG ||| S:9047 E:9055 ||| JJ
.  ||| S:9055 E:9057 ||| .
Similar  ||| S:9057 E:9065 ||| JJ
results  ||| S:9065 E:9073 ||| NNS
were  ||| S:9073 E:9078 ||| VBD
obtained  ||| S:9078 E:9087 ||| VBN
when  ||| S:9087 E:9092 ||| WRB
the  ||| S:9092 E:9106 ||| DT
cell-bound  ||| S:9106 E:9117 ||| JJ
125I-PEDF  ||| S:9117 E:9127 ||| NN
was  ||| S:9127 E:9131 ||| VBD
separated  ||| S:9131 E:9141 ||| VBN
by  ||| S:9141 E:9144 ||| IN
centrifugation ||| S:9144 E:9158 ||| NN
,  ||| S:9158 E:9170 ||| ,
rather  ||| S:9170 E:9177 ||| RB
than  ||| S:9177 E:9182 ||| IN
filtration  ||| S:9182 E:9193 ||| NN
through  ||| S:9193 E:9201 ||| IN
glass-fiber  ||| S:9201 E:9213 ||| JJ
filters ||| S:9213 E:9220 ||| NNS
,  ||| S:9220 E:9222 ||| ,
and  ||| S:9222 E:9236 ||| CC
comparing  ||| S:9236 E:9246 ||| VBG
reactions  ||| S:9246 E:9256 ||| NNS
with  ||| S:9256 E:9261 ||| IN
CM  ||| S:9261 E:9264 ||| NNP
versus  ||| S:9264 E:9271 ||| CC
those  ||| S:9271 E:9277 ||| DT
with  ||| S:9277 E:9282 ||| IN
1 ||| S:9282 E:9283 ||| CD
%  ||| S:9283 E:9285 ||| NN
BSA  ||| S:9285 E:9289 ||| NN
in  ||| S:9289 E:9302 ||| IN
PBS  ||| S:9302 E:9306 ||| NNP
( ||| S:9306 E:9307 ||| -LRB-
data  ||| S:9307 E:9312 ||| NNS
not  ||| S:9312 E:9316 ||| RB
shown ||| S:9316 E:9321 ||| VBN
) ||| S:9321 E:9322 ||| -RRB-
.  ||| S:9322 E:9324 ||| .
These  ||| S:9324 E:9330 ||| DT
observations  ||| S:9330 E:9343 ||| NNS
showed  ||| S:9343 E:9350 ||| VBD
that  ||| S:9350 E:9355 ||| IN
a  ||| S:9355 E:9367 ||| DT
component ||| S:9367 E:9376 ||| NN
( ||| S:9376 E:9377 ||| -LRB-
s ||| S:9377 E:9378 ||| LS
)  ||| S:9378 E:9380 ||| -RRB-
secreted  ||| S:9380 E:9389 ||| NN
by  ||| S:9389 E:9392 ||| IN
retinoblastoma  ||| S:9392 E:9407 ||| NN
cells  ||| S:9407 E:9413 ||| NNS
enhanced  ||| S:9413 E:9432 ||| VBN
the  ||| S:9432 E:9436 ||| DT
PEDF-receptor  ||| S:9436 E:9450 ||| JJ
interactions ||| S:9450 E:9462 ||| NNS
.  ||| S:9462 E:9492 ||| .
Effect  ||| S:9492 E:9499 ||| NN
of  ||| S:9499 E:9502 ||| IN
GAG  ||| S:9502 E:9506 ||| NNP
lyases  ||| S:9506 E:9513 ||| NN
and  ||| S:9513 E:9517 ||| CC
chlorate  ||| S:9517 E:9526 ||| NN
on  ||| S:9526 E:9529 ||| IN
125I-PEDF  ||| S:9529 E:9549 ||| CD
binding  ||| S:9549 E:9557 ||| NN
to  ||| S:9557 E:9560 ||| TO
cell-surface  ||| S:9560 E:9573 ||| JJ
receptors  ||| S:9573 E:9593 ||| NNS
To  ||| S:9593 E:9596 ||| TO
deplete  ||| S:9596 E:9604 ||| VB
the  ||| S:9604 E:9608 ||| DT
Y-79  ||| S:9608 E:9613 ||| JJ
cell  ||| S:9613 E:9618 ||| NN
cultures  ||| S:9618 E:9627 ||| NNS
of  ||| S:9627 E:9630 ||| IN
HS  ||| S:9630 E:9633 ||| NNP
and  ||| S:9633 E:9647 ||| CC
heparin-like  ||| S:9647 E:9660 ||| JJ
GAGs ||| S:9660 E:9664 ||| NN
,  ||| S:9664 E:9666 ||| ,
we  ||| S:9666 E:9669 ||| PRP
used  ||| S:9669 E:9674 ||| VBD
heparitinase  ||| S:9674 E:9687 ||| JJ
and  ||| S:9687 E:9691 ||| CC
heparinase ||| S:9691 E:9701 ||| NN
,  ||| S:9701 E:9713 ||| ,
respectively ||| S:9713 E:9725 ||| RB
.  ||| S:9725 E:9727 ||| .
The  ||| S:9727 E:9731 ||| DT
cultures  ||| S:9731 E:9740 ||| NNS
were  ||| S:9740 E:9745 ||| VBD
pretreated  ||| S:9745 E:9756 ||| VBN
with  ||| S:9756 E:9761 ||| IN
each  ||| S:9761 E:9766 ||| DT
GAG  ||| S:9766 E:9780 ||| NNP
lyase  ||| S:9780 E:9786 ||| NN
before  ||| S:9786 E:9793 ||| IN
using  ||| S:9793 E:9799 ||| VBG
them  ||| S:9799 E:9804 ||| PRP
in  ||| S:9804 E:9807 ||| IN
radioligand  ||| S:9807 E:9819 ||| JJ
binding  ||| S:9819 E:9827 ||| JJ
assays ||| S:9827 E:9833 ||| NN
.  ||| S:9833 E:9845 ||| .
The  ||| S:9845 E:9849 ||| DT
morphology  ||| S:9849 E:9860 ||| NN
and  ||| S:9860 E:9864 ||| CC
viability  ||| S:9864 E:9874 ||| NN
of  ||| S:9874 E:9877 ||| IN
the  ||| S:9877 E:9881 ||| DT
cells  ||| S:9881 E:9887 ||| NNS
were  ||| S:9887 E:9892 ||| VBD
not  ||| S:9892 E:9906 ||| RB
affected  ||| S:9906 E:9915 ||| VBN
with  ||| S:9915 E:9920 ||| IN
the  ||| S:9920 E:9924 ||| DT
GAG  ||| S:9924 E:9928 ||| NNP
lyase  ||| S:9928 E:9934 ||| NN
treatments ||| S:9934 E:9944 ||| NNS
.  ||| S:9944 E:9946 ||| .
Figure  ||| S:9946 E:9953 ||| NN
5Ashows  ||| S:9953 E:9971 ||| NN
that  ||| S:9971 E:9976 ||| IN
specific  ||| S:9976 E:9985 ||| JJ
125I-PEDF  ||| S:9985 E:9995 ||| CD
binding  ||| S:9995 E:10003 ||| NNS
decreased  ||| S:10003 E:10013 ||| VBD
significantly  ||| S:10013 E:10037 ||| RB
in  ||| S:10037 E:10040 ||| IN
heparitinase  ||| S:10040 E:10053 ||| JJ
treated  ||| S:10053 E:10061 ||| JJ
cultures  ||| S:10061 E:10070 ||| NNS
compared  ||| S:10070 E:10079 ||| VBN
to  ||| S:10079 E:10082 ||| TO
untreated  ||| S:10082 E:10102 ||| VB
controls ||| S:10102 E:10110 ||| NNS
,  ||| S:10110 E:10112 ||| ,
and  ||| S:10112 E:10116 ||| CC
less  ||| S:10116 E:10121 ||| RBR
drastically  ||| S:10121 E:10133 ||| RB
in  ||| S:10133 E:10136 ||| IN
heparinase  ||| S:10136 E:10147 ||| JJ
treated  ||| S:10147 E:10165 ||| JJ
ones ||| S:10165 E:10169 ||| NNS
.  ||| S:10169 E:10171 ||| .
Hyaluronidase  ||| S:10171 E:10185 ||| JJ
treatment  ||| S:10185 E:10195 ||| NN
to  ||| S:10195 E:10198 ||| TO
deplete  ||| S:10198 E:10206 ||| VB
the  ||| S:10206 E:10210 ||| DT
cultures  ||| S:10210 E:10219 ||| NNS
of  ||| S:10219 E:10232 ||| IN
hyaluronan  ||| S:10232 E:10243 ||| NN
did  ||| S:10243 E:10247 ||| VBD
not  ||| S:10247 E:10251 ||| RB
have  ||| S:10251 E:10256 ||| VB
an  ||| S:10256 E:10259 ||| DT
effect  ||| S:10259 E:10266 ||| NN
on  ||| S:10266 E:10269 ||| IN
the  ||| S:10269 E:10273 ||| DT
binding ||| S:10273 E:10280 ||| NN
.  ||| S:10280 E:10282 ||| .
These  ||| S:10282 E:10298 ||| DT
results  ||| S:10298 E:10306 ||| NNS
demonstrated  ||| S:10306 E:10319 ||| VBD
that  ||| S:10319 E:10324 ||| DT
removal  ||| S:10324 E:10332 ||| NN
of  ||| S:10332 E:10335 ||| IN
heparin ||| S:10335 E:10342 ||| JJ
/ ||| S:10342 E:10343 ||| NNP
HS  ||| S:10343 E:10346 ||| NNP
from  ||| S:10346 E:10351 ||| IN
the  ||| S:10351 E:10365 ||| DT
cell  ||| S:10365 E:10370 ||| NN
cultures  ||| S:10370 E:10379 ||| NNS
decreased  ||| S:10379 E:10389 ||| VBD
the  ||| S:10389 E:10393 ||| DT
PEDF  ||| S:10393 E:10398 ||| NNP
binding  ||| S:10398 E:10406 ||| VBD
to  ||| S:10406 E:10409 ||| TO
receptors  ||| S:10409 E:10419 ||| VB
on  ||| S:10419 E:10432 ||| IN
Y-79  ||| S:10432 E:10437 ||| CD
cells ||| S:10437 E:10442 ||| NNS
.  ||| S:10442 E:10444 ||| .
Chlorate  ||| S:10444 E:10453 ||| NNP
is  ||| S:10453 E:10456 ||| VBZ
a  ||| S:10456 E:10458 ||| DT
competitive  ||| S:10458 E:10470 ||| JJ
inhibitor  ||| S:10470 E:10480 ||| NN
of  ||| S:10480 E:10493 ||| IN
ATP-sulfurylase ||| S:10493 E:10508 ||| NNP
,  ||| S:10508 E:10510 ||| ,
and  ||| S:10510 E:10514 ||| CC
inhibition  ||| S:10514 E:10525 ||| NN
of  ||| S:10525 E:10528 ||| IN
GAG  ||| S:10528 E:10532 ||| NNP
sulfation  ||| S:10532 E:10542 ||| NN
in  ||| S:10542 E:10545 ||| IN
cell  ||| S:10545 E:10560 ||| NN
cultures  ||| S:10560 E:10569 ||| NNS
can  ||| S:10569 E:10573 ||| MD
be  ||| S:10573 E:10576 ||| VB
achieved  ||| S:10576 E:10585 ||| VBN
by  ||| S:10585 E:10588 ||| IN
pretreatment  ||| S:10588 E:10601 ||| NN
of  ||| S:10601 E:10604 ||| IN
the  ||| S:10604 E:10608 ||| DT
cultures  ||| S:10608 E:10627 ||| NNS
with  ||| S:10627 E:10632 ||| IN
30  ||| S:10632 E:10635 ||| CD
mM  ||| S:10635 E:10638 ||| JJ
sodium  ||| S:10638 E:10645 ||| NN
chlorate  ||| S:10645 E:10654 ||| NNS
[  ||| S:10654 E:10656 ||| -LRB-
21  ||| S:10656 E:10659 ||| CD
]  ||| S:10659 E:10661 ||| -RRB-
.  ||| S:10661 E:10663 ||| .
The  ||| S:10663 E:10667 ||| DT
effect  ||| S:10667 E:10674 ||| NN
of  ||| S:10674 E:10687 ||| IN
undersulfated  ||| S:10687 E:10701 ||| JJ
GAGs  ||| S:10701 E:10706 ||| NN
on  ||| S:10706 E:10709 ||| IN
the  ||| S:10709 E:10713 ||| DT
PEDF  ||| S:10713 E:10718 ||| NNP
binding  ||| S:10718 E:10726 ||| VBD
to  ||| S:10726 E:10729 ||| TO
its  ||| S:10729 E:10733 ||| PRP$
receptor  ||| S:10733 E:10752 ||| NN
was  ||| S:10752 E:10756 ||| VBD
examined ||| S:10756 E:10764 ||| VBN
.  ||| S:10764 E:10766 ||| .
Cells  ||| S:10766 E:10772 ||| NNS
pretreated  ||| S:10772 E:10783 ||| VBN
with  ||| S:10783 E:10788 ||| IN
sodium  ||| S:10788 E:10795 ||| JJ
chlorate  ||| S:10795 E:10804 ||| NN
did  ||| S:10804 E:10818 ||| VBD
not  ||| S:10818 E:10822 ||| RB
show  ||| S:10822 E:10827 ||| VB
changes  ||| S:10827 E:10835 ||| NNS
in  ||| S:10835 E:10838 ||| IN
viability  ||| S:10838 E:10848 ||| NN
or  ||| S:10848 E:10851 ||| CC
morphology ||| S:10851 E:10861 ||| NNS
;  ||| S:10861 E:10863 ||| :
however ||| S:10863 E:10870 ||| RB
,  ||| S:10870 E:10872 ||| ,
the  ||| S:10872 E:10886 ||| DT
treatment  ||| S:10886 E:10896 ||| NN
resulted  ||| S:10896 E:10905 ||| VBD
in  ||| S:10905 E:10908 ||| IN
a  ||| S:10908 E:10910 ||| DT
decrease  ||| S:10910 E:10919 ||| NN
in  ||| S:10919 E:10922 ||| IN
the  ||| S:10922 E:10926 ||| DT
specific  ||| S:10926 E:10945 ||| JJ
125I-PEDF  ||| S:10945 E:10955 ||| NN
binding  ||| S:10955 E:10963 ||| VBG
to  ||| S:10963 E:10966 ||| TO
about  ||| S:10966 E:10972 ||| RB
35 ||| S:10972 E:10974 ||| CD
%  ||| S:10974 E:10976 ||| NN
relative  ||| S:10976 E:10985 ||| JJ
to  ||| S:10985 E:10988 ||| TO
untreated  ||| S:10988 E:11008 ||| VB
controls  ||| S:11008 E:11017 ||| NNS
( ||| S:11017 E:11018 ||| -LRB-
Fig.  ||| S:11018 E:11023 ||| NNP
5B ||| S:11023 E:11025 ||| NNP
) ||| S:11025 E:11026 ||| -RRB-
.  ||| S:11026 E:11028 ||| .
Sodium  ||| S:11028 E:11035 ||| JJ
sulfate  ||| S:11035 E:11043 ||| NN
was  ||| S:11043 E:11047 ||| VBD
used  ||| S:11047 E:11052 ||| VBN
to  ||| S:11052 E:11055 ||| TO
recover  ||| S:11055 E:11073 ||| VB
the  ||| S:11073 E:11077 ||| DT
loss  ||| S:11077 E:11082 ||| NN
of  ||| S:11082 E:11085 ||| IN
GAG  ||| S:11085 E:11089 ||| NNP
sulfation  ||| S:11089 E:11099 ||| NN
by  ||| S:11099 E:11102 ||| IN
chlorate  ||| S:11102 E:11111 ||| NNS
increasing  ||| S:11111 E:11122 ||| VBG
the  ||| S:11122 E:11136 ||| DT
binding  ||| S:11136 E:11144 ||| JJ
to  ||| S:11144 E:11147 ||| TO
55 ||| S:11147 E:11149 ||| CD
%  ||| S:11149 E:11151 ||| NN
maximal  ||| S:11151 E:11159 ||| NN
with  ||| S:11159 E:11164 ||| IN
10  ||| S:11164 E:11167 ||| CD
mM  ||| S:11167 E:11170 ||| JJ
sulfate  ||| S:11170 E:11178 ||| JJ
additions ||| S:11178 E:11187 ||| NNS
.  ||| S:11187 E:11189 ||| .
The  ||| S:11189 E:11203 ||| DT
data  ||| S:11203 E:11208 ||| NNS
revealed  ||| S:11208 E:11217 ||| VBD
that  ||| S:11217 E:11222 ||| DT
inhibition  ||| S:11222 E:11233 ||| NN
of  ||| S:11233 E:11236 ||| IN
sulfation  ||| S:11236 E:11246 ||| NN
of  ||| S:11246 E:11249 ||| IN
GAGs  ||| S:11249 E:11264 ||| NNP
reduced  ||| S:11264 E:11272 ||| VBD
the  ||| S:11272 E:11276 ||| DT
PEDF  ||| S:11276 E:11281 ||| NNP
binding  ||| S:11281 E:11289 ||| VBD
to  ||| S:11289 E:11292 ||| TO
cell-surface  ||| S:11292 E:11305 ||| JJ
receptors  ||| S:11305 E:11315 ||| NNS
of  ||| S:11315 E:11328 ||| IN
Y-79  ||| S:11328 E:11333 ||| CD
cells ||| S:11333 E:11338 ||| NNS
,  ||| S:11338 E:11340 ||| ,
with  ||| S:11340 E:11345 ||| IN
about  ||| S:11345 E:11351 ||| IN
20 ||| S:11351 E:11353 ||| CD
%  ||| S:11353 E:11355 ||| NN
of  ||| S:11355 E:11358 ||| IN
specific  ||| S:11358 E:11367 ||| JJ
inhibition ||| S:11367 E:11377 ||| NN
.  ||| S:11377 E:11379 ||| .
Thus ||| S:11379 E:11383 ||| RB
,  ||| S:11383 E:11395 ||| ,
these  ||| S:11395 E:11401 ||| DT
observations  ||| S:11401 E:11414 ||| NNS
implied  ||| S:11414 E:11422 ||| VBN
that  ||| S:11422 E:11427 ||| IN
HS ||| S:11427 E:11429 ||| NNP
/ ||| S:11429 E:11430 ||| NNP
heparin  ||| S:11430 E:11438 ||| NN
might  ||| S:11438 E:11444 ||| MD
play  ||| S:11444 E:11449 ||| VB
a  ||| S:11449 E:11461 ||| DT
functional  ||| S:11461 E:11472 ||| JJ
role  ||| S:11472 E:11477 ||| NN
in  ||| S:11477 E:11480 ||| IN
the  ||| S:11480 E:11484 ||| DT
binding  ||| S:11484 E:11492 ||| NN
of  ||| S:11492 E:11495 ||| IN
PEDF  ||| S:11495 E:11500 ||| NNP
to  ||| S:11500 E:11503 ||| TO
its  ||| S:11503 E:11517 ||| PRP$
cell-surface  ||| S:11517 E:11530 ||| JJ
receptor ||| S:11530 E:11538 ||| NN
.  ||| S:11538 E:11571 ||| .
Discussion  ||| S:11571 E:11590 ||| NN
It  ||| S:11590 E:11593 ||| PRP
has  ||| S:11593 E:11597 ||| VBZ
been  ||| S:11597 E:11602 ||| VBN
proposed  ||| S:11602 E:11611 ||| VBN
that  ||| S:11611 E:11616 ||| IN
the  ||| S:11616 E:11620 ||| DT
GAG-binding  ||| S:11620 E:11632 ||| JJ
property  ||| S:11632 E:11641 ||| NN
of  ||| S:11641 E:11652 ||| IN
PEDF  ||| S:11652 E:11657 ||| NNP
provides  ||| S:11657 E:11666 ||| VBZ
the  ||| S:11666 E:11670 ||| DT
molecular  ||| S:11670 E:11680 ||| JJ
basis  ||| S:11680 E:11686 ||| NN
for  ||| S:11686 E:11690 ||| IN
its  ||| S:11690 E:11694 ||| PRP$
association  ||| S:11694 E:11706 ||| NN
with  ||| S:11706 E:11719 ||| IN
extracellular  ||| S:11719 E:11733 ||| JJ
matrices  ||| S:11733 E:11742 ||| NN
and  ||| S:11742 E:11746 ||| CC
may  ||| S:11746 E:11750 ||| MD
serve  ||| S:11750 E:11756 ||| VB
to  ||| S:11756 E:11759 ||| TO
localize  ||| S:11759 E:11768 ||| VB
PEDF  ||| S:11768 E:11781 ||| JJ
activity  ||| S:11781 E:11790 ||| NN
in  ||| S:11790 E:11793 ||| IN
the  ||| S:11793 E:11797 ||| DT
retina  ||| S:11797 E:11804 ||| NN
and  ||| S:11804 E:11808 ||| CC
CNS  ||| S:11808 E:11812 ||| NNP
[  ||| S:11812 E:11814 ||| -LRB-
14  ||| S:11814 E:11817 ||| CD
19  ||| S:11817 E:11820 ||| CD
]  ||| S:11820 E:11822 ||| -RRB-
.  ||| S:11822 E:11824 ||| .
However ||| S:11824 E:11831 ||| RB
,  ||| S:11831 E:11833 ||| ,
the  ||| S:11833 E:11845 ||| DT
present  ||| S:11845 E:11853 ||| JJ
results  ||| S:11853 E:11861 ||| NNS
point  ||| S:11861 E:11867 ||| VBP
to  ||| S:11867 E:11870 ||| TO
direct  ||| S:11870 E:11877 ||| JJ
effects  ||| S:11877 E:11885 ||| NNS
these  ||| S:11885 E:11899 ||| DT
polysaccharides  ||| S:11899 E:11915 ||| NN
might  ||| S:11915 E:11921 ||| MD
have  ||| S:11921 E:11926 ||| VB
on  ||| S:11926 E:11929 ||| IN
the  ||| S:11929 E:11933 ||| DT
biochemical  ||| S:11933 E:11945 ||| JJ
interactions  ||| S:11945 E:11966 ||| NNS
between  ||| S:11966 E:11974 ||| IN
PEDF  ||| S:11974 E:11979 ||| NNP
and  ||| S:11979 E:11983 ||| CC
PEDF  ||| S:11983 E:11988 ||| NNP
receptors  ||| S:11988 E:11998 ||| NNS
on  ||| S:11998 E:12001 ||| IN
the  ||| S:12001 E:12005 ||| DT
surfaces  ||| S:12005 E:12014 ||| NN
of  ||| S:12014 E:12017 ||| IN
cells  ||| S:12017 E:12031 ||| NNS
that  ||| S:12031 E:12036 ||| WDT
respond  ||| S:12036 E:12044 ||| VBP
to  ||| S:12044 E:12047 ||| TO
this  ||| S:12047 E:12052 ||| DT
neurotrophic  ||| S:12052 E:12065 ||| JJ
factor ||| S:12065 E:12071 ||| NN
.  ||| S:12071 E:12073 ||| .
We  ||| S:12073 E:12076 ||| PRP
have  ||| S:12076 E:12081 ||| VBP
shown  ||| S:12081 E:12095 ||| VBN
that  ||| S:12095 E:12100 ||| IN
the  ||| S:12100 E:12104 ||| DT
binding  ||| S:12104 E:12112 ||| NN
of  ||| S:12112 E:12115 ||| IN
PEDF  ||| S:12115 E:12120 ||| NNP
to  ||| S:12120 E:12123 ||| TO
receptors  ||| S:12123 E:12133 ||| VB
in  ||| S:12133 E:12136 ||| IN
retinoblastoma  ||| S:12136 E:12159 ||| NN
cells  ||| S:12159 E:12165 ||| NNS
is  ||| S:12165 E:12168 ||| VBZ
enhanced  ||| S:12168 E:12177 ||| VBN
by  ||| S:12177 E:12180 ||| IN
the  ||| S:12180 E:12184 ||| DT
presence  ||| S:12184 E:12193 ||| NN
of  ||| S:12193 E:12196 ||| IN
extracellular  ||| S:12196 E:12218 ||| FW
heparin ||| S:12218 E:12225 ||| FW
/ ||| S:12225 E:12226 ||| FW
HS-like  ||| S:12226 E:12234 ||| FW
GAGs ||| S:12234 E:12238 ||| FW
,  ||| S:12238 E:12240 ||| ,
which  ||| S:12240 E:12246 ||| WDT
can  ||| S:12246 E:12250 ||| MD
be  ||| S:12250 E:12253 ||| VB
found  ||| S:12253 E:12259 ||| VBN
in  ||| S:12259 E:12262 ||| IN
the  ||| S:12262 E:12266 ||| DT
culture  ||| S:12266 E:12282 ||| NN
medium  ||| S:12282 E:12289 ||| NN
of  ||| S:12289 E:12292 ||| IN
retinoblastoma  ||| S:12292 E:12307 ||| NN
cells ||| S:12307 E:12312 ||| NNS
.  ||| S:12312 E:12314 ||| .
The  ||| S:12314 E:12318 ||| DT
fact  ||| S:12318 E:12323 ||| NN
that  ||| S:12323 E:12328 ||| IN
the  ||| S:12328 E:12332 ||| DT
binding  ||| S:12332 E:12348 ||| NN
of  ||| S:12348 E:12351 ||| IN
PEDF  ||| S:12351 E:12356 ||| NNP
to  ||| S:12356 E:12359 ||| TO
cell  ||| S:12359 E:12364 ||| VB
surfaces  ||| S:12364 E:12373 ||| JJ
decreases  ||| S:12373 E:12383 ||| NNS
with  ||| S:12383 E:12388 ||| IN
heparin ||| S:12388 E:12395 ||| JJ
/ ||| S:12395 E:12396 ||| NNP
HS  ||| S:12396 E:12407 ||| NNP
depletion ||| S:12407 E:12416 ||| NN
,  ||| S:12416 E:12418 ||| ,
implies  ||| S:12418 E:12426 ||| VBZ
that  ||| S:12426 E:12431 ||| DT
heparin ||| S:12431 E:12438 ||| JJ
/ ||| S:12438 E:12439 ||| NNP
HS  ||| S:12439 E:12442 ||| NNP
molecules  ||| S:12442 E:12452 ||| NNS
might  ||| S:12452 E:12458 ||| MD
act  ||| S:12458 E:12462 ||| VB
as  ||| S:12462 E:12473 ||| IN
cofactors  ||| S:12473 E:12483 ||| NN
for  ||| S:12483 E:12487 ||| IN
PEDF-receptor  ||| S:12487 E:12501 ||| JJ
interactions ||| S:12501 E:12513 ||| NNS
.  ||| S:12513 E:12515 ||| .
Interactions  ||| S:12515 E:12536 ||| NNS
between  ||| S:12536 E:12544 ||| IN
PEDF  ||| S:12544 E:12549 ||| NNP
and  ||| S:12549 E:12553 ||| CC
extracellular  ||| S:12553 E:12567 ||| JJ
GAGs  ||| S:12567 E:12572 ||| NN
can  ||| S:12572 E:12576 ||| MD
also  ||| S:12576 E:12581 ||| RB
explain  ||| S:12581 E:12589 ||| VB
the  ||| S:12589 E:12601 ||| DT
complex  ||| S:12601 E:12609 ||| NN
formed  ||| S:12609 E:12616 ||| VBN
by  ||| S:12616 E:12619 ||| IN
PEDF  ||| S:12619 E:12624 ||| NNP
with  ||| S:12624 E:12629 ||| IN
CM  ||| S:12629 E:12632 ||| NNP
even  ||| S:12632 E:12637 ||| RB
after  ||| S:12637 E:12643 ||| IN
protease  ||| S:12643 E:12660 ||| JJ
treatment  ||| S:12660 E:12670 ||| NN
of  ||| S:12670 E:12673 ||| IN
the  ||| S:12673 E:12677 ||| DT
latter ||| S:12677 E:12683 ||| NN
.  ||| S:12683 E:12685 ||| .
The  ||| S:12685 E:12689 ||| DT
PEDF-heparin ||| S:12689 E:12701 ||| JJ
/ ||| S:12701 E:12702 ||| NNP
HS  ||| S:12702 E:12705 ||| NNP
complex  ||| S:12705 E:12713 ||| NN
may  ||| S:12713 E:12725 ||| MD
somehow  ||| S:12725 E:12733 ||| RB
facilitate  ||| S:12733 E:12744 ||| VB
encounters  ||| S:12744 E:12755 ||| VBN
between  ||| S:12755 E:12763 ||| IN
PEDF  ||| S:12763 E:12768 ||| NNP
and  ||| S:12768 E:12772 ||| CC
its  ||| S:12772 E:12784 ||| PRP$
receptor ||| S:12784 E:12792 ||| NN
,  ||| S:12792 E:12803 ||| ,
e.g.  ||| S:12803 E:12808 ||| NNP
,  ||| S:12808 E:12810 ||| ,
by  ||| S:12810 E:12813 ||| IN
inducing  ||| S:12813 E:12822 ||| VBG
a  ||| S:12822 E:12824 ||| DT
conformational  ||| S:12824 E:12847 ||| JJ
change  ||| S:12847 E:12854 ||| NN
in  ||| S:12854 E:12857 ||| IN
PEDF ||| S:12857 E:12861 ||| NNP
,  ||| S:12861 E:12863 ||| ,
which  ||| S:12863 E:12869 ||| WDT
might  ||| S:12869 E:12875 ||| MD
accelerate  ||| S:12875 E:12886 ||| VB
the  ||| S:12886 E:12890 ||| DT
ligand-receptor  ||| S:12890 E:12914 ||| JJ
interactions ||| S:12914 E:12926 ||| NNS
.  ||| S:12926 E:12928 ||| .
In  ||| S:12928 E:12931 ||| IN
addition ||| S:12931 E:12939 ||| NN
,  ||| S:12939 E:12941 ||| ,
the  ||| S:12941 E:12945 ||| DT
receptor  ||| S:12945 E:12954 ||| NN
may  ||| S:12954 E:12958 ||| MD
also  ||| S:12958 E:12963 ||| RB
form  ||| S:12963 E:12968 ||| VB
a  ||| S:12968 E:12978 ||| DT
complex  ||| S:12978 E:12986 ||| NN
with  ||| S:12986 E:12991 ||| IN
heparin ||| S:12991 E:12998 ||| JJ
/ ||| S:12998 E:12999 ||| NNP
HS  ||| S:12999 E:13002 ||| NNP
to  ||| S:13002 E:13005 ||| TO
facilitate  ||| S:13005 E:13016 ||| VB
interactions  ||| S:13016 E:13029 ||| VBN
with  ||| S:13029 E:13034 ||| IN
the  ||| S:13034 E:13046 ||| DT
ligand ||| S:13046 E:13052 ||| NN
.  ||| S:13052 E:13062 ||| .
To  ||| S:13062 E:13065 ||| TO
our  ||| S:13065 E:13069 ||| PRP$
knowledge ||| S:13069 E:13078 ||| NN
,  ||| S:13078 E:13080 ||| ,
this  ||| S:13080 E:13085 ||| DT
is  ||| S:13085 E:13088 ||| VBZ
the  ||| S:13088 E:13092 ||| DT
first  ||| S:13092 E:13098 ||| JJ
report  ||| S:13098 E:13105 ||| NN
on  ||| S:13105 E:13108 ||| IN
the  ||| S:13108 E:13120 ||| DT
production  ||| S:13120 E:13131 ||| NN
of  ||| S:13131 E:13134 ||| IN
GAGs  ||| S:13134 E:13139 ||| JJ
by  ||| S:13139 E:13142 ||| IN
retinoblastoma  ||| S:13142 E:13157 ||| NN
cells ||| S:13157 E:13162 ||| NNS
.  ||| S:13162 E:13164 ||| .
We  ||| S:13164 E:13167 ||| PRP
found  ||| S:13167 E:13173 ||| VBD
that  ||| S:13173 E:13186 ||| IN
these  ||| S:13186 E:13192 ||| DT
cells  ||| S:13192 E:13198 ||| NNS
produce  ||| S:13198 E:13206 ||| VBP
HS ||| S:13206 E:13208 ||| NNP
/ ||| S:13208 E:13209 ||| NNP
heparin  ||| S:13209 E:13217 ||| VBD
secreted  ||| S:13217 E:13226 ||| VBN
into  ||| S:13226 E:13231 ||| IN
the  ||| S:13231 E:13235 ||| DT
culturing  ||| S:13235 E:13253 ||| JJ
media ||| S:13253 E:13258 ||| NNS
.  ||| S:13258 E:13260 ||| .
The  ||| S:13260 E:13264 ||| DT
retina  ||| S:13264 E:13271 ||| NN
and  ||| S:13271 E:13275 ||| CC
malignant  ||| S:13275 E:13285 ||| JJ
solid  ||| S:13285 E:13291 ||| JJ
tumors  ||| S:13291 E:13298 ||| NNS
also  ||| S:13298 E:13303 ||| RB
produce  ||| S:13303 E:13319 ||| VB
the  ||| S:13319 E:13323 ||| DT
sulfated  ||| S:13323 E:13332 ||| JJ
GAGs  ||| S:13332 E:13337 ||| NN
[  ||| S:13337 E:13339 ||| -LRB-
1  ||| S:13339 E:13341 ||| CD
2  ||| S:13341 E:13343 ||| CD
22  ||| S:13343 E:13346 ||| CD
23  ||| S:13346 E:13349 ||| CD
24  ||| S:13349 E:13352 ||| CD
25  ||| S:13352 E:13355 ||| CD
26  ||| S:13355 E:13358 ||| CD
]  ||| S:13358 E:13360 ||| -RRB-
.  ||| S:13360 E:13362 ||| .
Although  ||| S:13362 E:13371 ||| IN
HSs  ||| S:13371 E:13375 ||| NNS
are  ||| S:13375 E:13387 ||| VBP
mostly  ||| S:13387 E:13394 ||| RB
found  ||| S:13394 E:13400 ||| VBN
as  ||| S:13400 E:13403 ||| IN
proteoglycans  ||| S:13403 E:13417 ||| VBG
associated  ||| S:13417 E:13428 ||| VBN
with  ||| S:13428 E:13433 ||| IN
the  ||| S:13433 E:13437 ||| DT
basal  ||| S:13437 E:13451 ||| JJ
lamina  ||| S:13451 E:13458 ||| NN
or  ||| S:13458 E:13461 ||| CC
the  ||| S:13461 E:13465 ||| DT
plasma  ||| S:13465 E:13472 ||| JJ
membrane ||| S:13472 E:13480 ||| NN
,  ||| S:13480 E:13482 ||| ,
the  ||| S:13482 E:13486 ||| DT
presence  ||| S:13486 E:13495 ||| NN
of  ||| S:13495 E:13498 ||| IN
HSs  ||| S:13498 E:13502 ||| JJ
in  ||| S:13502 E:13505 ||| IN
the  ||| S:13505 E:13517 ||| DT
culturing  ||| S:13517 E:13527 ||| JJ
medium  ||| S:13527 E:13534 ||| NN
might  ||| S:13534 E:13540 ||| MD
be  ||| S:13540 E:13543 ||| VB
a  ||| S:13543 E:13545 ||| DT
result  ||| S:13545 E:13552 ||| NN
of  ||| S:13552 E:13555 ||| IN
shedding  ||| S:13555 E:13564 ||| VBG
or  ||| S:13564 E:13567 ||| CC
release  ||| S:13567 E:13583 ||| NN
of  ||| S:13583 E:13586 ||| IN
their  ||| S:13586 E:13592 ||| PRP$
extracellular  ||| S:13592 E:13606 ||| JJ
domains  ||| S:13606 E:13614 ||| NN
from  ||| S:13614 E:13619 ||| IN
the  ||| S:13619 E:13623 ||| DT
cell  ||| S:13623 E:13628 ||| NN
membranes  ||| S:13628 E:13638 ||| NN
as  ||| S:13638 E:13649 ||| IN
soluble  ||| S:13649 E:13657 ||| JJ
components ||| S:13657 E:13667 ||| NNS
.  ||| S:13667 E:13669 ||| .
Cell-associated  ||| S:13669 E:13685 ||| NNP
HS  ||| S:13685 E:13688 ||| NNP
proteoglycans  ||| S:13688 E:13702 ||| NN
can  ||| S:13702 E:13714 ||| MD
undergo  ||| S:13714 E:13722 ||| VB
regulated  ||| S:13722 E:13732 ||| VBN
shedding  ||| S:13732 E:13741 ||| VBG
from  ||| S:13741 E:13746 ||| IN
the  ||| S:13746 E:13750 ||| DT
membrane  ||| S:13750 E:13759 ||| NN
into  ||| S:13759 E:13764 ||| IN
the  ||| S:13764 E:13776 ||| DT
soluble  ||| S:13776 E:13784 ||| JJ
extracellular  ||| S:13784 E:13798 ||| JJ
matrix  ||| S:13798 E:13805 ||| NN
or  ||| S:13805 E:13808 ||| CC
culturing  ||| S:13808 E:13818 ||| JJ
medium  ||| S:13818 E:13825 ||| NN
converting  ||| S:13825 E:13844 ||| VBG
the  ||| S:13844 E:13848 ||| DT
membrane  ||| S:13848 E:13857 ||| JJ
anchored  ||| S:13857 E:13866 ||| JJ
molecules  ||| S:13866 E:13876 ||| NNS
into  ||| S:13876 E:13881 ||| IN
soluble  ||| S:13881 E:13889 ||| JJ
effectors  ||| S:13889 E:13899 ||| NNS
[  ||| S:13899 E:13901 ||| -LRB-
1  ||| S:13901 E:13911 ||| CD
2  ||| S:13911 E:13913 ||| CD
]  ||| S:13913 E:13915 ||| -RRB-
.  ||| S:13915 E:13917 ||| .
In  ||| S:13917 E:13920 ||| IN
the  ||| S:13920 E:13924 ||| DT
conditioned  ||| S:13924 E:13936 ||| JJ
media  ||| S:13936 E:13942 ||| NNS
of  ||| S:13942 E:13945 ||| IN
all  ||| S:13945 E:13949 ||| PDT
the  ||| S:13949 E:13953 ||| DT
tested  ||| S:13953 E:13960 ||| JJ
batches  ||| S:13960 E:13968 ||| NNS
of  ||| S:13968 E:13979 ||| IN
retinoblastoma  ||| S:13979 E:13994 ||| NN
cells ||| S:13994 E:13999 ||| NNS
,  ||| S:13999 E:14001 ||| ,
we  ||| S:14001 E:14004 ||| PRP
detected  ||| S:14004 E:14013 ||| VBD
heparin  ||| S:14013 E:14021 ||| JJ
and  ||| S:14021 E:14025 ||| CC
HS  ||| S:14025 E:14028 ||| NNP
with  ||| S:14028 E:14041 ||| IN
binding  ||| S:14041 E:14049 ||| JJ
affinity  ||| S:14049 E:14058 ||| NN
for  ||| S:14058 E:14062 ||| IN
PEDF ||| S:14062 E:14066 ||| NNP
.  ||| S:14066 E:14068 ||| .
The  ||| S:14068 E:14072 ||| DT
estimated  ||| S:14072 E:14082 ||| JJ
concentrations  ||| S:14082 E:14097 ||| NNS
of  ||| S:14097 E:14108 ||| IN
these  ||| S:14108 E:14114 ||| DT
GAGs  ||| S:14114 E:14119 ||| JJ
in  ||| S:14119 E:14122 ||| IN
the  ||| S:14122 E:14126 ||| DT
media  ||| S:14126 E:14132 ||| NNS
may  ||| S:14132 E:14136 ||| MD
vary  ||| S:14136 E:14141 ||| VB
with  ||| S:14141 E:14146 ||| IN
cell  ||| S:14146 E:14151 ||| NN
density  ||| S:14151 E:14159 ||| NN
and  ||| S:14159 E:14171 ||| CC
conditioning  ||| S:14171 E:14184 ||| JJ
time ||| S:14184 E:14188 ||| NN
.  ||| S:14188 E:14190 ||| .
However ||| S:14190 E:14197 ||| RB
,  ||| S:14197 E:14199 ||| ,
under  ||| S:14199 E:14205 ||| IN
the  ||| S:14205 E:14209 ||| DT
conditions  ||| S:14209 E:14220 ||| NNS
used ||| S:14220 E:14224 ||| VBN
,  ||| S:14224 E:14226 ||| ,
they  ||| S:14226 E:14239 ||| PRP
were  ||| S:14239 E:14244 ||| VBD
within  ||| S:14244 E:14251 ||| IN
the  ||| S:14251 E:14255 ||| DT
linear  ||| S:14255 E:14262 ||| JJ
range  ||| S:14262 E:14268 ||| NN
of  ||| S:14268 E:14271 ||| IN
HS-PEDF  ||| S:14271 E:14279 ||| JJ
complex  ||| S:14279 E:14287 ||| JJ
formation  ||| S:14287 E:14297 ||| NN
(  ||| S:14297 E:14316 ||| -LRB-
EC  ||| S:14316 E:14328 ||| NNP
50  ||| S:14328 E:14331 ||| CD
=  ||| S:14331 E:14333 ||| SYM
40  ||| S:14333 E:14336 ||| CD
μg ||| S:14336 E:14338 ||| CD
/ ||| S:14338 E:14339 ||| CD
ml ||| S:14339 E:14341 ||| CD
)  ||| S:14341 E:14343 ||| -RRB-
[  ||| S:14343 E:14345 ||| -LRB-
14  ||| S:14345 E:14348 ||| CD
]  ||| S:14348 E:14350 ||| -RRB-
.  ||| S:14350 E:14360 ||| .
The  ||| S:14360 E:14364 ||| DT
fact  ||| S:14364 E:14369 ||| NN
that  ||| S:14369 E:14374 ||| IN
depletion  ||| S:14374 E:14384 ||| NN
of  ||| S:14384 E:14387 ||| IN
heparin ||| S:14387 E:14394 ||| CD
/ ||| S:14394 E:14395 ||| CD
HS-like  ||| S:14395 E:14403 ||| JJ
GAGs  ||| S:14403 E:14408 ||| NN
from  ||| S:14408 E:14413 ||| IN
the  ||| S:14413 E:14425 ||| DT
culturing  ||| S:14425 E:14435 ||| JJ
media  ||| S:14435 E:14441 ||| NNS
results  ||| S:14441 E:14449 ||| NNS
in  ||| S:14449 E:14452 ||| IN
inhibition  ||| S:14452 E:14463 ||| NN
of  ||| S:14463 E:14466 ||| IN
PEDF  ||| S:14466 E:14471 ||| NNP
binding  ||| S:14471 E:14479 ||| VBD
to  ||| S:14479 E:14490 ||| TO
cell  ||| S:14490 E:14495 ||| NN
surface  ||| S:14495 E:14503 ||| NN
receptors  ||| S:14503 E:14513 ||| NN
points  ||| S:14513 E:14520 ||| NNS
to  ||| S:14520 E:14523 ||| TO
functional  ||| S:14523 E:14534 ||| VB
roles  ||| S:14534 E:14540 ||| NNS
for  ||| S:14540 E:14544 ||| IN
these  ||| S:14544 E:14558 ||| DT
GAGs  ||| S:14558 E:14563 ||| JJ
such  ||| S:14563 E:14568 ||| JJ
as  ||| S:14568 E:14571 ||| IN
those  ||| S:14571 E:14577 ||| DT
of  ||| S:14577 E:14580 ||| IN
positive  ||| S:14580 E:14589 ||| JJ
modulators  ||| S:14589 E:14600 ||| NN
of  ||| S:14600 E:14603 ||| IN
PEDF-receptor  ||| S:14603 E:14625 ||| JJ
interactions ||| S:14625 E:14637 ||| NNS
.  ||| S:14637 E:14639 ||| .
In  ||| S:14639 E:14642 ||| IN
this  ||| S:14642 E:14647 ||| DT
regard ||| S:14647 E:14653 ||| NN
,  ||| S:14653 E:14655 ||| ,
we  ||| S:14655 E:14658 ||| PRP
observed  ||| S:14658 E:14667 ||| VBD
that  ||| S:14667 E:14672 ||| DT
depletion  ||| S:14672 E:14690 ||| NN
from  ||| S:14690 E:14695 ||| IN
the  ||| S:14695 E:14699 ||| DT
Y-79  ||| S:14699 E:14704 ||| JJ
cell  ||| S:14704 E:14709 ||| NN
cultures  ||| S:14709 E:14718 ||| NNS
of  ||| S:14718 E:14721 ||| IN
heparin  ||| S:14721 E:14729 ||| NN
with  ||| S:14729 E:14734 ||| IN
heparinase  ||| S:14734 E:14745 ||| NN
was  ||| S:14745 E:14757 ||| VBD
lower  ||| S:14757 E:14763 ||| JJR
than  ||| S:14763 E:14768 ||| IN
those  ||| S:14768 E:14774 ||| DT
depleted  ||| S:14774 E:14783 ||| NN
of  ||| S:14783 E:14786 ||| IN
HS  ||| S:14786 E:14789 ||| NNP
with  ||| S:14789 E:14794 ||| IN
heparitinase ||| S:14794 E:14806 ||| NN
,  ||| S:14806 E:14816 ||| ,
suggesting  ||| S:14816 E:14827 ||| VBG
that  ||| S:14827 E:14832 ||| IN
the  ||| S:14832 E:14836 ||| DT
retinoblastoma-derived  ||| S:14836 E:14859 ||| JJ
HS  ||| S:14859 E:14862 ||| NNP
was  ||| S:14862 E:14866 ||| VBD
more  ||| S:14866 E:14879 ||| RBR
effective  ||| S:14879 E:14889 ||| JJ
than  ||| S:14889 E:14894 ||| IN
the  ||| S:14894 E:14898 ||| DT
retinoblastoma-derived  ||| S:14898 E:14921 ||| JJ
heparin ||| S:14921 E:14928 ||| NN
.  ||| S:14928 E:14930 ||| .
This  ||| S:14930 E:14943 ||| DT
observation  ||| S:14943 E:14955 ||| NN
can  ||| S:14955 E:14959 ||| MD
be  ||| S:14959 E:14962 ||| VB
explained  ||| S:14962 E:14972 ||| VBN
by  ||| S:14972 E:14975 ||| IN
structural ||| S:14975 E:14985 ||| JJ
,  ||| S:14985 E:14987 ||| ,
compositional  ||| S:14987 E:15009 ||| NN
and  ||| S:15009 E:15013 ||| CC
functional  ||| S:15013 E:15024 ||| JJ
differences  ||| S:15024 E:15036 ||| NNS
between  ||| S:15036 E:15044 ||| IN
heparin  ||| S:15044 E:15052 ||| NN
and  ||| S:15052 E:15056 ||| CC
HS  ||| S:15056 E:15059 ||| NNP
GAGs ||| S:15059 E:15063 ||| NNP
.  ||| S:15063 E:15073 ||| .
GAG-binding  ||| S:15073 E:15085 ||| JJ
proteins  ||| S:15085 E:15094 ||| NNS
can  ||| S:15094 E:15098 ||| MD
be  ||| S:15098 E:15101 ||| VB
differentially  ||| S:15101 E:15116 ||| JJ
sensitive  ||| S:15116 E:15126 ||| JJ
to  ||| S:15126 E:15137 ||| TO
variations  ||| S:15137 E:15148 ||| NNS
in  ||| S:15148 E:15151 ||| IN
GAG  ||| S:15151 E:15155 ||| NNP
structure  ||| S:15155 E:15165 ||| NN
[  ||| S:15165 E:15167 ||| -LRB-
27  ||| S:15167 E:15170 ||| CD
]  ||| S:15170 E:15172 ||| -RRB-
.  ||| S:15172 E:15174 ||| .
GAGs  ||| S:15174 E:15179 ||| NNP
produced  ||| S:15179 E:15188 ||| VBD
among  ||| S:15188 E:15202 ||| IN
different  ||| S:15202 E:15212 ||| JJ
cell  ||| S:15212 E:15217 ||| NN
types  ||| S:15217 E:15223 ||| NNS
have  ||| S:15223 E:15228 ||| VBP
structural  ||| S:15228 E:15239 ||| JJ
and  ||| S:15239 E:15243 ||| CC
compositional  ||| S:15243 E:15265 ||| JJ
differences  ||| S:15265 E:15277 ||| NNS
and  ||| S:15277 E:15281 ||| CC
structural  ||| S:15281 E:15292 ||| JJ
changes  ||| S:15292 E:15300 ||| NNS
in  ||| S:15300 E:15303 ||| IN
GAGs  ||| S:15303 E:15308 ||| NNS
are  ||| S:15308 E:15312 ||| VBP
known  ||| S:15312 E:15318 ||| VBN
to  ||| S:15318 E:15329 ||| TO
occur  ||| S:15329 E:15335 ||| VB
in  ||| S:15335 E:15338 ||| IN
cells  ||| S:15338 E:15344 ||| NNS
undergoing  ||| S:15344 E:15355 ||| VBG
morphological  ||| S:15355 E:15369 ||| JJ
differentiation  ||| S:15369 E:15393 ||| NN
and ||| S:15393 E:15396 ||| CC
/ ||| S:15396 E:15397 ||| NNP
or  ||| S:15397 E:15400 ||| CC
malignant  ||| S:15400 E:15410 ||| JJ
transformations  ||| S:15410 E:15426 ||| NNS
[  ||| S:15426 E:15428 ||| -LRB-
28  ||| S:15428 E:15431 ||| CD
29  ||| S:15431 E:15434 ||| CD
30  ||| S:15434 E:15437 ||| CD
31  ||| S:15437 E:15440 ||| CD
]  ||| S:15440 E:15442 ||| -RRB-
.  ||| S:15442 E:15444 ||| .
Thus ||| S:15444 E:15448 ||| RB
,  ||| S:15448 E:15450 ||| ,
in  ||| S:15450 E:15461 ||| IN
the  ||| S:15461 E:15465 ||| DT
native  ||| S:15465 E:15472 ||| JJ
retina ||| S:15472 E:15478 ||| NN
,  ||| S:15478 E:15480 ||| ,
or  ||| S:15480 E:15483 ||| CC
other  ||| S:15483 E:15489 ||| JJ
tissue ||| S:15489 E:15495 ||| NN
,  ||| S:15495 E:15497 ||| ,
modulation  ||| S:15497 E:15508 ||| VBG
of  ||| S:15508 E:15511 ||| IN
the  ||| S:15511 E:15523 ||| DT
PEDF-receptor  ||| S:15523 E:15537 ||| JJ
interactions  ||| S:15537 E:15550 ||| NNS
may  ||| S:15550 E:15554 ||| MD
depend  ||| S:15554 E:15561 ||| VB
on  ||| S:15561 E:15564 ||| IN
the  ||| S:15564 E:15568 ||| DT
expression  ||| S:15568 E:15579 ||| NN
of  ||| S:15579 E:15590 ||| IN
GAGs ||| S:15590 E:15594 ||| NNP
,  ||| S:15594 E:15596 ||| ,
which  ||| S:15596 E:15602 ||| WDT
occur  ||| S:15602 E:15608 ||| VBP
during  ||| S:15608 E:15615 ||| IN
development  ||| S:15615 E:15627 ||| NN
and  ||| S:15627 E:15631 ||| CC
pathological  ||| S:15631 E:15652 ||| JJ
conditions ||| S:15652 E:15662 ||| NNS
.  ||| S:15662 E:15672 ||| .
Our  ||| S:15672 E:15676 ||| PRP$
data  ||| S:15676 E:15681 ||| NNS
offer  ||| S:15681 E:15687 ||| VBP
interesting  ||| S:15687 E:15699 ||| JJ
possibilities  ||| S:15699 E:15713 ||| NNS
of  ||| S:15713 E:15716 ||| IN
regulation  ||| S:15716 E:15735 ||| NN
of  ||| S:15735 E:15738 ||| IN
the  ||| S:15738 E:15742 ||| DT
activity  ||| S:15742 E:15751 ||| NN
of  ||| S:15751 E:15754 ||| IN
PEDF ||| S:15754 E:15758 ||| NNP
.  ||| S:15758 E:15760 ||| .
The  ||| S:15760 E:15764 ||| DT
ratio  ||| S:15764 E:15770 ||| NN
and  ||| S:15770 E:15774 ||| CC
amount  ||| S:15774 E:15781 ||| NN
of  ||| S:15781 E:15784 ||| IN
production  ||| S:15784 E:15803 ||| NN
of  ||| S:15803 E:15806 ||| IN
heparin  ||| S:15806 E:15814 ||| NN
and  ||| S:15814 E:15818 ||| CC
HS  ||| S:15818 E:15821 ||| NNP
by  ||| S:15821 E:15824 ||| IN
cells  ||| S:15824 E:15830 ||| NNS
bearing  ||| S:15830 E:15838 ||| VBG
PEDF  ||| S:15838 E:15843 ||| NNP
receptors  ||| S:15843 E:15853 ||| NNS
may  ||| S:15853 E:15857 ||| MD
be  ||| S:15857 E:15860 ||| VB
an  ||| S:15860 E:15871 ||| DT
important  ||| S:15871 E:15881 ||| JJ
mechanism  ||| S:15881 E:15891 ||| NN
to  ||| S:15891 E:15894 ||| TO
control  ||| S:15894 E:15902 ||| VB
the  ||| S:15902 E:15906 ||| DT
activity  ||| S:15906 E:15915 ||| NN
of  ||| S:15915 E:15918 ||| IN
PEDF  ||| S:15918 E:15923 ||| NNP
as  ||| S:15923 E:15926 ||| RB
is  ||| S:15926 E:15937 ||| VBZ
the  ||| S:15937 E:15941 ||| DT
modulation  ||| S:15941 E:15952 ||| NN
of  ||| S:15952 E:15955 ||| IN
the  ||| S:15955 E:15959 ||| DT
rate  ||| S:15959 E:15964 ||| NN
of  ||| S:15964 E:15967 ||| IN
expression  ||| S:15967 E:15978 ||| NN
of  ||| S:15978 E:15981 ||| IN
PEDF  ||| S:15981 E:15986 ||| NNP
receptors ||| S:15986 E:15995 ||| NNS
.  ||| S:15995 E:16005 ||| .
The  ||| S:16005 E:16009 ||| DT
data  ||| S:16009 E:16014 ||| NNS
obtained  ||| S:16014 E:16023 ||| VBD
so  ||| S:16023 E:16026 ||| RB
far  ||| S:16026 E:16030 ||| RB
on  ||| S:16030 E:16033 ||| IN
the  ||| S:16033 E:16037 ||| DT
action  ||| S:16037 E:16044 ||| NN
of  ||| S:16044 E:16047 ||| IN
PEDF  ||| S:16047 E:16052 ||| NNP
on  ||| S:16052 E:16055 ||| IN
different  ||| S:16055 E:16073 ||| JJ
cells  ||| S:16073 E:16079 ||| NNS
may  ||| S:16079 E:16083 ||| MD
have  ||| S:16083 E:16088 ||| VB
not  ||| S:16088 E:16092 ||| RB
considered  ||| S:16092 E:16103 ||| VBN
the  ||| S:16103 E:16107 ||| DT
presence  ||| S:16107 E:16116 ||| NN
of  ||| S:16116 E:16119 ||| IN
these  ||| S:16119 E:16133 ||| DT
cofactors  ||| S:16133 E:16143 ||| NN
in  ||| S:16143 E:16146 ||| IN
the  ||| S:16146 E:16150 ||| DT
media ||| S:16150 E:16155 ||| NNS
.  ||| S:16155 E:16157 ||| .
The  ||| S:16157 E:16161 ||| DT
binding  ||| S:16161 E:16169 ||| NN
of  ||| S:16169 E:16172 ||| IN
GAGs  ||| S:16172 E:16177 ||| JJ
to  ||| S:16177 E:16180 ||| TO
PEDF  ||| S:16180 E:16185 ||| NNP
that  ||| S:16185 E:16198 ||| WDT
modulate  ||| S:16198 E:16207 ||| VBP
the  ||| S:16207 E:16211 ||| DT
binding  ||| S:16211 E:16219 ||| NN
of  ||| S:16219 E:16222 ||| IN
these  ||| S:16222 E:16228 ||| DT
factors  ||| S:16228 E:16236 ||| NNS
to  ||| S:16236 E:16239 ||| TO
its  ||| S:16239 E:16243 ||| PRP$
receptor  ||| S:16243 E:16252 ||| NN
opens  ||| S:16252 E:16266 ||| VBZ
also  ||| S:16266 E:16271 ||| RB
the  ||| S:16271 E:16275 ||| DT
possibility  ||| S:16275 E:16287 ||| NN
that  ||| S:16287 E:16292 ||| IN
different  ||| S:16292 E:16302 ||| JJ
GAGs  ||| S:16302 E:16307 ||| NN
may  ||| S:16307 E:16311 ||| MD
modulate  ||| S:16311 E:16328 ||| VB
differently  ||| S:16328 E:16340 ||| RB
the  ||| S:16340 E:16344 ||| DT
affinity  ||| S:16344 E:16353 ||| NN
of  ||| S:16353 E:16356 ||| IN
PEDF  ||| S:16356 E:16361 ||| NNP
for  ||| S:16361 E:16365 ||| IN
its  ||| S:16365 E:16369 ||| PRP$
receptors ||| S:16369 E:16378 ||| NNS
,  ||| S:16378 E:16380 ||| ,
by  ||| S:16380 E:16391 ||| IN
increasing  ||| S:16391 E:16402 ||| VBG
or  ||| S:16402 E:16405 ||| CC
even  ||| S:16405 E:16410 ||| RB
decreasing  ||| S:16410 E:16421 ||| VBG
it  ||| S:16421 E:16424 ||| PRP
in  ||| S:16424 E:16427 ||| IN
some  ||| S:16427 E:16432 ||| DT
cases ||| S:16432 E:16437 ||| NNS
.  ||| S:16437 E:16439 ||| .
Finally ||| S:16439 E:16446 ||| RB
,  ||| S:16446 E:16456 ||| ,
the  ||| S:16456 E:16460 ||| DT
fact  ||| S:16460 E:16465 ||| NN
that  ||| S:16465 E:16470 ||| IN
the  ||| S:16470 E:16474 ||| DT
GAG  ||| S:16474 E:16478 ||| NNP
and  ||| S:16478 E:16482 ||| CC
receptor  ||| S:16482 E:16491 ||| JJ
binding  ||| S:16491 E:16499 ||| JJ
regions  ||| S:16499 E:16507 ||| NNS
are  ||| S:16507 E:16511 ||| VBP
on  ||| S:16511 E:16522 ||| IN
opposite  ||| S:16522 E:16531 ||| JJ
regions  ||| S:16531 E:16539 ||| NNS
of  ||| S:16539 E:16542 ||| IN
the  ||| S:16542 E:16546 ||| DT
PEDF  ||| S:16546 E:16551 ||| NNP
molecule ||| S:16551 E:16559 ||| NN
,  ||| S:16559 E:16561 ||| ,
suggest  ||| S:16561 E:16569 ||| VBP
the  ||| S:16569 E:16581 ||| DT
possibility  ||| S:16581 E:16593 ||| NN
of  ||| S:16593 E:16596 ||| IN
the  ||| S:16596 E:16600 ||| DT
existence  ||| S:16600 E:16610 ||| NN
of  ||| S:16610 E:16613 ||| IN
PEDF  ||| S:16613 E:16618 ||| NNP
mutants  ||| S:16618 E:16626 ||| NN
or  ||| S:16626 E:16629 ||| CC
engineered  ||| S:16629 E:16648 ||| JJ
variants  ||| S:16648 E:16657 ||| NN
that ||| S:16657 E:16661 ||| IN
,  ||| S:16661 E:16663 ||| ,
having  ||| S:16663 E:16670 ||| VBG
lost  ||| S:16670 E:16675 ||| VBN
or  ||| S:16675 E:16678 ||| CC
decreased  ||| S:16678 E:16688 ||| VBD
GAG-binding  ||| S:16688 E:16708 ||| JJ
capabilities ||| S:16708 E:16720 ||| NNS
,  ||| S:16720 E:16722 ||| ,
still  ||| S:16722 E:16728 ||| RB
show  ||| S:16728 E:16733 ||| VB
high  ||| S:16733 E:16738 ||| JJ
affinity  ||| S:16738 E:16747 ||| NN
for  ||| S:16747 E:16751 ||| IN
the  ||| S:16751 E:16755 ||| DT
PEDF  ||| S:16755 E:16768 ||| NNP
receptor  ||| S:16768 E:16777 ||| NN
in  ||| S:16777 E:16780 ||| IN
a  ||| S:16780 E:16782 ||| DT
way  ||| S:16782 E:16786 ||| NN
not  ||| S:16786 E:16790 ||| RB
dependent  ||| S:16790 E:16800 ||| JJ
upon  ||| S:16800 E:16805 ||| IN
GAGs  ||| S:16805 E:16810 ||| JJ
content  ||| S:16810 E:16818 ||| NN
or  ||| S:16818 E:16829 ||| CC
composition ||| S:16829 E:16840 ||| NN
.  ||| S:16840 E:16842 ||| .
These  ||| S:16842 E:16848 ||| DT
possibilities  ||| S:16848 E:16862 ||| NNS
are  ||| S:16862 E:16866 ||| VBP
discussed  ||| S:16866 E:16876 ||| VBN
under  ||| S:16876 E:16882 ||| IN
the  ||| S:16882 E:16894 ||| DT
consideration  ||| S:16894 E:16908 ||| NN
that  ||| S:16908 E:16913 ||| IN
some  ||| S:16913 E:16918 ||| DT
of  ||| S:16918 E:16921 ||| IN
them  ||| S:16921 E:16926 ||| PRP
may  ||| S:16926 E:16930 ||| MD
have  ||| S:16930 E:16935 ||| VB
important  ||| S:16935 E:16953 ||| JJ
implications  ||| S:16953 E:16966 ||| NNS
if  ||| S:16966 E:16969 ||| IN
PEDF ||| S:16969 E:16973 ||| NNP
,  ||| S:16973 E:16975 ||| ,
or  ||| S:16975 E:16978 ||| CC
molecules  ||| S:16978 E:16988 ||| NNS
derived  ||| S:16988 E:16996 ||| VBN
from  ||| S:16996 E:17001 ||| IN
it ||| S:17001 E:17003 ||| PRP
,  ||| S:17003 E:17005 ||| ,
are  ||| S:17005 E:17009 ||| VBP
to  ||| S:17009 E:17020 ||| TO
be  ||| S:17020 E:17023 ||| VB
used  ||| S:17023 E:17028 ||| VBN
in  ||| S:17028 E:17031 ||| IN
the  ||| S:17031 E:17035 ||| DT
future  ||| S:17035 E:17042 ||| NN
as  ||| S:17042 E:17045 ||| IN
therapeutic  ||| S:17045 E:17057 ||| JJ
agents ||| S:17057 E:17063 ||| NNS
.  ||| S:17063 E:17073 ||| .
The  ||| S:17073 E:17077 ||| DT
primary  ||| S:17077 E:17085 ||| JJ
consequence  ||| S:17085 E:17097 ||| NN
of  ||| S:17097 E:17100 ||| IN
reducing  ||| S:17100 E:17109 ||| VBG
the  ||| S:17109 E:17113 ||| DT
heparin ||| S:17113 E:17120 ||| JJ
/ ||| S:17120 E:17121 ||| NNP
HS  ||| S:17121 E:17124 ||| NNP
and  ||| S:17124 E:17136 ||| CC
its  ||| S:17136 E:17140 ||| PRP$
sulfation  ||| S:17140 E:17150 ||| NN
was  ||| S:17150 E:17154 ||| VBD
to  ||| S:17154 E:17157 ||| TO
minimize  ||| S:17157 E:17166 ||| VB
a  ||| S:17166 E:17168 ||| DT
binding  ||| S:17168 E:17176 ||| JJ
site  ||| S:17176 E:17181 ||| NN
required  ||| S:17181 E:17190 ||| VBN
for  ||| S:17190 E:17202 ||| IN
PEDF  ||| S:17202 E:17207 ||| NNP
activity ||| S:17207 E:17215 ||| NN
.  ||| S:17215 E:17217 ||| .
Although  ||| S:17217 E:17226 ||| IN
GAGs  ||| S:17226 E:17231 ||| JJ
store  ||| S:17231 E:17237 ||| NN
PEDF  ||| S:17237 E:17242 ||| NN
in  ||| S:17242 E:17245 ||| IN
the  ||| S:17245 E:17257 ||| DT
extracellular  ||| S:17257 E:17271 ||| JJ
matrix  ||| S:17271 E:17278 ||| NNS
[  ||| S:17278 E:17280 ||| -LRB-
14  ||| S:17280 E:17283 ||| CD
]  ||| S:17283 E:17285 ||| -RRB-
,  ||| S:17285 E:17287 ||| ,
a  ||| S:17287 E:17289 ||| DT
more  ||| S:17289 E:17294 ||| RBR
direct  ||| S:17294 E:17301 ||| JJ
mechanism  ||| S:17301 E:17319 ||| NN
appears  ||| S:17319 E:17327 ||| VBZ
necessary ||| S:17327 E:17336 ||| JJ
,  ||| S:17336 E:17338 ||| ,
namely ||| S:17338 E:17344 ||| RB
,  ||| S:17344 E:17346 ||| ,
its  ||| S:17346 E:17350 ||| PRP$
participation  ||| S:17350 E:17364 ||| NN
in  ||| S:17364 E:17367 ||| IN
the  ||| S:17367 E:17371 ||| DT
binding  ||| S:17371 E:17387 ||| NN
of  ||| S:17387 E:17390 ||| IN
PEDF  ||| S:17390 E:17395 ||| NNP
to  ||| S:17395 E:17398 ||| TO
its  ||| S:17398 E:17402 ||| PRP$
receptor ||| S:17402 E:17410 ||| NN
.  ||| S:17410 E:17412 ||| .
In  ||| S:17412 E:17415 ||| IN
a  ||| S:17415 E:17417 ||| DT
spatial  ||| S:17417 E:17425 ||| JJ
structure  ||| S:17425 E:17435 ||| NN
of  ||| S:17435 E:17438 ||| IN
PEDF ||| S:17438 E:17442 ||| NNP
,  ||| S:17442 E:17452 ||| ,
the  ||| S:17452 E:17456 ||| DT
heparin ||| S:17456 E:17463 ||| JJ
/ ||| S:17463 E:17464 ||| NNP
HS  ||| S:17464 E:17467 ||| NNP
binding  ||| S:17467 E:17475 ||| JJ
domain  ||| S:17475 E:17482 ||| NN
of  ||| S:17482 E:17485 ||| IN
PEDF  ||| S:17485 E:17490 ||| NNP
maps  ||| S:17490 E:17495 ||| NNS
to  ||| S:17495 E:17498 ||| TO
the  ||| S:17498 E:17502 ||| DT
opposite  ||| S:17502 E:17519 ||| JJ
side  ||| S:17519 E:17524 ||| NN
of  ||| S:17524 E:17527 ||| IN
the  ||| S:17527 E:17531 ||| DT
neurotrophic  ||| S:17531 E:17544 ||| JJ
active  ||| S:17544 E:17551 ||| JJ
region  ||| S:17551 E:17558 ||| NN
[  ||| S:17558 E:17560 ||| -LRB-
20  ||| S:17560 E:17563 ||| CD
]  ||| S:17563 E:17565 ||| -RRB-
,  ||| S:17565 E:17567 ||| ,
allowing  ||| S:17567 E:17584 ||| VBG
distinct  ||| S:17584 E:17593 ||| JJ
and  ||| S:17593 E:17597 ||| CC
non-overlapping  ||| S:17597 E:17613 ||| JJ
interactions  ||| S:17613 E:17626 ||| NNS
with  ||| S:17626 E:17631 ||| IN
heparin ||| S:17631 E:17638 ||| JJ
/ ||| S:17638 E:17639 ||| NNP
HS  ||| S:17639 E:17650 ||| NNP
on  ||| S:17650 E:17653 ||| IN
one  ||| S:17653 E:17657 ||| CD
side  ||| S:17657 E:17662 ||| NN
of  ||| S:17662 E:17665 ||| IN
the  ||| S:17665 E:17669 ||| DT
protein ||| S:17669 E:17676 ||| NN
,  ||| S:17676 E:17678 ||| ,
and  ||| S:17678 E:17682 ||| CC
with  ||| S:17682 E:17687 ||| IN
the  ||| S:17687 E:17691 ||| DT
neurotrophic  ||| S:17691 E:17712 ||| JJ
receptor  ||| S:17712 E:17721 ||| NN
on  ||| S:17721 E:17724 ||| IN
its  ||| S:17724 E:17728 ||| PRP$
opposite  ||| S:17728 E:17737 ||| JJ
side ||| S:17737 E:17741 ||| NN
.  ||| S:17741 E:17743 ||| .
Our  ||| S:17743 E:17747 ||| PRP$
data  ||| S:17747 E:17752 ||| NNS
suggest  ||| S:17752 E:17760 ||| VBP
that  ||| S:17760 E:17765 ||| IN
the  ||| S:17765 E:17777 ||| DT
intrinsic  ||| S:17777 E:17787 ||| JJ
affinity  ||| S:17787 E:17796 ||| NN
of  ||| S:17796 E:17799 ||| IN
the  ||| S:17799 E:17803 ||| DT
cell  ||| S:17803 E:17808 ||| NN
surface  ||| S:17808 E:17816 ||| NN
receptor  ||| S:17816 E:17825 ||| NN
for  ||| S:17825 E:17829 ||| IN
PEDF  ||| S:17829 E:17842 ||| NNP
appears  ||| S:17842 E:17850 ||| VBZ
low ||| S:17850 E:17853 ||| JJ
,  ||| S:17853 E:17855 ||| ,
whereas  ||| S:17855 E:17863 ||| IN
the  ||| S:17863 E:17867 ||| DT
heparin ||| S:17867 E:17874 ||| JJ
/ ||| S:17874 E:17875 ||| CD
HS-PEDF  ||| S:17875 E:17883 ||| JJ
complex  ||| S:17883 E:17891 ||| NN
is  ||| S:17891 E:17902 ||| VBZ
recognized  ||| S:17902 E:17913 ||| VBN
with  ||| S:17913 E:17918 ||| IN
high  ||| S:17918 E:17923 ||| JJ
affinity ||| S:17923 E:17931 ||| NN
.  ||| S:17931 E:17933 ||| .
In  ||| S:17933 E:17936 ||| IN
addition ||| S:17936 E:17944 ||| NN
,  ||| S:17944 E:17946 ||| ,
a  ||| S:17946 E:17948 ||| DT
direct  ||| S:17948 E:17963 ||| JJ
interaction  ||| S:17963 E:17975 ||| NN
between  ||| S:17975 E:17983 ||| IN
the  ||| S:17983 E:17987 ||| DT
receptor  ||| S:17987 E:17996 ||| NN
and  ||| S:17996 E:18000 ||| CC
GAGs  ||| S:18000 E:18005 ||| NNP
may  ||| S:18005 E:18009 ||| MD
also  ||| S:18009 E:18014 ||| RB
be  ||| S:18014 E:18025 ||| VB
necessary ||| S:18025 E:18034 ||| JJ
.  ||| S:18034 E:18036 ||| .
Although  ||| S:18036 E:18045 ||| IN
details  ||| S:18045 E:18053 ||| NNS
of  ||| S:18053 E:18056 ||| IN
the  ||| S:18056 E:18060 ||| DT
mechanism  ||| S:18060 E:18070 ||| NN
remain  ||| S:18070 E:18077 ||| VBP
to  ||| S:18077 E:18080 ||| TO
be  ||| S:18080 E:18091 ||| VB
revealed ||| S:18091 E:18099 ||| VBN
,  ||| S:18099 E:18101 ||| ,
it  ||| S:18101 E:18104 ||| PRP
is  ||| S:18104 E:18107 ||| VBZ
clear  ||| S:18107 E:18113 ||| JJ
that  ||| S:18113 E:18118 ||| IN
heparin ||| S:18118 E:18125 ||| JJ
/ ||| S:18125 E:18126 ||| NNP
HS  ||| S:18126 E:18129 ||| NNP
is  ||| S:18129 E:18132 ||| VBZ
required  ||| S:18132 E:18141 ||| VBN
for  ||| S:18141 E:18145 ||| IN
the  ||| S:18145 E:18157 ||| DT
first  ||| S:18157 E:18163 ||| JJ
step  ||| S:18163 E:18168 ||| NN
of  ||| S:18168 E:18171 ||| IN
the  ||| S:18171 E:18175 ||| DT
neurotrophic  ||| S:18175 E:18188 ||| JJ
activity  ||| S:18188 E:18197 ||| NN
of  ||| S:18197 E:18200 ||| IN
PEDF ||| S:18200 E:18204 ||| NNP
,  ||| S:18204 E:18206 ||| ,
namely  ||| S:18206 E:18213 ||| RB
the  ||| S:18213 E:18225 ||| DT
encounters  ||| S:18225 E:18236 ||| NN
with  ||| S:18236 E:18241 ||| IN
its  ||| S:18241 E:18245 ||| PRP$
receptor  ||| S:18245 E:18254 ||| NN
at  ||| S:18254 E:18257 ||| IN
the  ||| S:18257 E:18261 ||| DT
cell  ||| S:18261 E:18266 ||| NN
surface ||| S:18266 E:18273 ||| NN
.  ||| S:18273 E:18275 ||| .
The  ||| S:18275 E:18287 ||| DT
differentiation  ||| S:18287 E:18303 ||| NN
and  ||| S:18303 E:18307 ||| CC
survival  ||| S:18307 E:18316 ||| NN
of  ||| S:18316 E:18319 ||| IN
cells  ||| S:18319 E:18325 ||| NNS
in  ||| S:18325 E:18328 ||| IN
vivo  ||| S:18328 E:18333 ||| NNS
may  ||| S:18333 E:18337 ||| MD
be  ||| S:18337 E:18348 ||| VB
regulated  ||| S:18348 E:18358 ||| VBN
not  ||| S:18358 E:18362 ||| RB
only  ||| S:18362 E:18367 ||| RB
by  ||| S:18367 E:18370 ||| IN
the  ||| S:18370 E:18374 ||| DT
expression  ||| S:18374 E:18385 ||| NN
of  ||| S:18385 E:18388 ||| IN
PEDF  ||| S:18388 E:18393 ||| NNP
and  ||| S:18393 E:18397 ||| CC
its  ||| S:18397 E:18409 ||| PRP$
receptor  ||| S:18409 E:18418 ||| NN
but  ||| S:18418 E:18422 ||| CC
also  ||| S:18422 E:18427 ||| RB
by  ||| S:18427 E:18430 ||| IN
the  ||| S:18430 E:18434 ||| DT
temporal  ||| S:18434 E:18443 ||| NN
and  ||| S:18443 E:18447 ||| CC
spatial  ||| S:18447 E:18455 ||| JJ
expression  ||| S:18455 E:18466 ||| NN
of  ||| S:18466 E:18477 ||| IN
GAGs ||| S:18477 E:18481 ||| JJ
.  ||| S:18481 E:18505 ||| .
Methods  ||| S:18505 E:18532 ||| NNP
Materials  ||| S:18532 E:18552 ||| NNPS
Heparin  ||| S:18552 E:18560 ||| NNP
purified  ||| S:18560 E:18569 ||| NN
from  ||| S:18569 E:18574 ||| IN
bovine  ||| S:18574 E:18581 ||| JJ
intestinal  ||| S:18581 E:18592 ||| JJ
mucosa ||| S:18592 E:18598 ||| NN
,  ||| S:18598 E:18610 ||| ,
chondroitin  ||| S:18610 E:18622 ||| FW
sulfates  ||| S:18622 E:18631 ||| FW
A ||| S:18631 E:18632 ||| NNP
,  ||| S:18632 E:18634 ||| ,
B  ||| S:18634 E:18636 ||| NNP
and  ||| S:18636 E:18640 ||| CC
C ||| S:18640 E:18641 ||| NNP
,  ||| S:18641 E:18643 ||| ,
chondroitinase  ||| S:18643 E:18658 ||| VBG
ABC ||| S:18658 E:18661 ||| NNP
,  ||| S:18661 E:18673 ||| ,
sodium  ||| S:18673 E:18680 ||| JJ
chlorate ||| S:18680 E:18688 ||| NN
,  ||| S:18688 E:18690 ||| ,
and  ||| S:18690 E:18694 ||| CC
Toluidine  ||| S:18694 E:18704 ||| NNP
Blue-O  ||| S:18704 E:18711 ||| NNP
were  ||| S:18711 E:18716 ||| VBD
purchased  ||| S:18716 E:18726 ||| VBN
from  ||| S:18726 E:18741 ||| IN
Sigma ||| S:18741 E:18746 ||| NNP
.  ||| S:18746 E:18748 ||| .
Subtilisin  ||| S:18748 E:18759 ||| NNP
was  ||| S:18759 E:18763 ||| VBD
from  ||| S:18763 E:18768 ||| IN
Boehringer  ||| S:18768 E:18779 ||| NNP
Mannheim ||| S:18779 E:18787 ||| NNP
.  ||| S:18787 E:18799 ||| .
Heparitinase  ||| S:18799 E:18812 ||| NNP
( ||| S:18812 E:18813 ||| -LRB-
E.C.4.2.2.8 ||| S:18813 E:18824 ||| NNP
)  ||| S:18824 E:18826 ||| -RRB-
and  ||| S:18826 E:18830 ||| CC
heparinase  ||| S:18830 E:18841 ||| NNS
( ||| S:18841 E:18842 ||| -LRB-
E.C.4.2.2.7 ||| S:18842 E:18853 ||| NNP
)  ||| S:18853 E:18865 ||| -RRB-
purified  ||| S:18865 E:18874 ||| NN
from  ||| S:18874 E:18890 ||| IN
Flavobacterium  ||| S:18890 E:18905 ||| NNP
heparinum  ||| S:18905 E:18915 ||| NN
were  ||| S:18915 E:18920 ||| VBD
from  ||| S:18920 E:18935 ||| IN
ICN  ||| S:18935 E:18939 ||| NNP
Biomedicals ||| S:18939 E:18950 ||| NNP
,  ||| S:18950 E:18952 ||| ,
Inc.  ||| S:18952 E:18957 ||| NNP
and  ||| S:18957 E:18961 ||| CC
alternatively  ||| S:18961 E:18975 ||| RB
from  ||| S:18975 E:18980 ||| IN
Seikagaku ||| S:18980 E:18989 ||| NNP
.  ||| S:18989 E:19001 ||| .
Heparan  ||| S:19001 E:19009 ||| JJ
sulfate  ||| S:19009 E:19017 ||| NNS
( ||| S:19017 E:19018 ||| -LRB-
HS ||| S:19018 E:19020 ||| NNP
)  ||| S:19020 E:19022 ||| -RRB-
purified  ||| S:19022 E:19031 ||| NN
from  ||| S:19031 E:19036 ||| IN
bovine  ||| S:19036 E:19043 ||| JJ
kidney  ||| S:19043 E:19050 ||| NN
was  ||| S:19050 E:19054 ||| VBD
from  ||| S:19054 E:19069 ||| IN
Seikagaku ||| S:19069 E:19078 ||| NNP
,  ||| S:19078 E:19080 ||| ,
hyaluronidase  ||| S:19080 E:19094 ||| NNS
( ||| S:19094 E:19095 ||| -LRB-
E.C.4.2.2.1 ||| S:19095 E:19106 ||| NNP
)  ||| S:19106 E:19108 ||| -RRB-
purified  ||| S:19108 E:19117 ||| NN
from  ||| S:19117 E:19133 ||| IN
Streptomyces  ||| S:19133 E:19146 ||| NNP
hyalurolyticus  ||| S:19146 E:19161 ||| NN
from  ||| S:19161 E:19176 ||| IN
ICN  ||| S:19176 E:19180 ||| NNP
Pharmaceuticals ||| S:19180 E:19195 ||| NNP
,  ||| S:19195 E:19197 ||| ,
Coomassie  ||| S:19197 E:19207 ||| NNP
Brilliant  ||| S:19207 E:19217 ||| NNP
Blue  ||| S:19217 E:19222 ||| NNP
from  ||| S:19222 E:19237 ||| IN
BioRad ||| S:19237 E:19243 ||| NNP
,  ||| S:19243 E:19245 ||| ,
and  ||| S:19245 E:19249 ||| CC
Q-Sepharose  ||| S:19249 E:19261 ||| JJ
from  ||| S:19261 E:19266 ||| IN
Pharmacia ||| S:19266 E:19275 ||| NNP
.  ||| S:19275 E:19277 ||| .
Recombinant  ||| S:19277 E:19289 ||| NNP
PEDF  ||| S:19289 E:19304 ||| NNP
was  ||| S:19304 E:19308 ||| VBD
purified  ||| S:19308 E:19317 ||| VBN
from  ||| S:19317 E:19322 ||| IN
BHK  ||| S:19322 E:19326 ||| NNP
cells  ||| S:19326 E:19332 ||| NNS
containing  ||| S:19332 E:19343 ||| VBG
an  ||| S:19343 E:19346 ||| DT
expression  ||| S:19346 E:19367 ||| NN
vector  ||| S:19367 E:19374 ||| NN
with  ||| S:19374 E:19379 ||| IN
human  ||| S:19379 E:19385 ||| JJ
PEDF  ||| S:19385 E:19390 ||| NNP
cDNA ||| S:19390 E:19394 ||| NNP
,  ||| S:19394 E:19396 ||| ,
as  ||| S:19396 E:19399 ||| RB
previously  ||| S:19399 E:19410 ||| RB
described  ||| S:19410 E:19420 ||| VBN
[  ||| S:19420 E:19422 ||| -LRB-
19  ||| S:19422 E:19435 ||| CD
]  ||| S:19435 E:19437 ||| -RRB-
.  ||| S:19437 E:19467 ||| .
Preparation  ||| S:19467 E:19479 ||| NN
of  ||| S:19479 E:19482 ||| IN
conditioned  ||| S:19482 E:19494 ||| JJ
media  ||| S:19494 E:19510 ||| NNS
Human  ||| S:19510 E:19516 ||| JJ
retinoblastoma  ||| S:19516 E:19531 ||| NN
Y-79  ||| S:19531 E:19536 ||| CD
cells  ||| S:19536 E:19542 ||| NNS
( ||| S:19542 E:19543 ||| -LRB-
0.45-5  ||| S:19543 E:19550 ||| CD
×  ||| S:19550 E:19552 ||| CD
10  ||| S:19552 E:19565 ||| CD
6cells ||| S:19565 E:19571 ||| CD
/ ||| S:19571 E:19572 ||| CD
ml ||| S:19572 E:19574 ||| CD
)  ||| S:19574 E:19576 ||| -RRB-
were  ||| S:19576 E:19581 ||| VBD
cultured  ||| S:19581 E:19590 ||| VBN
in  ||| S:19590 E:19593 ||| IN
defined  ||| S:19593 E:19601 ||| JJ
media  ||| S:19601 E:19607 ||| NNS
( ||| S:19607 E:19608 ||| -LRB-
MEM  ||| S:19608 E:19612 ||| NNP
containing  ||| S:19612 E:19633 ||| VBG
10  ||| S:19633 E:19636 ||| CD
mM  ||| S:19636 E:19639 ||| JJ
HEPES ||| S:19639 E:19644 ||| NNP
,  ||| S:19644 E:19646 ||| ,
1  ||| S:19646 E:19648 ||| CD
mM  ||| S:19648 E:19651 ||| JJ
Na-pyruvate ||| S:19651 E:19662 ||| NN
,  ||| S:19662 E:19664 ||| ,
0.1  ||| S:19664 E:19668 ||| CD
mM  ||| S:19668 E:19671 ||| JJ
non-essential  ||| S:19671 E:19685 ||| JJ
amino  ||| S:19685 E:19701 ||| JJ
acids ||| S:19701 E:19706 ||| NNS
,  ||| S:19706 E:19708 ||| ,
1  ||| S:19708 E:19710 ||| CD
mM  ||| S:19710 E:19713 ||| JJ
L-glutamine ||| S:19713 E:19724 ||| NN
,  ||| S:19724 E:19726 ||| ,
1 ||| S:19726 E:19727 ||| CD
%  ||| S:19727 E:19729 ||| NN
penicillin ||| S:19729 E:19739 ||| FW
/ ||| S:19739 E:19740 ||| FW
streptomycin  ||| S:19740 E:19763 ||| FW
( ||| S:19763 E:19764 ||| -LRB-
LifeTechnologies ||| S:19764 E:19780 ||| NNP
) ||| S:19780 E:19781 ||| -RRB-
)  ||| S:19781 E:19783 ||| -RRB-
at  ||| S:19783 E:19786 ||| IN
37°C  ||| S:19786 E:19791 ||| CD
for  ||| S:19791 E:19795 ||| IN
16-24  ||| S:19795 E:19801 ||| CD
h ||| S:19801 E:19802 ||| NNS
.  ||| S:19802 E:19804 ||| .
Media  ||| S:19804 E:19810 ||| NNS
exposed  ||| S:19810 E:19818 ||| VBN
to  ||| S:19818 E:19831 ||| TO
these  ||| S:19831 E:19837 ||| DT
conditions  ||| S:19837 E:19848 ||| NNS
is  ||| S:19848 E:19851 ||| VBZ
referred  ||| S:19851 E:19860 ||| VBN
as  ||| S:19860 E:19863 ||| IN
CM ||| S:19863 E:19865 ||| NNP
.  ||| S:19865 E:19867 ||| .
CM  ||| S:19867 E:19870 ||| NNP
was  ||| S:19870 E:19874 ||| VBD
separated  ||| S:19874 E:19884 ||| VBN
from  ||| S:19884 E:19899 ||| IN
cells  ||| S:19899 E:19905 ||| NNS
by  ||| S:19905 E:19908 ||| IN
centrifugation  ||| S:19908 E:19923 ||| NNS
( ||| S:19923 E:19924 ||| -LRB-
1000  ||| S:19924 E:19929 ||| CD
×  ||| S:19929 E:19942 ||| CD
g  ||| S:19942 E:19944 ||| NN
for  ||| S:19944 E:19948 ||| IN
5  ||| S:19948 E:19950 ||| CD
min  ||| S:19950 E:19954 ||| NN
at  ||| S:19954 E:19957 ||| IN
4°C ||| S:19957 E:19960 ||| CD
)  ||| S:19960 E:19962 ||| -RRB-
and  ||| S:19962 E:19976 ||| CC
concentrated  ||| S:19976 E:19989 ||| VBN
by  ||| S:19989 E:19992 ||| IN
ultrafiltration  ||| S:19992 E:20008 ||| NNS
using  ||| S:20008 E:20014 ||| VBG
membrane  ||| S:20014 E:20023 ||| JJ
filters  ||| S:20023 E:20041 ||| NNS
with  ||| S:20041 E:20046 ||| IN
MWCO  ||| S:20046 E:20051 ||| NNP
=  ||| S:20051 E:20053 ||| SYM
10,000  ||| S:20053 E:20060 ||| CD
( ||| S:20060 E:20061 ||| -LRB-
Amicon  ||| S:20061 E:20068 ||| NNP
YM10  ||| S:20068 E:20073 ||| NNP
filters ||| S:20073 E:20080 ||| NNS
) ||| S:20080 E:20081 ||| -RRB-
.  ||| S:20081 E:20083 ||| .
GAGs ||| S:20083 E:20087 ||| NNP
/ ||| S:20087 E:20088 ||| NNP
polyanions  ||| S:20088 E:20109 ||| NN
purification  ||| S:20109 E:20122 ||| NNS
was  ||| S:20122 E:20126 ||| VBD
performed  ||| S:20126 E:20136 ||| VBN
as  ||| S:20136 E:20139 ||| RB
follows ||| S:20139 E:20146 ||| VBZ
:  ||| S:20146 E:20148 ||| :
concentrated  ||| S:20148 E:20161 ||| VBD
CM  ||| S:20161 E:20174 ||| NNP
( ||| S:20174 E:20175 ||| -LRB-
15  ||| S:20175 E:20178 ||| CD
ml ||| S:20178 E:20180 ||| CD
)  ||| S:20180 E:20182 ||| -RRB-
was  ||| S:20182 E:20186 ||| VBD
dialyzed  ||| S:20186 E:20195 ||| VBN
against  ||| S:20195 E:20203 ||| IN
buffer  ||| S:20203 E:20210 ||| JJ
Q  ||| S:20210 E:20212 ||| NNP
( ||| S:20212 E:20213 ||| -LRB-
50  ||| S:20213 E:20216 ||| CD
mM  ||| S:20216 E:20219 ||| JJ
Tris-HCl ||| S:20219 E:20227 ||| NN
,  ||| S:20227 E:20229 ||| ,
pH  ||| S:20229 E:20242 ||| NNP
8.0 ||| S:20242 E:20245 ||| NNP
,  ||| S:20245 E:20247 ||| ,
0.2  ||| S:20247 E:20251 ||| CD
M  ||| S:20251 E:20253 ||| NNP
NaCl ||| S:20253 E:20257 ||| NNP
,  ||| S:20257 E:20259 ||| ,
6  ||| S:20259 E:20261 ||| CD
M  ||| S:20261 E:20263 ||| NNP
Urea ||| S:20263 E:20267 ||| NNP
,  ||| S:20267 E:20269 ||| ,
0.5 ||| S:20269 E:20272 ||| CD
%  ||| S:20272 E:20274 ||| NN
CHAPS ||| S:20274 E:20279 ||| NNP
) ||| S:20279 E:20280 ||| -RRB-
,  ||| S:20280 E:20282 ||| ,
filtered  ||| S:20282 E:20291 ||| VBG
through  ||| S:20291 E:20309 ||| IN
a  ||| S:20309 E:20311 ||| DT
0.4  ||| S:20311 E:20315 ||| CD
micron  ||| S:20315 E:20322 ||| CD
membrane  ||| S:20322 E:20331 ||| NNS
and  ||| S:20331 E:20335 ||| CC
its  ||| S:20335 E:20339 ||| PRP$
soluble  ||| S:20339 E:20347 ||| JJ
components  ||| S:20347 E:20368 ||| NNS
subjected  ||| S:20368 E:20378 ||| VBN
to  ||| S:20378 E:20381 ||| TO
anion-exchange  ||| S:20381 E:20396 ||| JJ
column  ||| S:20396 E:20403 ||| NN
chromatography  ||| S:20403 E:20418 ||| VBZ
using  ||| S:20418 E:20434 ||| VBG
Q-Sepharose  ||| S:20434 E:20446 ||| JJ
Fast  ||| S:20446 E:20451 ||| NNP
Flow  ||| S:20451 E:20456 ||| NNP
( ||| S:20456 E:20457 ||| -LRB-
1  ||| S:20457 E:20459 ||| CD
ml  ||| S:20459 E:20462 ||| JJ
bed  ||| S:20462 E:20466 ||| NN
volume ||| S:20466 E:20472 ||| NN
) ||| S:20472 E:20473 ||| -RRB-
.  ||| S:20473 E:20475 ||| .
The  ||| S:20475 E:20479 ||| DT
column  ||| S:20479 E:20486 ||| NN
was  ||| S:20486 E:20500 ||| VBD
washed  ||| S:20500 E:20507 ||| VBN
with  ||| S:20507 E:20512 ||| IN
15-column  ||| S:20512 E:20522 ||| CD
volumes  ||| S:20522 E:20530 ||| NNS
of  ||| S:20530 E:20533 ||| IN
buffer  ||| S:20533 E:20540 ||| JJ
Q ||| S:20540 E:20541 ||| NNP
,  ||| S:20541 E:20543 ||| ,
the  ||| S:20543 E:20547 ||| DT
bound  ||| S:20547 E:20563 ||| JJ
material  ||| S:20563 E:20572 ||| NN
eluted  ||| S:20572 E:20579 ||| NN
with  ||| S:20579 E:20584 ||| IN
1.2  ||| S:20584 E:20588 ||| CD
M  ||| S:20588 E:20590 ||| NNP
NaCl  ||| S:20590 E:20595 ||| NNP
and  ||| S:20595 E:20599 ||| CC
termed  ||| S:20599 E:20606 ||| FW
CM  ||| S:20606 E:20609 ||| FW
a ||| S:20609 E:20610 ||| FW
.  ||| S:20610 E:20622 ||| .
Alternatively ||| S:20622 E:20635 ||| RB
,  ||| S:20635 E:20637 ||| ,
a  ||| S:20637 E:20639 ||| DT
DEAE-Sephacel  ||| S:20639 E:20653 ||| JJ
column  ||| S:20653 E:20660 ||| NN
was  ||| S:20660 E:20664 ||| VBD
used ||| S:20664 E:20668 ||| VBN
.  ||| S:20668 E:20698 ||| .
PEDF-affinity  ||| S:20698 E:20712 ||| JJ
column  ||| S:20712 E:20719 ||| NN
chromatography  ||| S:20719 E:20744 ||| NN
To  ||| S:20744 E:20747 ||| TO
identify  ||| S:20747 E:20756 ||| VB
components  ||| S:20756 E:20767 ||| NNS
with  ||| S:20767 E:20772 ||| IN
PEDF-binding  ||| S:20772 E:20785 ||| JJ
affinity ||| S:20785 E:20793 ||| NN
,  ||| S:20793 E:20805 ||| ,
purified  ||| S:20805 E:20814 ||| JJ
recombinant  ||| S:20814 E:20826 ||| JJ
protein  ||| S:20826 E:20834 ||| NN
was  ||| S:20834 E:20838 ||| VBD
used  ||| S:20838 E:20843 ||| VBN
to  ||| S:20843 E:20846 ||| TO
prepare  ||| S:20846 E:20864 ||| VB
PEDF-affinity  ||| S:20864 E:20878 ||| JJ
resin  ||| S:20878 E:20884 ||| NN
with  ||| S:20884 E:20889 ||| IN
3  ||| S:20889 E:20891 ||| CD
M  ||| S:20891 E:20893 ||| NNP
Emphaze™  ||| S:20893 E:20902 ||| NNP
Biosupport  ||| S:20902 E:20913 ||| NNP
Medium  ||| S:20913 E:20930 ||| NNP
( ||| S:20930 E:20931 ||| -LRB-
Pierce  ||| S:20931 E:20938 ||| NNP
Chemical ||| S:20938 E:20946 ||| NNP
)  ||| S:20946 E:20948 ||| -RRB-
[  ||| S:20948 E:20950 ||| -LRB-
18  ||| S:20950 E:20953 ||| CD
]  ||| S:20953 E:20955 ||| -RRB-
.  ||| S:20955 E:20957 ||| .
CM  ||| S:20957 E:20960 ||| NNP
awas  ||| S:20960 E:20965 ||| VBD
dialyzed  ||| S:20965 E:20974 ||| VBN
against  ||| S:20974 E:20992 ||| IN
buffer  ||| S:20992 E:20999 ||| JJ
P  ||| S:20999 E:21001 ||| NN
( ||| S:21001 E:21002 ||| -LRB-
20  ||| S:21002 E:21005 ||| CD
mM  ||| S:21005 E:21008 ||| JJ
sodium  ||| S:21008 E:21015 ||| NNS
phosphate  ||| S:21015 E:21025 ||| VBP
pH  ||| S:21025 E:21028 ||| JJ
7 ||| S:21028 E:21029 ||| CD
,  ||| S:21029 E:21031 ||| ,
150  ||| S:21031 E:21035 ||| CD
mM  ||| S:21035 E:21038 ||| JJ
NaCl ||| S:21038 E:21042 ||| NN
,  ||| S:21042 E:21044 ||| ,
0.5 ||| S:21044 E:21047 ||| CD
%  ||| S:21047 E:21059 ||| NN
CHAPS ||| S:21059 E:21064 ||| NNP
)  ||| S:21064 E:21066 ||| -RRB-
and  ||| S:21066 E:21070 ||| CC
filtrated  ||| S:21070 E:21080 ||| NN
through  ||| S:21080 E:21088 ||| IN
0.4  ||| S:21088 E:21092 ||| CD
μm  ||| S:21092 E:21095 ||| CD
filters ||| S:21095 E:21102 ||| NNS
.  ||| S:21102 E:21104 ||| .
The  ||| S:21104 E:21108 ||| DT
soluble  ||| S:21108 E:21126 ||| JJ
dialysate  ||| S:21126 E:21136 ||| NN
was  ||| S:21136 E:21140 ||| VBD
mixed  ||| S:21140 E:21146 ||| VBN
with  ||| S:21146 E:21151 ||| IN
PEDF-resin  ||| S:21151 E:21162 ||| NNP
( ||| S:21162 E:21163 ||| -LRB-
6  ||| S:21163 E:21165 ||| CD
mg  ||| S:21165 E:21168 ||| FW
PEDF ||| S:21168 E:21172 ||| FW
/ ||| S:21172 E:21173 ||| FW
ml  ||| S:21173 E:21176 ||| FW
resin ||| S:21176 E:21181 ||| FW
)  ||| S:21181 E:21193 ||| -RRB-
at  ||| S:21193 E:21196 ||| IN
a  ||| S:21196 E:21198 ||| DT
2 ||| S:21198 E:21199 ||| CD
: ||| S:21199 E:21200 ||| :
1  ||| S:21200 E:21202 ||| CD
volume-to-volume  ||| S:21202 E:21219 ||| JJ
ratio  ||| S:21219 E:21225 ||| NN
and  ||| S:21225 E:21229 ||| CC
incubated  ||| S:21229 E:21239 ||| NN
at  ||| S:21239 E:21242 ||| IN
4°C  ||| S:21242 E:21246 ||| CD
with  ||| S:21246 E:21261 ||| IN
gentle  ||| S:21261 E:21268 ||| JJ
rocking  ||| S:21268 E:21276 ||| NN
for  ||| S:21276 E:21280 ||| IN
16  ||| S:21280 E:21283 ||| CD
h ||| S:21283 E:21284 ||| NNS
.  ||| S:21284 E:21286 ||| .
The  ||| S:21286 E:21290 ||| DT
mixture  ||| S:21290 E:21298 ||| NN
was  ||| S:21298 E:21302 ||| VBD
packed  ||| S:21302 E:21309 ||| VBN
into  ||| S:21309 E:21314 ||| IN
a  ||| S:21314 E:21316 ||| DT
10  ||| S:21316 E:21329 ||| CD
ml  ||| S:21329 E:21332 ||| FW
Polyprep  ||| S:21332 E:21341 ||| FW
chromatography  ||| S:21341 E:21356 ||| FW
column  ||| S:21356 E:21363 ||| FW
( ||| S:21363 E:21364 ||| -LRB-
Bio-Rad ||| S:21364 E:21371 ||| NNP
)  ||| S:21371 E:21373 ||| -RRB-
and  ||| S:21373 E:21377 ||| CC
washed  ||| S:21377 E:21394 ||| VBN
with  ||| S:21394 E:21399 ||| IN
10-column  ||| S:21399 E:21409 ||| CD
volumes  ||| S:21409 E:21417 ||| NNS
of  ||| S:21417 E:21420 ||| IN
buffer  ||| S:21420 E:21427 ||| JJ
P.  ||| S:21427 E:21430 ||| NNP
The  ||| S:21430 E:21434 ||| DT
bound  ||| S:21434 E:21440 ||| JJ
material  ||| S:21440 E:21459 ||| NN
was  ||| S:21459 E:21463 ||| VBD
eluted  ||| S:21463 E:21470 ||| VBN
with  ||| S:21470 E:21475 ||| IN
10-column  ||| S:21475 E:21485 ||| CD
volumes  ||| S:21485 E:21493 ||| NNS
of  ||| S:21493 E:21496 ||| IN
3  ||| S:21496 E:21498 ||| CD
M  ||| S:21498 E:21500 ||| NNP
NaCl ||| S:21500 E:21504 ||| NNP
,  ||| S:21504 E:21506 ||| ,
desalted  ||| S:21506 E:21525 ||| VBG
with  ||| S:21525 E:21530 ||| IN
20  ||| S:21530 E:21533 ||| CD
mM  ||| S:21533 E:21536 ||| JJ
Tris-HCl  ||| S:21536 E:21545 ||| JJ
pH  ||| S:21545 E:21548 ||| JJ
8.0 ||| S:21548 E:21551 ||| NN
,  ||| S:21551 E:21553 ||| ,
10 ||| S:21553 E:21555 ||| CD
%  ||| S:21555 E:21557 ||| NN
glycerol ||| S:21557 E:21565 ||| NN
,  ||| S:21565 E:21567 ||| ,
treated  ||| S:21567 E:21575 ||| VBN
for  ||| S:21575 E:21589 ||| IN
protein  ||| S:21589 E:21597 ||| NN
depletion ||| S:21597 E:21606 ||| NN
,  ||| S:21606 E:21608 ||| ,
dialyzed  ||| S:21608 E:21617 ||| VBG
against  ||| S:21617 E:21625 ||| IN
deionized  ||| S:21625 E:21635 ||| JJ
water ||| S:21635 E:21640 ||| NN
,  ||| S:21640 E:21652 ||| ,
lyophilized  ||| S:21652 E:21664 ||| NN
and  ||| S:21664 E:21668 ||| CC
resuspended  ||| S:21668 E:21680 ||| NN
in  ||| S:21680 E:21683 ||| IN
deionized  ||| S:21683 E:21693 ||| JJ
water ||| S:21693 E:21698 ||| NN
.  ||| S:21698 E:21700 ||| .
The  ||| S:21700 E:21704 ||| DT
final  ||| S:21704 E:21720 ||| JJ
sample  ||| S:21720 E:21727 ||| NN
was  ||| S:21727 E:21731 ||| VBD
termed  ||| S:21731 E:21738 ||| VBN
CM  ||| S:21738 E:21741 ||| NNP
PEDF ||| S:21741 E:21745 ||| NNP
.  ||| S:21745 E:21747 ||| .
About  ||| S:21747 E:21753 ||| IN
100  ||| S:21753 E:21757 ||| CD
μl  ||| S:21757 E:21760 ||| NN
of  ||| S:21760 E:21763 ||| IN
CM  ||| S:21763 E:21766 ||| NNP
PEDFwere  ||| S:21766 E:21785 ||| NNP
obtained  ||| S:21785 E:21794 ||| VBD
from  ||| S:21794 E:21799 ||| IN
100  ||| S:21799 E:21803 ||| CD
ml  ||| S:21803 E:21806 ||| NN
of  ||| S:21806 E:21809 ||| IN
CM ||| S:21809 E:21811 ||| NNP
.  ||| S:21811 E:21813 ||| .
Alternatively ||| S:21813 E:21826 ||| RB
,  ||| S:21826 E:21828 ||| ,
concentrated  ||| S:21828 E:21851 ||| VBD
CM  ||| S:21851 E:21854 ||| NNP
was  ||| S:21854 E:21858 ||| VBD
used  ||| S:21858 E:21863 ||| VBN
as  ||| S:21863 E:21866 ||| IN
starting  ||| S:21866 E:21875 ||| VBG
material  ||| S:21875 E:21884 ||| NN
and  ||| S:21884 E:21888 ||| CC
protein  ||| S:21888 E:21896 ||| NN
depletion  ||| S:21896 E:21916 ||| NN
was  ||| S:21916 E:21920 ||| VBD
omitted ||| S:21920 E:21927 ||| VBN
.  ||| S:21927 E:21957 ||| .
Radioligand  ||| S:21957 E:21969 ||| FW
binding  ||| S:21969 E:21977 ||| FW
assays  ||| S:21977 E:21994 ||| FW
PEDF  ||| S:21994 E:21999 ||| FW
binding  ||| S:21999 E:22007 ||| FW
to  ||| S:22007 E:22010 ||| TO
cell-surface  ||| S:22010 E:22023 ||| JJ
receptors  ||| S:22023 E:22033 ||| NNS
was  ||| S:22033 E:22037 ||| VBD
assayed  ||| S:22037 E:22055 ||| VBN
using  ||| S:22055 E:22061 ||| VBG
biologically  ||| S:22061 E:22074 ||| JJ
active  ||| S:22074 E:22081 ||| JJ
radioligand  ||| S:22081 E:22093 ||| JJ
125I-PEDF  ||| S:22093 E:22103 ||| NN
and  ||| S:22103 E:22107 ||| CC
Y-79  ||| S:22107 E:22122 ||| CD
cells  ||| S:22122 E:22128 ||| NNS
[  ||| S:22128 E:22130 ||| -LRB-
18  ||| S:22130 E:22133 ||| CD
]  ||| S:22133 E:22135 ||| -RRB-
by  ||| S:22135 E:22138 ||| IN
a  ||| S:22138 E:22140 ||| DT
widely-used  ||| S:22140 E:22152 ||| JJ
method  ||| S:22152 E:22159 ||| NN
with  ||| S:22159 E:22164 ||| IN
a  ||| S:22164 E:22166 ||| DT
mechanism  ||| S:22166 E:22176 ||| NN
of  ||| S:22176 E:22189 ||| IN
retention  ||| S:22189 E:22199 ||| NN
of  ||| S:22199 E:22202 ||| IN
receptors  ||| S:22202 E:22212 ||| NNS
on  ||| S:22212 E:22215 ||| IN
polyethylenimine-treated  ||| S:22215 E:22250 ||| JJ
glass-fiber  ||| S:22250 E:22262 ||| JJ
filters  ||| S:22262 E:22270 ||| NNS
based  ||| S:22270 E:22276 ||| VBN
mainly  ||| S:22276 E:22283 ||| RB
on  ||| S:22283 E:22286 ||| IN
ionic  ||| S:22286 E:22292 ||| JJ
interactions  ||| S:22292 E:22305 ||| NNS
[  ||| S:22305 E:22317 ||| -LRB-
32  ||| S:22317 E:22320 ||| CD
]  ||| S:22320 E:22322 ||| -RRB-
.  ||| S:22322 E:22324 ||| .
Polyethylenimine  ||| S:22324 E:22341 ||| NNP
binds  ||| S:22341 E:22347 ||| VBD
strongly  ||| S:22347 E:22356 ||| RB
to  ||| S:22356 E:22359 ||| TO
glass ||| S:22359 E:22364 ||| NN
,  ||| S:22364 E:22366 ||| ,
which  ||| S:22366 E:22372 ||| WDT
is  ||| S:22372 E:22385 ||| VBZ
negatively  ||| S:22385 E:22396 ||| RB
charged  ||| S:22396 E:22404 ||| VBN
and  ||| S:22404 E:22408 ||| CC
integral  ||| S:22408 E:22417 ||| JJ
membrane  ||| S:22417 E:22426 ||| JJ
proteins  ||| S:22426 E:22435 ||| NNS
tend  ||| S:22435 E:22440 ||| VBP
to  ||| S:22440 E:22453 ||| TO
be  ||| S:22453 E:22456 ||| VB
acidic ||| S:22456 E:22462 ||| NNS
.  ||| S:22462 E:22464 ||| .
The  ||| S:22464 E:22468 ||| DT
resultant  ||| S:22468 E:22478 ||| JJ
polycationic  ||| S:22478 E:22501 ||| JJ
polyethylenimine-coated  ||| S:22501 E:22525 ||| JJ
glass  ||| S:22525 E:22531 ||| NN
can  ||| S:22531 E:22535 ||| MD
retain  ||| S:22535 E:22542 ||| VB
cell  ||| S:22542 E:22547 ||| NN
membranes  ||| S:22547 E:22567 ||| VBZ
due  ||| S:22567 E:22571 ||| JJ
to  ||| S:22571 E:22574 ||| TO
their  ||| S:22574 E:22580 ||| PRP$
negative  ||| S:22580 E:22589 ||| JJ
charges ||| S:22589 E:22596 ||| NNS
.  ||| S:22596 E:22598 ||| .
Because  ||| S:22598 E:22606 ||| IN
binding  ||| S:22606 E:22614 ||| VBG
of  ||| S:22614 E:22627 ||| IN
cell-surface  ||| S:22627 E:22640 ||| JJ
receptors  ||| S:22640 E:22650 ||| NNS
to  ||| S:22650 E:22653 ||| TO
polyethylenimine  ||| S:22653 E:22670 ||| VB
filters  ||| S:22670 E:22678 ||| NNS
is  ||| S:22678 E:22691 ||| VBZ
rather  ||| S:22691 E:22698 ||| RB
insensitive  ||| S:22698 E:22710 ||| VBN
to  ||| S:22710 E:22713 ||| TO
ionic  ||| S:22713 E:22719 ||| VB
strength ||| S:22719 E:22727 ||| NN
,  ||| S:22727 E:22729 ||| ,
the  ||| S:22729 E:22733 ||| DT
ionic  ||| S:22733 E:22749 ||| JJ
phenomenon  ||| S:22749 E:22760 ||| NN
is  ||| S:22760 E:22763 ||| VBZ
thought  ||| S:22763 E:22771 ||| VBN
to  ||| S:22771 E:22774 ||| TO
be  ||| S:22774 E:22777 ||| VB
supplemented  ||| S:22777 E:22790 ||| VBN
by  ||| S:22790 E:22793 ||| IN
hydrophobic  ||| S:22793 E:22815 ||| JJ
forces  ||| S:22815 E:22822 ||| NNS
and  ||| S:22822 E:22826 ||| CC
hydrogen  ||| S:22826 E:22835 ||| NN
binding  ||| S:22835 E:22843 ||| NNS
[  ||| S:22843 E:22845 ||| -LRB-
32  ||| S:22845 E:22848 ||| CD
]  ||| S:22848 E:22850 ||| -RRB-
.  ||| S:22850 E:22852 ||| .
The  ||| S:22852 E:22856 ||| DT
method  ||| S:22856 E:22863 ||| NN
used  ||| S:22863 E:22868 ||| VBN
with  ||| S:22868 E:22883 ||| IN
Y-79  ||| S:22883 E:22888 ||| CD
cells  ||| S:22888 E:22894 ||| NNS
and  ||| S:22894 E:22898 ||| CC
radiolabeled  ||| S:22898 E:22911 ||| JJ
PEDF  ||| S:22911 E:22916 ||| NNP
has  ||| S:22916 E:22920 ||| VBZ
been  ||| S:22920 E:22925 ||| VBN
described  ||| S:22925 E:22945 ||| VBN
before  ||| S:22945 E:22952 ||| IN
in  ||| S:22952 E:22955 ||| IN
detail  ||| S:22955 E:22962 ||| NN
[  ||| S:22962 E:22964 ||| -LRB-
18  ||| S:22964 E:22967 ||| CD
]  ||| S:22967 E:22969 ||| -RRB-
.  ||| S:22969 E:22971 ||| .
Briefly ||| S:22971 E:22978 ||| RB
,  ||| S:22978 E:22980 ||| ,
cells  ||| S:22980 E:22986 ||| NNS
cultured  ||| S:22986 E:23005 ||| VBP
overnight  ||| S:23005 E:23015 ||| RB
in  ||| S:23015 E:23018 ||| IN
serum-deprived  ||| S:23018 E:23033 ||| JJ
medium  ||| S:23033 E:23040 ||| NN
at  ||| S:23040 E:23043 ||| IN
37°C  ||| S:23043 E:23048 ||| NNP
were  ||| S:23048 E:23063 ||| VBD
transferred  ||| S:23063 E:23075 ||| VBN
to  ||| S:23075 E:23078 ||| TO
ice ||| S:23078 E:23081 ||| CD
/ ||| S:23081 E:23082 ||| CD
water  ||| S:23082 E:23088 ||| NN
bath  ||| S:23088 E:23093 ||| NN
for  ||| S:23093 E:23097 ||| IN
10  ||| S:23097 E:23100 ||| CD
minutes  ||| S:23100 E:23108 ||| NNS
before  ||| S:23108 E:23115 ||| IN
the  ||| S:23115 E:23129 ||| DT
addition  ||| S:23129 E:23138 ||| NN
of  ||| S:23138 E:23141 ||| IN
ligand ||| S:23141 E:23147 ||| NN
.  ||| S:23147 E:23149 ||| .
The  ||| S:23149 E:23153 ||| DT
reaction  ||| S:23153 E:23162 ||| NN
mixtures  ||| S:23162 E:23171 ||| NNS
containing  ||| S:23171 E:23182 ||| VBG
cell  ||| S:23182 E:23197 ||| NN
suspensions  ||| S:23197 E:23209 ||| NNS
with  ||| S:23209 E:23214 ||| IN
given  ||| S:23214 E:23220 ||| VBN
radioligand  ||| S:23220 E:23232 ||| JJ
concentrations  ||| S:23232 E:23247 ||| NNS
in  ||| S:23247 E:23260 ||| IN
untreated  ||| S:23260 E:23270 ||| NN
or  ||| S:23270 E:23273 ||| CC
treated  ||| S:23273 E:23281 ||| JJ
media  ||| S:23281 E:23287 ||| NNS
were  ||| S:23287 E:23292 ||| VBD
incubated  ||| S:23292 E:23302 ||| VBN
at  ||| S:23302 E:23305 ||| IN
4°C  ||| S:23305 E:23309 ||| CD
for  ||| S:23309 E:23313 ||| IN
90  ||| S:23313 E:23326 ||| CD
min ||| S:23326 E:23329 ||| NN
,  ||| S:23329 E:23331 ||| ,
unless  ||| S:23331 E:23338 ||| IN
indicated ||| S:23338 E:23347 ||| JJ
.  ||| S:23347 E:23349 ||| .
The  ||| S:23349 E:23353 ||| DT
free  ||| S:23353 E:23358 ||| JJ
and  ||| S:23358 E:23362 ||| CC
bound  ||| S:23362 E:23368 ||| VBN
125I-PEDF  ||| S:23368 E:23378 ||| NNP
were  ||| S:23378 E:23393 ||| VBD
separated  ||| S:23393 E:23403 ||| VBN
by  ||| S:23403 E:23406 ||| IN
filtration  ||| S:23406 E:23417 ||| NN
through  ||| S:23417 E:23425 ||| IN
glass-fiber  ||| S:23425 E:23437 ||| JJ
filters  ||| S:23437 E:23445 ||| NNS
and  ||| S:23445 E:23459 ||| CC
the  ||| S:23459 E:23463 ||| DT
bound  ||| S:23463 E:23469 ||| JJ
radioactivity  ||| S:23469 E:23483 ||| NN
was  ||| S:23483 E:23487 ||| VBD
determined  ||| S:23487 E:23498 ||| VBN
in  ||| S:23498 E:23501 ||| IN
the  ||| S:23501 E:23505 ||| DT
filters  ||| S:23505 E:23523 ||| NNS
using  ||| S:23523 E:23529 ||| VBG
a  ||| S:23529 E:23531 ||| DT
β-scintillation  ||| S:23531 E:23547 ||| JJ
counter  ||| S:23547 E:23555 ||| NN
( ||| S:23555 E:23556 ||| -LRB-
Beckman ||| S:23556 E:23563 ||| NNP
,  ||| S:23563 E:23565 ||| ,
model  ||| S:23565 E:23571 ||| NN
LS  ||| S:23571 E:23574 ||| NNP
3801 ||| S:23574 E:23578 ||| CD
) ||| S:23578 E:23579 ||| -RRB-
.  ||| S:23579 E:23591 ||| .
Nonspecific  ||| S:23591 E:23603 ||| JJ
binding  ||| S:23603 E:23611 ||| NN
was  ||| S:23611 E:23615 ||| VBD
calculated  ||| S:23615 E:23626 ||| VBN
from  ||| S:23626 E:23631 ||| IN
reactions  ||| S:23631 E:23641 ||| NNS
with  ||| S:23641 E:23646 ||| IN
a  ||| S:23646 E:23658 ||| DT
molar-excess  ||| S:23658 E:23671 ||| JJ
of  ||| S:23671 E:23674 ||| IN
unlabeled  ||| S:23674 E:23684 ||| JJ
ligand  ||| S:23684 E:23691 ||| NNS
( ||| S:23691 E:23692 ||| -LRB-
≥  ||| S:23692 E:23694 ||| NNP
50-fold ||| S:23694 E:23701 ||| NNP
)  ||| S:23701 E:23703 ||| -RRB-
over  ||| S:23703 E:23718 ||| IN
radioligand ||| S:23718 E:23729 ||| NN
.  ||| S:23729 E:23759 ||| .
Complex-formation  ||| S:23759 E:23777 ||| JJ
assays  ||| S:23777 E:23794 ||| JJ
Complex  ||| S:23794 E:23802 ||| JJ
formation  ||| S:23802 E:23812 ||| NN
between  ||| S:23812 E:23820 ||| IN
PEDF  ||| S:23820 E:23825 ||| NNP
and  ||| S:23825 E:23829 ||| CC
CM  ||| S:23829 E:23832 ||| NNP
components  ||| S:23832 E:23843 ||| NNS
was  ||| S:23843 E:23857 ||| VBD
assayed  ||| S:23857 E:23865 ||| VBN
by  ||| S:23865 E:23868 ||| IN
a  ||| S:23868 E:23870 ||| DT
method  ||| S:23870 E:23877 ||| NN
using  ||| S:23877 E:23883 ||| VBG
ultrafiltration  ||| S:23883 E:23899 ||| NN
through  ||| S:23899 E:23917 ||| IN
membranes  ||| S:23917 E:23927 ||| NN
of  ||| S:23927 E:23930 ||| IN
100,000  ||| S:23930 E:23938 ||| CD
MW  ||| S:23938 E:23941 ||| JJ
exclusion  ||| S:23941 E:23951 ||| NN
limit  ||| S:23951 E:23957 ||| NN
[  ||| S:23957 E:23959 ||| -LRB-
14  ||| S:23959 E:23962 ||| CD
]  ||| S:23962 E:23964 ||| -RRB-
.  ||| S:23964 E:23966 ||| .
Binding  ||| S:23966 E:23984 ||| JJ
reactions  ||| S:23984 E:23994 ||| NNS
were  ||| S:23994 E:23999 ||| VBD
performed  ||| S:23999 E:24009 ||| VBN
with  ||| S:24009 E:24014 ||| IN
a  ||| S:24014 E:24016 ||| DT
given  ||| S:24016 E:24022 ||| VBN
concentration  ||| S:24022 E:24036 ||| NN
of  ||| S:24036 E:24049 ||| IN
125I-PEDF  ||| S:24049 E:24059 ||| CD
in  ||| S:24059 E:24062 ||| IN
defined  ||| S:24062 E:24070 ||| VBN
or  ||| S:24070 E:24073 ||| CC
conditioned  ||| S:24073 E:24085 ||| JJ
media ||| S:24085 E:24090 ||| NNS
,  ||| S:24090 E:24092 ||| ,
and  ||| S:24092 E:24106 ||| CC
incubations  ||| S:24106 E:24118 ||| NN
with  ||| S:24118 E:24123 ||| IN
gentle  ||| S:24123 E:24130 ||| JJ
rotation  ||| S:24130 E:24139 ||| NN
at  ||| S:24139 E:24142 ||| IN
4°C  ||| S:24142 E:24146 ||| CD
for  ||| S:24146 E:24150 ||| IN
2  ||| S:24150 E:24152 ||| CD
h ||| S:24152 E:24153 ||| NNS
.  ||| S:24153 E:24155 ||| .
Free  ||| S:24155 E:24160 ||| JJ
and  ||| S:24160 E:24174 ||| CC
bound  ||| S:24174 E:24180 ||| JJ
ligand  ||| S:24180 E:24187 ||| NN
were  ||| S:24187 E:24192 ||| VBD
separated  ||| S:24192 E:24202 ||| VBN
by  ||| S:24202 E:24205 ||| IN
ultrafiltration  ||| S:24205 E:24221 ||| NN
through  ||| S:24221 E:24239 ||| IN
Microcon-100  ||| S:24239 E:24252 ||| NNP
( ||| S:24252 E:24253 ||| -LRB-
Amicon ||| S:24253 E:24259 ||| NNP
) ||| S:24259 E:24260 ||| -RRB-
.  ||| S:24260 E:24262 ||| .
The  ||| S:24262 E:24266 ||| DT
reaction  ||| S:24266 E:24275 ||| NN
mixtures  ||| S:24275 E:24284 ||| NNS
were  ||| S:24284 E:24289 ||| VBD
diluted  ||| S:24289 E:24307 ||| VBN
40-fold  ||| S:24307 E:24315 ||| CD
with  ||| S:24315 E:24320 ||| IN
cold  ||| S:24320 E:24325 ||| JJ
20  ||| S:24325 E:24328 ||| CD
mM  ||| S:24328 E:24331 ||| JJ
sodium  ||| S:24331 E:24338 ||| NNS
phosphate  ||| S:24338 E:24348 ||| VBP
pH  ||| S:24348 E:24351 ||| JJ
6.5 ||| S:24351 E:24354 ||| CD
,  ||| S:24354 E:24356 ||| ,
20  ||| S:24356 E:24359 ||| CD
mM  ||| S:24359 E:24372 ||| JJ
NaCl ||| S:24372 E:24376 ||| NN
,  ||| S:24376 E:24378 ||| ,
10 ||| S:24378 E:24380 ||| CD
%  ||| S:24380 E:24382 ||| NN
glycerol  ||| S:24382 E:24391 ||| NNS
and  ||| S:24391 E:24395 ||| CC
immediately  ||| S:24395 E:24407 ||| RB
ultrafiltrated ||| S:24407 E:24421 ||| JJ
,  ||| S:24421 E:24433 ||| ,
repeating  ||| S:24433 E:24443 ||| VBG
twice  ||| S:24443 E:24449 ||| RB
to  ||| S:24449 E:24452 ||| TO
ensure  ||| S:24452 E:24459 ||| VB
removal  ||| S:24459 E:24467 ||| NN
of  ||| S:24467 E:24470 ||| IN
free  ||| S:24470 E:24475 ||| JJ
ligand  ||| S:24475 E:24482 ||| NN
from  ||| S:24482 E:24487 ||| IN
the  ||| S:24487 E:24501 ||| DT
complexes ||| S:24501 E:24510 ||| NNS
.  ||| S:24510 E:24512 ||| .
Each  ||| S:24512 E:24517 ||| DT
Microcon  ||| S:24517 E:24526 ||| JJ
retenate  ||| S:24526 E:24535 ||| JJ
cup  ||| S:24535 E:24539 ||| NN
was  ||| S:24539 E:24543 ||| VBD
transferred  ||| S:24543 E:24555 ||| VBN
to  ||| S:24555 E:24568 ||| TO
scintillation  ||| S:24568 E:24582 ||| VB
vials ||| S:24582 E:24587 ||| NNS
,  ||| S:24587 E:24589 ||| ,
mixed  ||| S:24589 E:24595 ||| VBN
with  ||| S:24595 E:24600 ||| IN
5  ||| S:24600 E:24602 ||| CD
ml  ||| S:24602 E:24605 ||| CD
BioSafe  ||| S:24605 E:24613 ||| JJ
II  ||| S:24613 E:24616 ||| NNP
liquid  ||| S:24616 E:24633 ||| JJ
scintillation  ||| S:24633 E:24647 ||| JJ
solution  ||| S:24647 E:24656 ||| NN
( ||| S:24656 E:24657 ||| -LRB-
Research  ||| S:24657 E:24666 ||| NNP
Products  ||| S:24666 E:24675 ||| NNPS
International ||| S:24675 E:24688 ||| NNP
)  ||| S:24688 E:24700 ||| -RRB-
by  ||| S:24700 E:24703 ||| IN
extensive  ||| S:24703 E:24713 ||| JJ
vortexing ||| S:24713 E:24722 ||| NN
,  ||| S:24722 E:24724 ||| ,
and  ||| S:24724 E:24728 ||| CC
its  ||| S:24728 E:24732 ||| PRP$
radioactivity  ||| S:24732 E:24746 ||| NN
determined  ||| S:24746 E:24767 ||| VBN
using  ||| S:24767 E:24773 ||| VBG
a  ||| S:24773 E:24775 ||| DT
β-scintillation  ||| S:24775 E:24791 ||| JJ
counter ||| S:24791 E:24798 ||| NN
.  ||| S:24798 E:24800 ||| .
Nonspecific  ||| S:24800 E:24812 ||| JJ
binding ||| S:24812 E:24819 ||| NN
,  ||| S:24819 E:24831 ||| ,
calculated  ||| S:24831 E:24842 ||| VBN
from  ||| S:24842 E:24847 ||| IN
reactions  ||| S:24847 E:24857 ||| NNS
with  ||| S:24857 E:24862 ||| IN
an  ||| S:24862 E:24865 ||| DT
excess  ||| S:24865 E:24872 ||| NN
of  ||| S:24872 E:24875 ||| IN
unlabeled  ||| S:24875 E:24895 ||| JJ
ligand  ||| S:24895 E:24902 ||| NNS
( ||| S:24902 E:24903 ||| -LRB-
100-fold ||| S:24903 E:24911 ||| NNP
)  ||| S:24911 E:24913 ||| -RRB-
over  ||| S:24913 E:24918 ||| IN
radioligand ||| S:24918 E:24929 ||| NN
,  ||| S:24929 E:24931 ||| ,
reached  ||| S:24931 E:24939 ||| VBN
about  ||| S:24939 E:24945 ||| IN
40 ||| S:24945 E:24947 ||| CD
%  ||| S:24947 E:24949 ||| NN
of  ||| S:24949 E:24962 ||| IN
the  ||| S:24962 E:24966 ||| DT
total  ||| S:24966 E:24972 ||| JJ
binding ||| S:24972 E:24979 ||| NN
.  ||| S:24979 E:25009 ||| .
Enzymatic  ||| S:25009 E:25019 ||| JJ
digestion  ||| S:25019 E:25029 ||| JJ
treatments  ||| S:25029 E:25050 ||| NNS
The  ||| S:25050 E:25054 ||| DT
presence  ||| S:25054 E:25063 ||| NN
of  ||| S:25063 E:25066 ||| IN
GAGs  ||| S:25066 E:25071 ||| NNP
was  ||| S:25071 E:25075 ||| VBD
assayed  ||| S:25075 E:25083 ||| VBN
using  ||| S:25083 E:25089 ||| VBG
specific  ||| S:25089 E:25098 ||| JJ
GAG  ||| S:25098 E:25112 ||| NNP
lyases ||| S:25112 E:25118 ||| NN
,  ||| S:25118 E:25131 ||| ,
i.e.  ||| S:25131 E:25136 ||| FW
,  ||| S:25136 E:25138 ||| ,
the  ||| S:25138 E:25142 ||| DT
presence  ||| S:25142 E:25151 ||| NN
of  ||| S:25151 E:25154 ||| IN
heparin ||| S:25154 E:25161 ||| NN
,  ||| S:25161 E:25163 ||| ,
HS ||| S:25163 E:25165 ||| NNP
,  ||| S:25165 E:25177 ||| ,
and  ||| S:25177 E:25181 ||| CC
chondroitin  ||| S:25181 E:25193 ||| JJ
sulfates  ||| S:25193 E:25202 ||| NN
with  ||| S:25202 E:25207 ||| IN
heparinase ||| S:25207 E:25217 ||| NN
,  ||| S:25217 E:25219 ||| ,
heparitinase ||| S:25219 E:25231 ||| NN
,  ||| S:25231 E:25243 ||| ,
and  ||| S:25243 E:25247 ||| CC
chondroitin  ||| S:25247 E:25259 ||| JJ
ABC  ||| S:25259 E:25263 ||| NNP
respectively ||| S:25263 E:25275 ||| RB
.  ||| S:25275 E:25277 ||| .
The  ||| S:25277 E:25281 ||| DT
amount  ||| S:25281 E:25288 ||| NN
of  ||| S:25288 E:25291 ||| IN
GAGs  ||| S:25291 E:25296 ||| NNP
was  ||| S:25296 E:25310 ||| VBD
determined  ||| S:25310 E:25321 ||| VBN
by  ||| S:25321 E:25324 ||| IN
the  ||| S:25324 E:25328 ||| DT
amount  ||| S:25328 E:25335 ||| NN
of  ||| S:25335 E:25338 ||| IN
Δ  ||| S:25338 E:25340 ||| NNP
4-hexuronate  ||| S:25340 E:25353 ||| NNP
produced  ||| S:25353 E:25362 ||| VBD
after  ||| S:25362 E:25378 ||| IN
the  ||| S:25378 E:25382 ||| DT
eliminative  ||| S:25382 E:25394 ||| JJ
cleavage  ||| S:25394 E:25403 ||| NN
of  ||| S:25403 E:25406 ||| IN
each  ||| S:25406 E:25411 ||| DT
substrate  ||| S:25411 E:25421 ||| NN
by  ||| S:25421 E:25424 ||| IN
the  ||| S:25424 E:25438 ||| DT
corresponding  ||| S:25438 E:25452 ||| JJ
GAG  ||| S:25452 E:25456 ||| NNP
lyase ||| S:25456 E:25461 ||| NN
.  ||| S:25461 E:25463 ||| .
Samples  ||| S:25463 E:25471 ||| NNS
were  ||| S:25471 E:25476 ||| VBD
depleted  ||| S:25476 E:25485 ||| VBN
of  ||| S:25485 E:25498 ||| IN
proteins  ||| S:25498 E:25507 ||| NNS
by  ||| S:25507 E:25510 ||| IN
protease  ||| S:25510 E:25519 ||| JJ
treatment  ||| S:25519 E:25529 ||| NN
to  ||| S:25529 E:25532 ||| TO
avoid  ||| S:25532 E:25538 ||| VB
interference  ||| S:25538 E:25551 ||| NN
in  ||| S:25551 E:25564 ||| IN
absorbance  ||| S:25564 E:25575 ||| JJ
readings  ||| S:25575 E:25584 ||| NNS
of  ||| S:25584 E:25587 ||| IN
the  ||| S:25587 E:25591 ||| DT
product ||| S:25591 E:25598 ||| NN
.  ||| S:25598 E:25600 ||| .
For  ||| S:25600 E:25604 ||| IN
heparinase  ||| S:25604 E:25615 ||| NN
and  ||| S:25615 E:25629 ||| CC
heparitinase  ||| S:25629 E:25642 ||| JJ
reactions ||| S:25642 E:25651 ||| NNS
,  ||| S:25651 E:25653 ||| ,
samples  ||| S:25653 E:25661 ||| NNS
were  ||| S:25661 E:25666 ||| VBD
treated  ||| S:25666 E:25674 ||| VBN
with  ||| S:25674 E:25679 ||| IN
5  ||| S:25679 E:25691 ||| CD
milliunits  ||| S:25691 E:25702 ||| NN
of  ||| S:25702 E:25705 ||| IN
each  ||| S:25705 E:25710 ||| DT
enzyme  ||| S:25710 E:25717 ||| NN
in  ||| S:25717 E:25720 ||| IN
150  ||| S:25720 E:25724 ||| CD
μl  ||| S:25724 E:25727 ||| NN
of  ||| S:25727 E:25730 ||| IN
0.1  ||| S:25730 E:25734 ||| CD
M  ||| S:25734 E:25736 ||| NNP
sodium  ||| S:25736 E:25753 ||| NN
acetate  ||| S:25753 E:25761 ||| NN
and  ||| S:25761 E:25765 ||| CC
1  ||| S:25765 E:25767 ||| CD
mM  ||| S:25767 E:25770 ||| JJ
CaCl  ||| S:25770 E:25786 ||| JJ
2  ||| S:25786 E:25788 ||| CD
,  ||| S:25788 E:25790 ||| ,
pH  ||| S:25790 E:25793 ||| JJ
7  ||| S:25793 E:25795 ||| CD
and  ||| S:25795 E:25799 ||| CC
incubations  ||| S:25799 E:25811 ||| NN
at  ||| S:25811 E:25814 ||| IN
37°C  ||| S:25814 E:25819 ||| CD
for  ||| S:25819 E:25833 ||| IN
various  ||| S:25833 E:25841 ||| JJ
time  ||| S:25841 E:25846 ||| NN
periods ||| S:25846 E:25853 ||| NNS
.  ||| S:25853 E:25855 ||| .
The  ||| S:25855 E:25859 ||| DT
reactions  ||| S:25859 E:25869 ||| NNS
were  ||| S:25869 E:25874 ||| VBD
stopped  ||| S:25874 E:25882 ||| VBN
by  ||| S:25882 E:25885 ||| IN
the  ||| S:25885 E:25899 ||| DT
addition  ||| S:25899 E:25908 ||| NN
of  ||| S:25908 E:25911 ||| IN
1  ||| S:25911 E:25913 ||| CD
ml  ||| S:25913 E:25916 ||| NN
of  ||| S:25916 E:25919 ||| IN
0.06  ||| S:25919 E:25924 ||| NNP
M  ||| S:25924 E:25926 ||| NNP
HCl ||| S:25926 E:25929 ||| NNP
.  ||| S:25929 E:25931 ||| .
The  ||| S:25931 E:25935 ||| DT
soluble  ||| S:25935 E:25943 ||| JJ
material  ||| S:25943 E:25952 ||| NN
was  ||| S:25952 E:25966 ||| VBD
separated  ||| S:25966 E:25976 ||| VBN
by  ||| S:25976 E:25979 ||| IN
centrifugation  ||| S:25979 E:25994 ||| NNS
( ||| S:25994 E:25995 ||| -LRB-
3000  ||| S:25995 E:26000 ||| CD
×  ||| S:26000 E:26013 ||| CD
g  ||| S:26013 E:26015 ||| NN
,  ||| S:26015 E:26017 ||| ,
10  ||| S:26017 E:26020 ||| CD
min ||| S:26020 E:26023 ||| CD
)  ||| S:26023 E:26025 ||| -RRB-
and  ||| S:26025 E:26029 ||| CC
assayed  ||| S:26029 E:26037 ||| NN
for  ||| S:26037 E:26051 ||| IN
absorbance  ||| S:26051 E:26062 ||| NN
at  ||| S:26062 E:26065 ||| IN
235  ||| S:26065 E:26069 ||| CD
nm  ||| S:26069 E:26072 ||| NN
to  ||| S:26072 E:26075 ||| TO
measure  ||| S:26075 E:26083 ||| VB
the  ||| S:26083 E:26087 ||| DT
concentration  ||| S:26087 E:26101 ||| NN
of  ||| S:26101 E:26114 ||| IN
product  ||| S:26114 E:26122 ||| NN
Δ  ||| S:26122 E:26124 ||| NNP
4-hexuronate  ||| S:26124 E:26137 ||| NNP
( ||| S:26137 E:26138 ||| -LRB-
Molar  ||| S:26138 E:26144 ||| FW
extinction  ||| S:26144 E:26155 ||| FW
coefficient  ||| S:26155 E:26167 ||| FW
=  ||| S:26167 E:26179 ||| SYM
5500 ||| S:26179 E:26183 ||| CD
;  ||| S:26183 E:26185 ||| :
[  ||| S:26185 E:26187 ||| -LRB-
33  ||| S:26187 E:26190 ||| CD
]  ||| S:26190 E:26192 ||| CD
) ||| S:26192 E:26193 ||| -RRB-
.  ||| S:26193 E:26195 ||| .
For  ||| S:26195 E:26199 ||| IN
the  ||| S:26199 E:26203 ||| DT
chondroitinase  ||| S:26203 E:26218 ||| JJ
ABC  ||| S:26218 E:26222 ||| NNP
reactions ||| S:26222 E:26231 ||| NNS
,  ||| S:26231 E:26243 ||| ,
each  ||| S:26243 E:26248 ||| DT
chondroitin  ||| S:26248 E:26260 ||| JJ
sulfates  ||| S:26260 E:26269 ||| JJ
A ||| S:26269 E:26270 ||| NN
,  ||| S:26270 E:26272 ||| ,
B  ||| S:26272 E:26274 ||| NNP
and  ||| S:26274 E:26278 ||| CC
C  ||| S:26278 E:26280 ||| $
substrate  ||| S:26280 E:26290 ||| CD
( ||| S:26290 E:26291 ||| -LRB-
1  ||| S:26291 E:26293 ||| CD
mg  ||| S:26293 E:26306 ||| CD
each ||| S:26306 E:26310 ||| CD
)  ||| S:26310 E:26312 ||| -RRB-
and  ||| S:26312 E:26316 ||| CC
concentrated  ||| S:26316 E:26329 ||| JJ
CM ||| S:26329 E:26331 ||| NNP
,  ||| S:26331 E:26333 ||| ,
were  ||| S:26333 E:26338 ||| VBD
incubated  ||| S:26338 E:26348 ||| VBN
with  ||| S:26348 E:26353 ||| IN
0.12  ||| S:26353 E:26358 ||| CD
units  ||| S:26358 E:26374 ||| NNS
of  ||| S:26374 E:26377 ||| IN
chondroitinase  ||| S:26377 E:26392 ||| JJ
ABC  ||| S:26392 E:26396 ||| NNP
in  ||| S:26396 E:26399 ||| IN
1  ||| S:26399 E:26401 ||| CD
ml  ||| S:26401 E:26404 ||| NN
of  ||| S:26404 E:26407 ||| IN
50  ||| S:26407 E:26410 ||| CD
mM  ||| S:26410 E:26413 ||| JJ
Tris-HCl  ||| S:26413 E:26422 ||| JJ
pH  ||| S:26422 E:26425 ||| JJ
8.0 ||| S:26425 E:26428 ||| NN
,  ||| S:26428 E:26440 ||| ,
60  ||| S:26440 E:26443 ||| CD
mM  ||| S:26443 E:26446 ||| JJ
sodium  ||| S:26446 E:26453 ||| JJ
acetate ||| S:26453 E:26460 ||| NN
,  ||| S:26460 E:26462 ||| ,
and  ||| S:26462 E:26466 ||| CC
0.02 ||| S:26466 E:26470 ||| CD
%  ||| S:26470 E:26472 ||| NN
BSA  ||| S:26472 E:26476 ||| NN
at  ||| S:26476 E:26479 ||| IN
37°C ||| S:26479 E:26483 ||| CD
.  ||| S:26483 E:26485 ||| .
At  ||| S:26485 E:26488 ||| IN
various  ||| S:26488 E:26506 ||| JJ
time  ||| S:26506 E:26511 ||| NN
periods ||| S:26511 E:26518 ||| NNS
,  ||| S:26518 E:26520 ||| ,
aliquots  ||| S:26520 E:26529 ||| VBG
of  ||| S:26529 E:26532 ||| IN
0.1  ||| S:26532 E:26536 ||| CD
ml  ||| S:26536 E:26539 ||| NNS
were  ||| S:26539 E:26544 ||| VBD
removed  ||| S:26544 E:26552 ||| VBN
and  ||| S:26552 E:26556 ||| CC
mixed  ||| S:26556 E:26572 ||| VBN
with  ||| S:26572 E:26577 ||| IN
0.9  ||| S:26577 E:26581 ||| CD
ml  ||| S:26581 E:26584 ||| NN
of  ||| S:26584 E:26587 ||| IN
45  ||| S:26587 E:26590 ||| CD
mM  ||| S:26590 E:26593 ||| JJ
KCl  ||| S:26593 E:26597 ||| JJ
pH  ||| S:26597 E:26600 ||| JJ
1.8  ||| S:26600 E:26604 ||| CD
to  ||| S:26604 E:26607 ||| TO
stop  ||| S:26607 E:26612 ||| VB
the  ||| S:26612 E:26616 ||| DT
reaction ||| S:26616 E:26624 ||| NN
.  ||| S:26624 E:26636 ||| .
Insoluble  ||| S:26636 E:26646 ||| JJ
material  ||| S:26646 E:26655 ||| NN
was  ||| S:26655 E:26659 ||| VBD
removed  ||| S:26659 E:26667 ||| VBN
by  ||| S:26667 E:26670 ||| IN
centrifugation  ||| S:26670 E:26685 ||| NNS
( ||| S:26685 E:26686 ||| -LRB-
1000  ||| S:26686 E:26691 ||| CD
×  ||| S:26691 E:26704 ||| CD
g  ||| S:26704 E:26706 ||| NN
,  ||| S:26706 E:26708 ||| ,
10  ||| S:26708 E:26711 ||| CD
min ||| S:26711 E:26714 ||| CD
)  ||| S:26714 E:26716 ||| -RRB-
and  ||| S:26716 E:26720 ||| CC
the  ||| S:26720 E:26724 ||| DT
supernatant  ||| S:26724 E:26746 ||| JJ
assayed  ||| S:26746 E:26754 ||| NN
for  ||| S:26754 E:26758 ||| IN
absorbance  ||| S:26758 E:26769 ||| NN
of  ||| S:26769 E:26772 ||| IN
Δ  ||| S:26772 E:26774 ||| NNP
4-hexuronate  ||| S:26774 E:26787 ||| NNP
at  ||| S:26787 E:26790 ||| IN
232  ||| S:26790 E:26794 ||| CD
nm ||| S:26794 E:26796 ||| NNS
.  ||| S:26796 E:26798 ||| .
For  ||| S:26798 E:26812 ||| IN
protein  ||| S:26812 E:26820 ||| NN
depletion ||| S:26820 E:26829 ||| NN
,  ||| S:26829 E:26831 ||| ,
CM  ||| S:26831 E:26834 ||| NNP
was  ||| S:26834 E:26838 ||| VBD
mixed  ||| S:26838 E:26844 ||| VBN
with  ||| S:26844 E:26849 ||| IN
subtilisin  ||| S:26849 E:26860 ||| NN
at  ||| S:26860 E:26863 ||| IN
0.4  ||| S:26863 E:26877 ||| CD
μg ||| S:26877 E:26879 ||| CD
/ ||| S:26879 E:26880 ||| CD
ml  ||| S:26880 E:26883 ||| NN
in  ||| S:26883 E:26886 ||| IN
20  ||| S:26886 E:26889 ||| CD
mM  ||| S:26889 E:26892 ||| JJ
Tris-HCl  ||| S:26892 E:26901 ||| JJ
pH  ||| S:26901 E:26904 ||| JJ
8.0 ||| S:26904 E:26907 ||| NN
,  ||| S:26907 E:26909 ||| ,
10 ||| S:26909 E:26911 ||| CD
%  ||| S:26911 E:26913 ||| NN
glycerol  ||| S:26913 E:26922 ||| NNS
and  ||| S:26922 E:26936 ||| CC
incubated  ||| S:26936 E:26946 ||| NN
at  ||| S:26946 E:26949 ||| IN
37°C  ||| S:26949 E:26954 ||| CD
for  ||| S:26954 E:26958 ||| IN
16  ||| S:26958 E:26961 ||| CD
h ||| S:26961 E:26962 ||| NNS
.  ||| S:26962 E:26964 ||| .
Subtilisin  ||| S:26964 E:26975 ||| NNP
was  ||| S:26975 E:26989 ||| VBD
heat-inactivated  ||| S:26989 E:27006 ||| JJ
at  ||| S:27006 E:27009 ||| IN
75°C  ||| S:27009 E:27014 ||| CD
for  ||| S:27014 E:27018 ||| IN
25  ||| S:27018 E:27021 ||| CD
min ||| S:27021 E:27024 ||| NNS
.  ||| S:27024 E:27026 ||| .
The  ||| S:27026 E:27030 ||| DT
protein  ||| S:27030 E:27048 ||| NN
concentration  ||| S:27048 E:27062 ||| NN
after  ||| S:27062 E:27068 ||| IN
the  ||| S:27068 E:27072 ||| DT
reaction  ||| S:27072 E:27081 ||| NN
was  ||| S:27081 E:27085 ||| VBD
less  ||| S:27085 E:27090 ||| JJR
than  ||| S:27090 E:27095 ||| IN
0.1 ||| S:27095 E:27098 ||| CD
%  ||| S:27098 E:27100 ||| NN
of  ||| S:27100 E:27113 ||| IN
the  ||| S:27113 E:27117 ||| DT
starting  ||| S:27117 E:27126 ||| VBG
material ||| S:27126 E:27134 ||| NN
.  ||| S:27134 E:27146 ||| .
To  ||| S:27146 E:27149 ||| TO
deplete  ||| S:27149 E:27157 ||| VB
cell  ||| S:27157 E:27162 ||| NN
cultures  ||| S:27162 E:27171 ||| NNS
of  ||| S:27171 E:27174 ||| IN
GAGs ||| S:27174 E:27178 ||| NNP
,  ||| S:27178 E:27180 ||| ,
Y-79  ||| S:27180 E:27185 ||| CD
cells  ||| S:27185 E:27191 ||| NNS
in  ||| S:27191 E:27204 ||| IN
defined  ||| S:27204 E:27212 ||| VBN
serum-free  ||| S:27212 E:27223 ||| JJ
medium  ||| S:27223 E:27230 ||| NN
( ||| S:27230 E:27231 ||| -LRB-
as  ||| S:27231 E:27234 ||| IN
above ||| S:27234 E:27239 ||| JJ
)  ||| S:27239 E:27241 ||| -RRB-
at  ||| S:27241 E:27244 ||| IN
a  ||| S:27244 E:27246 ||| DT
density  ||| S:27246 E:27254 ||| NN
of  ||| S:27254 E:27257 ||| IN
1.25  ||| S:27257 E:27272 ||| CD
×  ||| S:27272 E:27274 ||| CD
10  ||| S:27274 E:27277 ||| CD
5cells ||| S:27277 E:27283 ||| CD
/ ||| S:27283 E:27284 ||| CD
ml  ||| S:27284 E:27287 ||| NNS
were  ||| S:27287 E:27292 ||| VBD
cultured  ||| S:27292 E:27301 ||| VBN
in  ||| S:27301 E:27304 ||| IN
96-well  ||| S:27304 E:27312 ||| CD
culture  ||| S:27312 E:27320 ||| NN
plates  ||| S:27320 E:27337 ||| NNS
( ||| S:27337 E:27338 ||| -LRB-
150  ||| S:27338 E:27342 ||| CD
μl ||| S:27342 E:27344 ||| NNS
/ ||| S:27344 E:27345 ||| VBP
well ||| S:27345 E:27349 ||| RB
)  ||| S:27349 E:27351 ||| -RRB-
and  ||| S:27351 E:27355 ||| CC
incubated  ||| S:27355 E:27365 ||| NN
at  ||| S:27365 E:27368 ||| IN
37°C  ||| S:27368 E:27373 ||| CD
in  ||| S:27373 E:27376 ||| IN
a  ||| S:27376 E:27378 ||| DT
5 ||| S:27378 E:27379 ||| CD
%  ||| S:27379 E:27381 ||| NN
CO  ||| S:27381 E:27395 ||| NNP
2  ||| S:27395 E:27397 ||| CD
environment  ||| S:27397 E:27409 ||| NN
for  ||| S:27409 E:27413 ||| IN
16  ||| S:27413 E:27416 ||| CD
h ||| S:27416 E:27417 ||| NNS
.  ||| S:27417 E:27419 ||| .
Hyaluronidase  ||| S:27419 E:27443 ||| NNP
( ||| S:27443 E:27444 ||| -LRB-
> ||| S:27444 E:27445 ||| FW
1TRU ||| S:27445 E:27449 ||| FW
/ ||| S:27449 E:27450 ||| FW
μl ||| S:27450 E:27452 ||| FW
) ||| S:27452 E:27453 ||| -RRB-
,  ||| S:27453 E:27455 ||| ,
heparinase  ||| S:27455 E:27466 ||| NNS
( ||| S:27466 E:27467 ||| -LRB-
1  ||| S:27467 E:27469 ||| CD
mu ||| S:27469 E:27471 ||| CD
/ ||| S:27471 E:27472 ||| CD
μl ||| S:27472 E:27474 ||| CD
)  ||| S:27474 E:27476 ||| -RRB-
or  ||| S:27476 E:27479 ||| CC
heparitinase  ||| S:27479 E:27492 ||| NNS
( ||| S:27492 E:27493 ||| -LRB-
1  ||| S:27493 E:27505 ||| CD
mu ||| S:27505 E:27507 ||| CD
/ ||| S:27507 E:27508 ||| CD
μl ||| S:27508 E:27510 ||| CD
)  ||| S:27510 E:27512 ||| -RRB-
were  ||| S:27512 E:27517 ||| VBD
each  ||| S:27517 E:27522 ||| DT
added  ||| S:27522 E:27528 ||| VBN
to  ||| S:27528 E:27531 ||| TO
various  ||| S:27531 E:27539 ||| JJ
wells  ||| S:27539 E:27545 ||| NNS
and  ||| S:27545 E:27549 ||| CC
incubated  ||| S:27549 E:27559 ||| NN
at  ||| S:27559 E:27572 ||| IN
37°C  ||| S:27572 E:27577 ||| CD
in  ||| S:27577 E:27580 ||| IN
a  ||| S:27580 E:27582 ||| DT
5 ||| S:27582 E:27583 ||| CD
%  ||| S:27583 E:27585 ||| NN
CO  ||| S:27585 E:27599 ||| NNP
2  ||| S:27599 E:27601 ||| CD
environment  ||| S:27601 E:27613 ||| NN
for  ||| S:27613 E:27617 ||| IN
1  ||| S:27617 E:27619 ||| CD
h ||| S:27619 E:27620 ||| NNS
.  ||| S:27620 E:27650 ||| .
Chlorate  ||| S:27650 E:27659 ||| JJ
treatment  ||| S:27659 E:27669 ||| NN
of  ||| S:27669 E:27672 ||| IN
cell  ||| S:27672 E:27677 ||| NN
cultures  ||| S:27677 E:27696 ||| NNS
To  ||| S:27696 E:27699 ||| TO
prevent  ||| S:27699 E:27707 ||| VB
sulfation  ||| S:27707 E:27717 ||| VBN
of  ||| S:27717 E:27720 ||| IN
GAGs  ||| S:27720 E:27725 ||| JJ
in  ||| S:27725 E:27728 ||| IN
cell  ||| S:27728 E:27733 ||| NN
cultures ||| S:27733 E:27741 ||| NNS
,  ||| S:27741 E:27743 ||| ,
we  ||| S:27743 E:27746 ||| PRP
used  ||| S:27746 E:27761 ||| VBD
a  ||| S:27761 E:27763 ||| DT
method  ||| S:27763 E:27770 ||| NN
previously  ||| S:27770 E:27781 ||| RB
described  ||| S:27781 E:27791 ||| VBN
[  ||| S:27791 E:27793 ||| -LRB-
33  ||| S:27793 E:27796 ||| CD
]  ||| S:27796 E:27798 ||| -RRB-
.  ||| S:27798 E:27800 ||| .
Y-79  ||| S:27800 E:27805 ||| NNP
cells  ||| S:27805 E:27811 ||| NNS
( ||| S:27811 E:27812 ||| -LRB-
1.25  ||| S:27812 E:27817 ||| CD
×  ||| S:27817 E:27829 ||| CD
10  ||| S:27829 E:27832 ||| CD
5cells ||| S:27832 E:27838 ||| CD
/ ||| S:27838 E:27839 ||| CD
ml ||| S:27839 E:27841 ||| CD
)  ||| S:27841 E:27843 ||| -RRB-
were  ||| S:27843 E:27848 ||| VBD
cultured  ||| S:27848 E:27857 ||| VBN
in  ||| S:27857 E:27860 ||| IN
48-well  ||| S:27860 E:27868 ||| CD
plates  ||| S:27868 E:27875 ||| NNS
( ||| S:27875 E:27876 ||| -LRB-
300  ||| S:27876 E:27890 ||| CD
μl ||| S:27890 E:27892 ||| NNS
/ ||| S:27892 E:27893 ||| VBP
well ||| S:27893 E:27897 ||| RB
)  ||| S:27897 E:27899 ||| -RRB-
in  ||| S:27899 E:27902 ||| IN
defined  ||| S:27902 E:27910 ||| VBN
serum-free  ||| S:27910 E:27921 ||| JJ
medium  ||| S:27921 E:27928 ||| NN
with  ||| S:27928 E:27933 ||| IN
or  ||| S:27933 E:27936 ||| CC
without  ||| S:27936 E:27944 ||| IN
30  ||| S:27944 E:27957 ||| CD
mM  ||| S:27957 E:27960 ||| JJ
sodium  ||| S:27960 E:27967 ||| NN
chlorate  ||| S:27967 E:27976 ||| NNS
and  ||| S:27976 E:27980 ||| CC
10  ||| S:27980 E:27983 ||| CD
mM  ||| S:27983 E:27986 ||| JJ
sodium  ||| S:27986 E:27993 ||| JJ
sulfate  ||| S:27993 E:28001 ||| NN
at  ||| S:28001 E:28004 ||| IN
37°C  ||| S:28004 E:28009 ||| CD
in  ||| S:28009 E:28012 ||| IN
a  ||| S:28012 E:28024 ||| DT
5 ||| S:28024 E:28025 ||| CD
%  ||| S:28025 E:28027 ||| NN
CO  ||| S:28027 E:28041 ||| NNP
2  ||| S:28041 E:28043 ||| CD
environment  ||| S:28043 E:28055 ||| NN
for  ||| S:28055 E:28059 ||| IN
24  ||| S:28059 E:28062 ||| CD
h ||| S:28062 E:28063 ||| NNS
.  ||| S:28063 E:28093 ||| .
GAG  ||| S:28093 E:28097 ||| NNP
detection  ||| S:28097 E:28107 ||| FW
assays  ||| S:28107 E:28124 ||| FW
GAGs  ||| S:28124 E:28129 ||| FW
and  ||| S:28129 E:28133 ||| CC
proteins  ||| S:28133 E:28142 ||| NNS
resolved  ||| S:28142 E:28151 ||| VBN
by  ||| S:28151 E:28154 ||| IN
SDS-polyacrylamide  ||| S:28154 E:28173 ||| JJ
gel  ||| S:28173 E:28187 ||| JJ
electrophoresis  ||| S:28187 E:28203 ||| NN
in  ||| S:28203 E:28206 ||| IN
Tricine ||| S:28206 E:28213 ||| NNP
/ ||| S:28213 E:28214 ||| NNP
SDS  ||| S:28214 E:28218 ||| NNP
buffer ||| S:28218 E:28224 ||| NN
,  ||| S:28224 E:28226 ||| ,
as  ||| S:28226 E:28229 ||| RB
instructed  ||| S:28229 E:28240 ||| VBN
by  ||| S:28240 E:28253 ||| IN
manufacturer  ||| S:28253 E:28266 ||| NN
( ||| S:28266 E:28267 ||| -LRB-
Novex ||| S:28267 E:28272 ||| NNP
) ||| S:28272 E:28273 ||| -RRB-
,  ||| S:28273 E:28275 ||| ,
were  ||| S:28275 E:28280 ||| VBD
detected  ||| S:28280 E:28289 ||| VBN
with  ||| S:28289 E:28294 ||| IN
specific  ||| S:28294 E:28303 ||| JJ
stains ||| S:28303 E:28309 ||| NNS
.  ||| S:28309 E:28321 ||| .
For  ||| S:28321 E:28325 ||| IN
GAG  ||| S:28325 E:28329 ||| NNP
detection ||| S:28329 E:28338 ||| NN
,  ||| S:28338 E:28340 ||| ,
the  ||| S:28340 E:28344 ||| DT
gels  ||| S:28344 E:28349 ||| NN
were  ||| S:28349 E:28354 ||| VBD
incubated  ||| S:28354 E:28364 ||| JJ
sequentially  ||| S:28364 E:28387 ||| NN
in  ||| S:28387 E:28390 ||| IN
0.2 ||| S:28390 E:28393 ||| CD
%  ||| S:28393 E:28395 ||| NN
Toluidine  ||| S:28395 E:28405 ||| NNP
Blue-O  ||| S:28405 E:28412 ||| NNP
in  ||| S:28412 E:28415 ||| IN
ethanol-water-acetic  ||| S:28415 E:28436 ||| JJ
acid  ||| S:28436 E:28451 ||| NN
( ||| S:28451 E:28452 ||| -LRB-
50 ||| S:28452 E:28454 ||| CD
: ||| S:28454 E:28455 ||| :
49 ||| S:28455 E:28457 ||| CD
: ||| S:28457 E:28458 ||| :
1 ||| S:28458 E:28459 ||| LS
)  ||| S:28459 E:28461 ||| -RRB-
for  ||| S:28461 E:28465 ||| IN
30  ||| S:28465 E:28468 ||| CD
minutes ||| S:28468 E:28475 ||| NNS
,  ||| S:28475 E:28477 ||| ,
in  ||| S:28477 E:28480 ||| IN
ethanol-water-acetic  ||| S:28480 E:28501 ||| JJ
acid  ||| S:28501 E:28516 ||| NN
( ||| S:28516 E:28517 ||| -LRB-
50 ||| S:28517 E:28519 ||| CD
: ||| S:28519 E:28520 ||| :
49 ||| S:28520 E:28522 ||| CD
: ||| S:28522 E:28523 ||| :
1 ||| S:28523 E:28524 ||| LS
)  ||| S:28524 E:28526 ||| -RRB-
for  ||| S:28526 E:28530 ||| IN
1  ||| S:28530 E:28532 ||| CD
h ||| S:28532 E:28533 ||| NN
,  ||| S:28533 E:28535 ||| ,
and  ||| S:28535 E:28539 ||| CC
in  ||| S:28539 E:28542 ||| IN
H  ||| S:28542 E:28555 ||| NNP
2  ||| S:28555 E:28557 ||| CD
O  ||| S:28557 E:28559 ||| NN
for  ||| S:28559 E:28563 ||| IN
16  ||| S:28563 E:28566 ||| CD
h.  ||| S:28566 E:28569 ||| CD
[  ||| S:28569 E:28571 ||| -LRB-
34  ||| S:28571 E:28574 ||| CD
]  ||| S:28574 E:28576 ||| -RRB-
.  ||| S:28576 E:28578 ||| .
For  ||| S:28578 E:28582 ||| IN
protein  ||| S:28582 E:28600 ||| NN
detection ||| S:28600 E:28609 ||| NN
,  ||| S:28609 E:28611 ||| ,
the  ||| S:28611 E:28615 ||| DT
gels  ||| S:28615 E:28620 ||| NN
were  ||| S:28620 E:28625 ||| VBD
sequentially  ||| S:28625 E:28638 ||| JJ
incubated  ||| S:28638 E:28648 ||| NN
in  ||| S:28648 E:28651 ||| IN
0.5 ||| S:28651 E:28654 ||| CD
%  ||| S:28654 E:28666 ||| NN
Coomassie  ||| S:28666 E:28676 ||| NNP
Brilliant  ||| S:28676 E:28686 ||| NNP
Blue  ||| S:28686 E:28691 ||| NNP
in  ||| S:28691 E:28694 ||| IN
50 ||| S:28694 E:28696 ||| CD
%  ||| S:28696 E:28698 ||| NN
methanol ||| S:28698 E:28706 ||| VBD
/ ||| S:28706 E:28707 ||| CD
10 ||| S:28707 E:28709 ||| CD
%  ||| S:28709 E:28711 ||| NN
acetic  ||| S:28711 E:28718 ||| NN
acid  ||| S:28718 E:28733 ||| NN
and  ||| S:28733 E:28737 ||| CC
in  ||| S:28737 E:28740 ||| IN
10 ||| S:28740 E:28742 ||| CD
%  ||| S:28742 E:28744 ||| NN
methanol ||| S:28744 E:28752 ||| VBD
/ ||| S:28752 E:28753 ||| CD
10 ||| S:28753 E:28755 ||| CD
%  ||| S:28755 E:28757 ||| NN
isopropanol ||| S:28757 E:28768 ||| NN
.  ||| S:28768 E:28770 ||| .
GAG  ||| S:28770 E:28774 ||| NNP
detection  ||| S:28774 E:28784 ||| NN
was  ||| S:28784 E:28798 ||| VBD
also  ||| S:28798 E:28803 ||| RB
performed  ||| S:28803 E:28813 ||| VBN
by  ||| S:28813 E:28816 ||| IN
the  ||| S:28816 E:28820 ||| DT
Toluidine  ||| S:28820 E:28830 ||| JJ
Blue-O  ||| S:28830 E:28837 ||| JJ
precipitation  ||| S:28837 E:28851 ||| NN
and  ||| S:28851 E:28865 ||| CC
dot-blot  ||| S:28865 E:28874 ||| JJ
method  ||| S:28874 E:28881 ||| NN
as  ||| S:28881 E:28884 ||| IN
described  ||| S:28884 E:28894 ||| VBN
previously  ||| S:28894 E:28905 ||| RB
[  ||| S:28905 E:28907 ||| -LRB-
34  ||| S:28907 E:28910 ||| CD
]  ||| S:28910 E:28912 ||| -RRB-
.  ||| S:28912 E:28914 ||| .
Briefly ||| S:28914 E:28921 ||| RB
,  ||| S:28921 E:28933 ||| ,
200  ||| S:28933 E:28937 ||| CD
μl  ||| S:28937 E:28940 ||| NN
of  ||| S:28940 E:28943 ||| IN
sample  ||| S:28943 E:28950 ||| NN
were  ||| S:28950 E:28955 ||| VBD
applied  ||| S:28955 E:28963 ||| VBN
to  ||| S:28963 E:28966 ||| TO
each  ||| S:28966 E:28971 ||| DT
well  ||| S:28971 E:28976 ||| RB
of  ||| S:28976 E:28979 ||| IN
a  ||| S:28979 E:28981 ||| DT
48-well  ||| S:28981 E:28999 ||| CD
manifold  ||| S:28999 E:29008 ||| NNS
( ||| S:29008 E:29009 ||| -LRB-
Life  ||| S:29009 E:29014 ||| NNP
Technologies ||| S:29014 E:29026 ||| NNPS
)  ||| S:29026 E:29028 ||| -RRB-
onto  ||| S:29028 E:29033 ||| IN
a  ||| S:29033 E:29035 ||| DT
PVDF  ||| S:29035 E:29040 ||| NNP
membrane  ||| S:29040 E:29049 ||| NN
without  ||| S:29049 E:29067 ||| IN
vacuum ||| S:29067 E:29073 ||| NN
.  ||| S:29073 E:29075 ||| .
Then ||| S:29075 E:29079 ||| RB
,  ||| S:29079 E:29081 ||| ,
5  ||| S:29081 E:29083 ||| CD
μl  ||| S:29083 E:29086 ||| NN
of  ||| S:29086 E:29089 ||| IN
0.2 ||| S:29089 E:29092 ||| CD
%  ||| S:29092 E:29094 ||| NN
Toluidine  ||| S:29094 E:29104 ||| NNP
blue-O  ||| S:29104 E:29111 ||| NNP
were  ||| S:29111 E:29116 ||| VBD
added  ||| S:29116 E:29122 ||| VBN
to  ||| S:29122 E:29135 ||| TO
each  ||| S:29135 E:29140 ||| DT
well  ||| S:29140 E:29145 ||| RB
and  ||| S:29145 E:29149 ||| CC
vacuum  ||| S:29149 E:29156 ||| NN
was  ||| S:29156 E:29160 ||| VBD
applied ||| S:29160 E:29167 ||| VBN
.  ||| S:29167 E:29169 ||| .
The  ||| S:29169 E:29173 ||| DT
membrane  ||| S:29173 E:29182 ||| NN
was  ||| S:29182 E:29196 ||| VBD
removed ||| S:29196 E:29203 ||| VBN
,  ||| S:29203 E:29205 ||| ,
washed  ||| S:29205 E:29212 ||| VBD
twice  ||| S:29212 E:29218 ||| RB
with  ||| S:29218 E:29223 ||| IN
destaining  ||| S:29223 E:29234 ||| JJ
solution  ||| S:29234 E:29253 ||| NN
( ||| S:29253 E:29254 ||| -LRB-
ethanol-water-acetic  ||| S:29254 E:29275 ||| JJ
acid ||| S:29275 E:29279 ||| NN
,  ||| S:29279 E:29281 ||| ,
50 ||| S:29281 E:29283 ||| CD
: ||| S:29283 E:29284 ||| :
49 ||| S:29284 E:29286 ||| CD
: ||| S:29286 E:29287 ||| :
1 ||| S:29287 E:29288 ||| LS
)  ||| S:29288 E:29290 ||| -RRB-
for  ||| S:29290 E:29294 ||| IN
5  ||| S:29294 E:29296 ||| CD
min  ||| S:29296 E:29300 ||| NNS
and  ||| S:29300 E:29314 ||| CC
air-dried ||| S:29314 E:29323 ||| JJ
.  ||| S:29323 E:29353 ||| .
Other  ||| S:29353 E:29359 ||| JJ
methods  ||| S:29359 E:29377 ||| NNS
The  ||| S:29377 E:29381 ||| DT
protein  ||| S:29381 E:29389 ||| NN
concentration  ||| S:29389 E:29403 ||| NN
was  ||| S:29403 E:29407 ||| VBD
determined  ||| S:29407 E:29418 ||| VBN
using  ||| S:29418 E:29424 ||| VBG
BioRad  ||| S:29424 E:29441 ||| JJ
Protein  ||| S:29441 E:29449 ||| NNP
Assay  ||| S:29449 E:29455 ||| NNP
( ||| S:29455 E:29456 ||| -LRB-
BioRad ||| S:29456 E:29462 ||| NNP
) ||| S:29462 E:29463 ||| -RRB-
.  ||| S:29463 E:29496 ||| .
Abbreviations  ||| S:29496 E:29518 ||| NNP
PEDF ||| S:29518 E:29522 ||| NNP
,  ||| S:29522 E:29524 ||| ,
pigment  ||| S:29524 E:29532 ||| JJ
epithelium-derived  ||| S:29532 E:29551 ||| JJ
factor ||| S:29551 E:29557 ||| NN
;  ||| S:29557 E:29559 ||| :
GAG ||| S:29559 E:29562 ||| NNP
,  ||| S:29562 E:29572 ||| ,
glycosaminoglycan ||| S:29572 E:29589 ||| NNS
;  ||| S:29589 E:29591 ||| :
HS ||| S:29591 E:29593 ||| NNP
,  ||| S:29593 E:29595 ||| ,
heparan  ||| S:29595 E:29603 ||| JJ
sulfate ||| S:29603 E:29610 ||| NN
;  ||| S:29610 E:29612 ||| :
CM ||| S:29612 E:29614 ||| NNP
,  ||| S:29614 E:29616 ||| ,
media  ||| S:29616 E:29630 ||| NNS
conditioned  ||| S:29630 E:29642 ||| VBN
by  ||| S:29642 E:29645 ||| IN
retinoblastoma  ||| S:29645 E:29660 ||| NN
cells ||| S:29660 E:29665 ||| NNS
.  ||| S:29665 E:29689 ||| .
Authors ||| S:29689 E:29696 ||| NNP
'  ||| S:29696 E:29698 ||| POS
contributions  ||| S:29698 E:29720 ||| NNS
EMA  ||| S:29720 E:29724 ||| NNP
participated  ||| S:29724 E:29737 ||| VBD
in  ||| S:29737 E:29740 ||| IN
the  ||| S:29740 E:29744 ||| DT
design ||| S:29744 E:29750 ||| NN
,  ||| S:29750 E:29752 ||| ,
assay  ||| S:29752 E:29758 ||| JJ
development  ||| S:29758 E:29770 ||| NN
and  ||| S:29770 E:29782 ||| CC
carried  ||| S:29782 E:29790 ||| VBD
out  ||| S:29790 E:29794 ||| RP
the  ||| S:29794 E:29798 ||| DT
complex-formation ||| S:29798 E:29815 ||| JJ
,  ||| S:29815 E:29817 ||| ,
GAG  ||| S:29817 E:29821 ||| NNP
detection  ||| S:29821 E:29831 ||| NN
and  ||| S:29831 E:29843 ||| CC
receptor  ||| S:29843 E:29852 ||| JJ
binding  ||| S:29852 E:29860 ||| JJ
assays ||| S:29860 E:29866 ||| NN
.  ||| S:29866 E:29868 ||| .
JEW  ||| S:29868 E:29872 ||| NNP
carried  ||| S:29872 E:29880 ||| VBD
out  ||| S:29880 E:29884 ||| RP
the  ||| S:29884 E:29888 ||| DT
purification  ||| S:29888 E:29909 ||| NN
and  ||| S:29909 E:29913 ||| CC
characterization  ||| S:29913 E:29930 ||| NN
of  ||| S:29930 E:29933 ||| IN
GAGs ||| S:29933 E:29937 ||| NNP
,  ||| S:29937 E:29939 ||| ,
the  ||| S:29939 E:29943 ||| DT
enzymatic  ||| S:29943 E:29953 ||| NN
and  ||| S:29953 E:29957 ||| CC
chemical  ||| S:29957 E:29974 ||| JJ
treatments  ||| S:29974 E:29985 ||| NNS
of  ||| S:29985 E:29988 ||| IN
cell  ||| S:29988 E:29993 ||| NN
cultures  ||| S:29993 E:30002 ||| NNS
for  ||| S:30002 E:30006 ||| IN
receptor  ||| S:30006 E:30015 ||| JJ
binding  ||| S:30015 E:30023 ||| JJ
studies ||| S:30023 E:30030 ||| NNS
,  ||| S:30030 E:30040 ||| ,
and  ||| S:30040 E:30044 ||| CC
drafted  ||| S:30044 E:30052 ||| VBD
the  ||| S:30052 E:30056 ||| DT
manuscript ||| S:30056 E:30066 ||| NN
.  ||| S:30066 E:30068 ||| .
SPB  ||| S:30068 E:30072 ||| NNP
conceived  ||| S:30072 E:30082 ||| VBD
the  ||| S:30082 E:30086 ||| DT
study ||| S:30086 E:30091 ||| NN
,  ||| S:30091 E:30093 ||| ,
and  ||| S:30093 E:30105 ||| CC
participated  ||| S:30105 E:30118 ||| VBD
in  ||| S:30118 E:30121 ||| IN
its  ||| S:30121 E:30125 ||| PRP$
design  ||| S:30125 E:30132 ||| NN
and  ||| S:30132 E:30136 ||| CC
coordination ||| S:30136 E:30148 ||| NN
.  ||| S:30148 E:30150 ||| .
All  ||| S:30150 E:30154 ||| DT
authors  ||| S:30154 E:30170 ||| NNS
read  ||| S:30170 E:30175 ||| VBP
and  ||| S:30175 E:30179 ||| CC
approved  ||| S:30179 E:30188 ||| VBD
the  ||| S:30188 E:30192 ||| DT
final  ||| S:30192 E:30198 ||| JJ
manuscript ||| S:30198 E:30208 ||| NN
.  ||| S:30208 E:30225 ||| .
